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“So many of our dreams at first seem impossible, then they seem improbable, 
 And then, when we summon the will, they soon become inevitable.”  
 
Christopher Reeve (1952 – 2004) 
Inscription on the Lois Pope Life Center fountain. 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Another way of looking at it. 
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 CELL TARGETED NANOPARTICLE-BASED DRUG DELIVERY SYSTEMS 
FOR SPINAL CORD INJURY REGENERATION 
 
ABSTRACT 
 
Spinal cord injuries (SCI) afflict millions of people every year worldwide. Since no cure exists for 
such neurotraumatic episodes, patients thus experience highly debilitating symptoms. These 
comprehend partial to complete muscular weakness and sensory loss, and commonly lead to 
paraplegia or tetraplegia. The tremendous complexity of cellular and biochemical reactions that 
follow the initial trauma, along with the lack of specificity of the drugs used, are hindering the 
development of effective treatments for SCI. Current clinical options are thus mainly based on 
palliative care, and systemic high dose administration of methylprednisolone (MP), a powerful 
anti-inflammatory and antioxidant corticosteroid that has shown to lead to functional recovery. 
However, the unspecificity and deleterious side effects of MP are making some clinicians 
cautious towards its administration. Actually, this treatment is very controversial, therefore, new 
enhanced approaches are needed to repair the injured spine and provide SCI patients a better 
quality of life. 
The most recent developments in nanotechnology show great promise for tissue engineering 
advanced solutions. Recently, poly(amido)amine (PAMAM) dendrimer nanoparticles grafted with 
CMCht have been proposed as intracellular nanocarriers for stem cell osteogenic differentiation. 
In this thesis, it was explored the application of the developed CMCht/PAMAM dendrimer 
nanoparticles for neuroprotection of the injured spinal cord tissue, ultimately contributing to 
regeneration and repair. Firstly, functionalization of CMCht/PAMAM dendrimer nanoparticles was 
performed covalently binding an antibody to its structure, and then incorporating a relevant drug, 
such as MP. Both modifications were confirmed using spectroscopic techniques and in vitro 
biological evaluation was performed in primary cortical glial cultures. No cytotoxicity associated 
with the multifunctional CMCht/PAMAM dendrimer nanoparticles was observed. In vitro 
internalization studies revealed a differential uptake, when the antibody was bond to the 
CMCht/PAMAM dendrimer nanoparticles. Therefore, the addition of targeting moieties to the 
nanoparticles contributed to a modulation of the nanoparticle uptake by glial cells. In order to 
analyze the intracellular trafficking, as well as internalization and clearance routes, 
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electrophysiology recordings of live astrocyte (single-cell) membrane capacitance were performed 
after incubation with MP-loaded CMCht/PAMAM dendrimer nanoparticles. The patch-clamp 
studies showed that nanoparticles do affect both endocytosis and exocytosis rates. In fact, these 
observations were further confirmed by confocal microscope visualization of astrocyte endocytotic 
and exocytotic vesicles. To our knowledge, this study clarified for the first time the 
endocytotic/exocytotic pathways that nanoparticles follow in primary nervous cells, 
demonstrating for the first time the exocytotic clearance of the nanoparticles. Following this, 
administration of FITC-labeled MP-loaded CMCht/PAMAM dendrimer nanoparticles in the 
cerebrospinal fluid (CSF) of healthy rats was performed. The distribution of the nanoparticles was 
widespread along several brain areas and layers, showing that once the blood-brain barrier (BBB) 
is overcome the nanoparticles are easily transported and retained in the brain tissue. Moreover, 
the drug was shown to be acting intracellularly by protein expression quantification. 
Subsequently, extensive investigation of the physico-chemical characteristics of the MP-loaded 
nanoparticles was carried out revealing its spherical 109 nm structure and zeta potential stability. 
Moreover, a preliminary therapeutic assessment of this system was analyzed in vitro in microglial 
cultures, and in vivo in an animal model of SCI. Promising results were obtained with the 
successful modulation of microglia proliferation, and significant locomotor improvements in the 
treated injured animals. Finnaly, biocompatibility and functionality studies were performed in 
Schwann cell pure cultures and co-cultures with dorsal root ganglia neurons, when in contact 
with the MP-loaded CMCht/PAMAM dendrimer nanoparticles. The presence of nanoparticles has 
not affected the cell morphology or typical distribution in culture. Moreover, extensive myelination 
was performed by Schwann cells that enveloped the axons of dorsal root ganglia neurons, 
showing normal viability and function. These results open new possibilities for therapeutic 
strategies, namely combination of Schwann cell transplantation and nanoparticle administration. 
From these findings, new knowledge regarding nanoparticle interaction with nervous cells was 
obtained, along with the potential therapeutic value. For the first time, multifunctionalization of 
CMCh/PAMAM dendrimer nanoparticles was successfully accomplished and proved to modulate 
the cell uptake rates. Moreover, the innovative use of patch-clamp electrophysiology for the 
quantification of vesicle formation/fusion in the cell membrane following nanoparticle incubation 
proved to be useful in this type of studies. The promising locomotor improvements observed in 
nanoparticle-treated SCI animals, along with the biocompatibility of these nanoparticles for CNS 
applications, bring new hopes for the development of successful strategies for SCI repair. 
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SISTEMAS DE LIBERTAÇÃO DE FÁRMACOS BASEADOS EM 
NANOPARTÍCULAS PARA DIRECCIONAMENTO CELULAR E 
REGENERAÇÃO DE LESÕES DE ESPINAL MEDULA 
 
RESUMO 
 
Lesões traumáticas na espinal medula afetam anualmente milhões de pessoas em todo o 
mundo. Atualmente não existe cura para lesões neurotraumáticas, e os pacientes vivenciam 
sintomas altamente debilitantes. Estes vão desde parcial a total perda de força muscular e 
perceção sensorial, e comummente culminam em paraplegia ou tetraplegia. A elevada 
complexidade de reações celulares e bioquímicas que se seguem ao trauma inicial, associada à 
falta de especificidade das drogas em uso, têm vindo a dificultar o desenvolvimento de terapias 
eficazes para o tratamento de lesões na espinal medula. Como consequência, as opções clínicas 
atuais centram-se maioritariamente em cuidados paliativos e na administração sistémica aguda 
de metilprednisolona (MP), um poderoso corticosteroide anti-inflamatório e antioxidante que 
demonstrou melhorias funcionais em pacientes. No entanto, a falta de especificidade e os graves 
efeitos secundários associados à administração sistémica de MP estão a levar alguns 
especialistas a administrá-la com grande precaução. De facto, a aplicação desta terapêutica é 
bastante controversa logo, é essencial e urgente desenvolver novas estratégias mais eficazes e 
seguras para regenerar a espinal medula, de forma a poder proporcionar aos pacientes uma 
melhor qualidade de vida. 
Os mais recentes desenvolvimentos na área da nanotecnologia têm mostrado grande potencial 
para aplicação em estratégias avançadas de engenharia de tecidos. Recentemente, 
nanopartículas dendriméricas de poliamidoamina (PAMAM) superficialmente modificadas com 
carboximetilquitosano (CMCht) foram propostas para transporte intracelular de fármacos. Nesta 
tese, a aplicação destas nanopartículas dendriméricas de CMCht/PAMAM é explorada para 
neuroprotecção da espinal medula após lesão, tendo como objetivo permitir a regeneração do 
tecido. Primeiramente procedeu-se à funcionalização das nanopartículas dendriméricas 
CMCht/PAMAM através da ligação covalente de um anticorpo à sua estrutura, e subsequente 
incorporação do corticosteroide MP. Ambas as modificações foram confirmadas por análise 
espectroscópica, e de seguida efetuou-se uma avaliação biológica in vitro em culturas primárias 
de células da glia. Não foi observado qualquer efeito citotóxico relacionado com a presença das 
nanopartículas multifuncionais nas culturas e a presença do anticorpo na sua estrutura originou 
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uma alteração do perfil de internalização das mesmas nas culturas de glia. Confirmou-se, assim, 
que a adição de agentes de direcionamento à estrutura das nanopartículas CMCht/PAMAM 
contribui para a alteração da distribuição da internalização celular. Com a finalidade de analisar 
a distribuição intracelular das nanopartículas, assim como as vias de internalização e remoção, 
efetuaram-se análises eletrofisiológicas para medir a capacitância de membrana de astrócitos 
viáveis após incubação com nanopartículas com MP. Os estudos de patch-clamp demonstraram 
que as nanopartículas afetam as taxas de endocitose e exocitose destas células. Estas 
observações foram também confirmadas por observação por microscopia confocal e 
quantificação de fluorescência. Este estudo clarifica pela primeira vez as vias que estas 
nanopartículas seguem em células nervosas, nomeadamente endocitose e exocitose. 
Seguidamente, administrou-se nanopartículas com MP e marcadas com o fluorocromo FITC no 
líquido cefalorraquidiano de ratos saudáveis e verificou-se uma distribuição ampla ao longo de 
várias regiões e camadas do cérebro, provando que uma vez ultrapassada a barreira 
hematoencefálica as nanopartículas facilmente são transportadas no tecido nervoso. 
Posteriormente, procedeu-se à caracterização físico-química das nanopartículas incorporadas 
com MP e efetuou-se uma avaliação preliminar do potencial terapêutico deste sistema em 
culturas de microglia e in vivo num modelo animal de lesão de espinal medula. A modulação da 
proliferação de microglias in vitro, assim como as melhorias locomotoras registadas nos animais 
lesionados tratados com nanopartículas são resultados bastante encorajadores. Finalmente, os 
estudos de biocompatibilidade e funcionalidade em células de Schwann expostas a 
nanopartículas incorporadas com MP não indicaram qualquer anomalia na morfologia celular ou 
na típica distribuição destas células em cultura. Quando em co-cultura com neurónios de 
gânglios espinais, as células de Schwann mielinizaram de forma extensa os axónios destas 
células, comprovando a sua normal viabilidade e funcionalidade. 
Destes resultados, obteve-se novo conhecimento acerca da interação de nanopartículas 
dendriméricas CMCht/PAMAM multifuncionalizadas com células nervosas, assim como do seu 
potencial valor terapêutico em lesões de espinal medula. Efetuou-se com sucesso uma 
funcionalização que conduziu à alteração do perfil de internalização celular. O uso inovador de 
eletrofisiologia patch-clamp para quantificar a formação/fusão de vesículas na membrana celular 
após incubação com nanopartículas demostrou ter extrema utilidade neste tipo de estudos. Os 
resultados obtidos revelando melhorias locomotoras em animais lesionados e tratados com 
nanopartículas com metilprednisolona, associados à biocompatibilidade destas nanopartículas 
para aplicações do foro neurológico, traz renovada esperança na busca de melhores estratégias 
para tratar de forma eficaz as consequências de lesões na espinal medula. 
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INTRODUCTION TO THE THESIS FORMAT 
 
This thesis is divided into four sections that comprise a total of eight chapters. The body of the 
thesis chapters is based on a series of related articles published or submitted for publication in 
international peer-reviewed journals. Each of the chapters is presented in the manuscript form, 
i.e., starting with an abstract and followed by introduction, materials and methods, results, 
discussion and conclusions. A list of references is also provided in the end of each chapter. The 
contents of each chapter are summarized below. 
 
Section I 
Chapter I presents a comprehensive overview on the aims of this work. It starts 
elucidating the reader on the physiology of the central nervous system and pathophysiology of 
neurotrauma, focusing on spinal cord injury (SCI). Going through the current clinical options to 
treat this condition, some innovative tissue engineering approaches are reviewed, focusing on 
drug delivery strategies using nanoparticles.    
 
Section II 
Chapter II describes the experimental techniques and protocols used to obtain the 
herein presented results. Although each chapter is accompanied by the description of the 
materials and methods utilized, this chapter intends to assemble all the relevant information 
concerning this matter. 
 
Section III 
This section describes the experimental work conducted within the scope of this thesis.  
Chapter III reports the functionalization of MP-loaded CMCht/PAMAM dendrimer 
nanoparticles with a targeting agent and evaluation of the uptake of functionalized nanoparticles 
by primary glial cells. The viability of glia and microglia primary cultures is also taken into 
account to assess possible cytotoxicity of the newly developed multifunctional nanoparticles. 
 xl 
 
 
Chapter IV presents the investigation of the MP-loaded CMCht/PAMAM dendrimer 
nanoparticle uptake mechanisms, intracellular trafficking and possible clearance routes. Two 
combined techniques are exploited to conduct the investigation: patch-clamp electrophysiology 
recordings and confocal microscopy of primary live astrocytes. 
 
Chapter V describes the assessment of the brain distribution of MP-loaded 
CMCht/PAMAM dendrimer nanoparticles following intracisternal administration. Confocal 
microscopy is used to examine the preferential localization and distribution of the injected 
nanoparticles in healthy Wistar rats. 
 
Chapter VI presents a detailed physico-chemical characterization of the MP-loaded 
nanoparticles and assesses their influence in the metabolic activity and proliferation of primary 
glial cultures. Moreover, preliminary therapeutic activity of the nanoparticle-system is assessed in 
microglia cultures and in a rat model of SCI. 
 
Chapter VII depicts the analysis of the interaction of MP-loaded dendrimer 
nanoparticles with Schwann cells. The characterization of the nanoparticle uptake profile is done, 
along with fluorescence microscopy assessment of the cells. Electron micrographs are observed 
to analyse possible nanoparticle caused ultrastructural alterations. Also, the myelination capacity 
of Schwann cells is verified in co-cultures of these cells with dorsal root ganglia neuron co-
cultures previously incubated with nanoparticles. 
 
Section IV 
 Chapter VIII contains the general conclusions of the works carried out under the scope 
of this thesis. General remarks and future directions are also provided. 
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CHAPTER I 
Introduction – Recent nanotechnology advances in tissue engineering for 
drug delivery following neurotrauma 
 
Abstract  
Neurotraumatic conditions, such as spinal cord injury (SCI), are devastating and highly 
debilitating neurological disorders that tremendously affect our society. Although some 
remarkable advances have been made in the last decades concerning its pathophysiology, no 
similar translation has been achieved in terms of clinical treatments. In fact, there is no effective 
therapeutic option for SCI yet. This has been mainly associated with the extremely complex 
cascade of events following trauma, a highly inhibitory set that is established at the lesion site, as 
well as the natural barriers that prevent the entry of pharmaceutics into the CNS. Current clinical 
practices in SCI management involve column stabilization and decompression, and the 
administration of high dosage of the corticosteroid methylprednisolone, with sometimes only 
modest functional improvements, however. The main reasons for treatment failure are thus the 
restricted access and lack of specificity of therapeutic drugs to the spine. Nanotechnology and 
tissue engineering are bringing new possibilities for treatment and targeted drug delivery, 
engineering more refined and advanced strategies for SCI repair. Herein, the most recent 
advances in tissue engineering for SCI will be addressed, focusing particularly on the 
contributions of nanotechnology for the design of new and improved drug delivery systems 
following neurotrauma. Some fundamental aspects of CNS cellular organization will also be 
briefly discussed, as well as relevant hallmarks on the pathophysiology of SCI.  
 
 
 
 
 
This chapter is based on the following publication: 
Susana R. Cerqueira, Joaquim M. Oliveira, Nuno Sousa, Rui L. Reis, “Recent nanotechnology 
advances in tissue engineering for drug delivery following neurotrauma”, submitted. 
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1. Introduction 
 
Richard P. Feynman first proposed the direct manipulation of atoms as a more powerful chemical 
synthesis technique.1 Since then, a vast number of nanoparticles has been developed for 
biomedical purposes, namely liposomes, fullerenes, magnetic, and natural-based and synthetic 
polymeric nanoparticles.2 Many central nervous system (CNS) disorders still completely lack 
effective treatments, for example spinal cord injury (SCI), leading to an urgent demand for 
enhanced therapeutic strategies that will provide patients with a better quality of life.3 
Neurotraumatic ailments, comprising stroke and brain/spinal cord injuries currently affect 
millions of people worldwide and result in severe neurological deficits, commonly accompanied 
by other harsh disabilities.4 In this review, the pathophysiology of SCI and the constraints for 
successful therapies, namely the existence of blood-CNS barriers associated with the extreme 
complexity of events following injury, will be briefly addressed along with the current clinical 
options. Afterwards, the most promising tissue engineering approaches for neurotrauma repair, 
focusing on the most recent advances of nanotechnology for intracellular drug delivery will be 
presented.   
 
 
1.1. Glia: Cellular targets to restore nerve function after injury 
 
Similarly to other systems in the mammalian organism, the nervous system is constituted by a 
set of specialized cells that perfectly combine and intricate to maintain the ideal conditions for 
the nerve impulse to occur. Neurons are responsible for the conduction of the nerve impulse 
along the organism, receiving and transmitting essential information in the form of electrical 
impulses.5 Different categories of neurons have been defined, whether having inhibitory or 
excitatory actions and depending on the type and extent of the connections they make.6 The ideal 
conditions for the perfect functioning of neurons, however, are assured by glial cells, which are 
divided in three major cell types and intimately interact with neurons, displaying a vast array of 
functions. Glial cells, often referred to as support cells, have however been recently accounted for 
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more active roles in neuronal processing and are now recognized as new potential therapeutic 
targets following CNS disorders.7  
Astrocyte characterization is still incomplete, with some authors defending that they represent 
more than one cell type given the complexity and variety of morphological, molecular and 
functional profiles.8 The accurate performance of astrocytes and its interactions with other cells is 
imperative for nervous tissue function, nevertheless astrocytes also play a central role following 
injury or during disease.9 The formation of a glial scar, which has a primary protective role, aims 
at limiting the spread of inflammation or infection in the nervous tissue.10 However, it can also 
bring some detrimental consequences restricting the establishment of neuronal re-connections 
following trauma, for example. Hence, astrocytes are an important therapeutic target concerning 
neuroinflammation and neurodegeneration, and the control and management of astrogliosis and 
scar formation have been attracting a great deal of attention in biomedical research.11 Microglia 
functions in the healthy CNS are still to be completely understood, nonetheless it is known that 
these cells promptly respond to alterations in the environment with a very low threshold of 
activation.12 Unlike astrocytes, microglia do not connect with each other therefore acting in a 
more individual manner and mainly based in autocrine and paracrine mechanisms.13 The intrinsic 
neuroinflammatory and neuroprotective profiles of microglia are leading some researchers to 
attempt to modulate its action, trying to reinforce the neuroprotective effect in pathological 
conditions.14 Finally, oligodendrocytes are the glial cells that most intimately interact with 
neurons, particularly axons, producing and wrapping them in a myelin sheath.15 In pathology, 
oligodendrocytes are directly involved in some degenerating diseases, such as multiple sclerosis, 
and are particularly vulnerable cells if alterations in the neural environment occur.16 
Consequently, protection of oligodendrocytes should be a critical issue in therapeutic 
interventions following disease or trauma to the CNS.17  
Thus, to restore the neuronal network following trauma, glial cells are important cellular targets to 
consider in an attempt to optimize and program neuronal and functional recovery.18 As shown in 
Table 1, each glial cell type exerts particular functions in the maintenance of neural integrity and 
activity, both in health and disease. Therapies to restore and improve function should therefore 
aim at maximizing the neuroprotective and reparative intrinsic capacity of these cells, while 
modulating and minimizing potential deleterious actions and the progression of injury. 
 8 
 
Nonetheless, drug access to the nervous tissue is restricted due to the presence of cellular 
barriers, which will be addressed in the next section. 
 
Table 1 – Glial cells overview: characteristics and main functions. 
Cell type Characteristics Main functions 
Astrocytes Most abundant CNS cells Essential during development to the migration and guidance of 
neurons.8  
 Variable morphology Constituents of the BBB, in proximity to endothelial cells.19 
 Usually star-shaped Continuous monitoring of and modulation of neuronal activity.20 
  Functional connection of distant cells and structures.21 
  Gliotransmitter and other factor (glutamate, ATP) secretion.22 
  Become reactive and hypertrophy following injury.23 
  Formation of a glial scar (astrogliosis).10 
Microglia Very plastic Removal of degenerating structures and cell debris.24 
 Various mobile processes Assist in the maintenance of neuronal cell activity.25 
 Rod-shaped soma Can become macrophage to perform immunological functions.24 
 Resting ramified state Sense the CNS environment.26 
 Reactive amoeboid state. Secrete pro-inflammatory/immunomodulatory mediators, and 
neurotrophic factors.27 
Oligodendrocytes Variable morphology Production of myelin sheaths around axons.15 
 Ramified processes Essential in neuronal survival and integrity.17,28,29 
 
 
1.2. The blood-CNS barriers limiting therapeutic intervention  
 
Both the brain and the spinal cord need to be highly irrigated in order to obtain the nutrients that 
fulfill its high metabolic requirements for proper functioning. However, the blood vessels in the 
CNS have some particular characteristics as compared to the capillaries irrigating the rest of the 
body. It was in the 19th century that Ehrlich discovered that systemic administration of vital dyes 
in mammalians stained all organs of the organism, except the brain and the spinal cord.30 
Conversely, if a dye is injected in the cerebrospinal fluid (CSF), it would stain the CNS but none of 
the peripheral organs. Thus, a century ago it was discovered that a barrier exists between the 
blood and the CNS organs. More recently, it was shown that CNS vasculature presents distinctive 
physical and enzymatic properties, including association with cells that constitute this shield – 
designated as the neurovascular unit - and limit the entrance of solutes to the CNS.31 The 
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neurovascular unit has four main functions: (i) regulation of CNS homeostasis; (ii) protection 
against potential environmental threats; (iii) provision of nutrients; and (iv) guidance of 
inflammatory cell response.30 Although exceedingly important in healthy circumstances, both the 
blood-brain barrier (BBB) and blood-spinal cord barrier (BSCB) dramatically limit the penetration 
of pharmaceutics in case of disease.32 Simultaneously, some impairments in the BBB are closely 
associated with neuropathological conditions.31 Essentially, the BBB is composed by the 
microvascular endothelial cells surrounded by an extracellular base membrane in close 
interaction with adjacent astrocyte end-feet, pericytes and neurons. Its selective permeability is 
mainly due to the lack of endothelial cell fenestrations and the presence of tight junctions, 
allowing the transport of substances only if the respective transporters are present in the 
membrane (e.g., glucose, transferrin and insulin).32 The spinal cord possesses similar features in 
its neurovascular unit. 
Although most of the present studies focus on the BBB, there is an additional blood-CNS barrier 
at the choroid plexus level. This additional barrier is needed since the capillaries that irrigate this 
area do not possess tight junctions. In this case, the brain protection is assured by the presence 
of a monolayer of epithelial cells with tight juntions on its apical side.33 This interface in the 
choroid plexus is known as the blood-CSF barrier (BCSFB).34 Consequently, if one intends to 
therapeutically target the CNS administrating a drug aimed at healing a damaged tissue, these 
barriers present serious obstacles to that purpose.  
 
1.3. Current local delivery options to circumvent the BSCB 
 
Safely delivering optimal doses of drugs to the CNS is one of the most challenging problems 
faced in the treatment of neurotraumatic diseases. Generally, therapies directed to the nervous 
tissue need high dosage systemic administration of compounds in order to reach beneficial 
effects. This is necessary due to the short half-life of drugs and often results in undesired 
deleterious side effects.35 More importantly, most of the pharmaceutics do not even pass the 
barriers that protect the CNS due to the neurovascular unit properties that limit passage to the 
CNS.36 Consequently, and since systemic administration of pharmaceuticals has proven most of 
the times to be inefficacious in the treatment of CNS conditions, with additional problems of  
drug degradation and rapid renal clearance, local delivery methods have been attempted as 
alternative options.37 Local routes for spinal cord delivery include: epidural, intrathecal and 
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intraspinal.38 Epidural injection refers to fluid introduction in the epidural space, between the 
vertebrae and the dura, while intrathecal administrations are made in the sub-arachnoid region. 
These two methods are clinically performed, particularly for pain and spasticity management.39 
Intraspinal delivery, on the other hand is a more invasive route that can damage the nervous 
tissue and is not usually used in the clinics, although it is being investigated in research to 
directly introduce therapeutic compounds or cells in damaged areas.40 From these options, it is 
possible to select between single bolus injection and continuous infusion using appropriate 
devices. Bolus injections provide local short-term delivery, while continuous infusion presents 
some advantages with the possibility of controlled administration over periods of weeks, using for 
that purpose mini-pumps.41 Although advantageous as compared to systemic administration, the 
use of implantable devices for the continuous sustained delivery to the intrathecal or epidural 
spaces has been associated with infections, as well as some scarring and compression of the 
spinal cord.42 Moreover, the invasive character of mini-pump implantation associated with the 
subsequent inflammatory response is undermining its use in human patients. Thus, improved 
means of delivery are required to tackle the deleterious reactions that occur following injury and 
lead to degeneration and loss of function.  
 
2. Consequences of neurotrauma: Neurodegeneration and axon failure 
 
Several causes can impair the integrity of the CNS organs causing subsequent devastating costs 
to the patient’s life. Among neurotraumatic ailments, stroke can occur as a result of partial or 
total obstruction of the cerebral blood flow in the brain, while brain and spinal cord injuries are 
usually a consequence of mechanical insults.43 Not only severe neurological deficits arise from 
these type of injuries, but also peripheral organs can be seriously affected following 
neurotrauma.4 In terms of incidence, it is estimated that 10 million people are afflicted every year 
worldwide from traumatic brain injuries (TBI), while the figures can ascend to 15 million suffering 
from stroke, and 80 million in the case of spinal cord injuries (SCI).44 
The temporal cascade of events that follow these incidents is similar independently of the cause 
and affected organ.45,46 The immediate result of such occurrences is massive cell death, generally 
followed by a series of biochemical and cellular events, designated as secondary injury reactions 
that contribute to the degeneration and progressive death of neuronal cells.47 In order to re-
establish function in the affected tissue it is imperative to restore neuronal connections, which is 
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currently difficult to accomplish. The post-injury environment becomes very aggressive for axonal 
re-growth and even neuronal survival. In the case of neuronal injury, the affected areas can 
become permanently demyelinated and an anterograde degenerative process, designated as 
Wallerian degeneration, can arise leading to complete neuronal loss.48 In this section, particular 
focus will be given to SCI providing an overview on the pathophysiology, current options for drug 
delivery and future therapeutic trends for the field. 
 
2.1. Epidemiology and pathophysiology of SCI 
 
According to recent health epidemiological studies, traumatic SCI afflicts primarily young adults 
and the elderly population, still resulting in high mortality rates in developing countries and 
devastating personal and societal costs.49 The main causes of these injuries are associated with: 
vehicle accidents, violence/self-harm acts, falls and sports-related activities.50 Nonetheless, non-
traumatic SCI can also develop from congenital or developmental disorders, infection, 
inflammation and tumors, with equally devastating outcomes.51 The level and intensity of the 
lesion determines the extent of damage and the neurological deficits, giving rise to clinical signs 
that go from partial to complete muscular weakness and sensory loss at and below that level, 
potentially resulting in paraplegia or tetraplegia.52 Cervical injuries are the most common SCI in 
humans, followed by thoracic, lumbar and sacral injuries.53 Since there is no effective treatment 
for this condition, SCI patients experience besides the highly debilitating neurological deficits, 
frequent bladder, bowel and kidney infections, along with cardiac and respiratory problems, in 
addition to autonomic dysreflexia.54 As a result, the life of SCI patients suffers drastic alterations 
in their daily routines, which become conditioned by a series of mandatory regimens to ensure 
proper body function and commonly the dependence on assistive devices, such as wheelchairs 
or ventilators.  
When the primary insult distresses the spinal cord generally there is a compression of neural 
elements and the blood vessels resulting in axon disruption. Immediately after, hemorrhage, 
swelling and ischemia occur triggering a series of secondary reactions that exacerbate the extent 
of the initial primary injury.55 The secondary injury is actually the first opportunity for therapeutic 
interventions aiming at managing and minimizing the overall impact of the damage, sparing the 
neurologic tissue as much as possible. In order to do that, accurate knowledge on the ongoing 
reactions is imperative for successful interventions. Diverse cellular and biochemical reactions 
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occur simultaneously at this stage (Figure 1), making SCI a complex pathology to deal with.56 
Secondary reactions include: (i) excitotoxicity, as a result of excess glutamate release;57 (ii) 
apoptotic cell death, predominantly neurons and oligodendrocytes;46 (iii) oxidative stress, with free 
radical production and lipid peroxidation;58 (iv) further edema, hypoxia and ischemia;59 and (v) 
inflammation, with the production of pro-inflammatory cytokines, microglia activation and 
leukocyte infiltration.60 Thereby, the lesion area becomes a very harsh environment for repair and 
functional recovery.61 The demyelination that initiates after injury is also responsible for the 
production of a series of myelin-related inhibitory molecules that obstruct regeneration, such as 
Nogo, myelin-based glycoprotein (MAG) and oligodendrocyte myelin protein (OMgp).62 Eventually, 
a chronic phase is established comprising irreversible white matter demyelination and the 
formation of a glial scar around the lesion, creating a barrier that inhibits axon regeneration.63 The 
glial scar is predominantely composed of proliferating astrocytes and inflammatory and fibrotic 
cells, and often surrounds a fluid-filled cystic cavity.10 These two structures are highly inhibitory for 
repair and reconnection, both physically and by expressing inhibitory molecules, such as 
chondroitin sulphate proteoglycans (CSPG).64 
 
 
Figure 1 – Schematic representation of the main cellular and biochemical events following SCI. 
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Therapeutic interventions tackling neuroprotection after SCI have to take into consideration this 
entire set of reactions, in an attempt to modulate the secondary events and attain a molecular 
balance where ideally regeneration is possible and more likely to occur than degeneration. 
However, the complexities of the spatio-temporal event sequence in SCI make it difficult to repair 
the tissue, and classical drugs and current treatments are very limited with few options for 
clinical intervention.65 
 
3. Current clinical practices to minimize the impact of the secondary 
injury 
 
The first supportive actions following SCI are crucial in the progression of damage. Presently, the 
current medical procedures involve three main actions: (i) stabilization of the spinal column; (ii) 
pharmacological management for prevention of the secondary injury; and (iii) enhancement of 
spinal cord perfusion.66 As for spinal perfusion procedures, selective perfusion of the injured spine 
has been accounted to maintain the blood flow in the cord and reduce the incidence of ischemic 
episodes during surgery.67 Early surgical intervention is usually performed to realign and stabilize 
the column, often associated with decompression that has also been recommended based on 
reported neurological and functional benefits.68,69 The basis of this decompression surgery focuses 
on prevention of secondary injury mechanisms, while stabilization has been reported to reduce 
the incidence and severity of sepsis and respiratory failure, improving survival in patients 
undergoing surgery.70 
Following these initial surgical procedures, the management of secondary injury by 
pharmacological means is pursued. The therapeutic agent recommended for clinical use in SCI 
patients is the corticosteroid MP, which was tested in three multicenter, randomized and double-
blinded clinical trials.71,72 Motor improvements were observed when a high dosage of the drug was 
administered 3 to 8 hours after injury and with 48-hour continued administration. However, 
severe undesired effects were simultaneously reported, as patients were showing higher 
incidence of gastrointestinal hemorrhage, wound infection, pulmonary embolism, severe 
pneumonia and sepsis, and even death due to respiratory complications, as a result of the 
necessary systemic high dose of the steroid.73 Consequently, its use has become extremely 
controversial with some clinicians arguing that the benefits are not significant enough to 
compensate for the occasionally drastic harmful side effects.74 MP is an anti-inflammatory and 
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antioxidant drug, also known to inhibit lipid peroxidation and maintain the integrity of the BSCB.75 
Though the precise molecular mechanisms of action through which MP exerts its actions remain 
undisclosed, some oligodendrocyte-specific anti-apoptotic effects have recently been discovered.76 
Moreover, reactive astrocyte CSPG expression has recently been reported to be inhibited by MP 
administration, as well as pro-inflammatory cytokine secretion by microglia.77,78 So, if appropriate 
means of delivering MP in a cell-targeted manner are developed, the drug beneficial actions can 
be maximized with elimination of the current negative side effects that systemic administration 
causes. Other drugs are also being tested or under pre-clinical investigations, such as riluzole, 
minocycline, erythropoietin and rolipram, but none of them has still proven effective clinical 
improvements.79 
 
4. Promising tissue engineering approaches in SCI repair 
 
While no successful therapeutic options exist yet to repair the damaged cord since none of the 
treatments so far can tackle all the factors that arise after damage, several advances in 
biomedical research and regenerative medicine are bringing new hopes for people suffering from 
SCI.80 Emerging therapies from tissue engineering involve areas from biomolecular therapies to 
cell transplantation and advanced strategies based in biomaterials. Tissue engineering applies 
the principles of biology and engineering to the development of functional substitutes for 
damaged tissue.81 These approaches are used to alter the local chemical and physical 
environment around the lesion site to facilitate tissue repair and modulate biochemical 
distresses. Lately, some combinatorial approaches have also been considered to tackle the 
complexity of SCI (Figure 2).82 Herein, we will briefly discuss the most recent developments in 
neural tissue engineering for SCI repair, giving a particular and more careful consideration to the 
design of targeted drug delivery systems for neuroprotection of the spinal cord following injury. 
Each of the tissue engineering strategies will be presented separately, nonetheless combination 
of two or more approaches can be advantageous and some examples of combinatorial 
approaches will also be presented. 
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Figure 2 – Representation of the main tissue engineering strategies for spinal cord injury repair. 
 
4.1. Cellular transplantation 
 
Cell therapies currently being considered to repair the spinal cord address the use of Schwann 
cells (SCs), olfactory ensheathing cells (OECs) and embryonic and adult neural stem cells 
(NSCs), bone marrow stromal cells (BMSC) and, more recently, induced pluripotent stem cells 
(iPSCs).83,84 The use of cell therapy in the injured spinal cord usually involves cell transplantation 
and the rationale behind its application focuses on cell replacement (mainly neurons and 
oligodendrocytes) and trophic factor delivery, modulating the environment in the lesion area to 
facilitate axon regeneration.84 Schwann cells produce extracellular matrix (ECM) and adhesion 
molecules, as well as neurotrophins and integrins that can support axon growth. The ability of 
SCs to promote nerve regeneration has been investigated since highly pure cultures of these cells 
can be obtained from nerve autografts, for future transplantation purposes.85 Recent studies have 
been focusing on combining SC transplantation with other strategies that provide a more prone 
environment for regeneration. For instance, Pearse et al. transplanted SCs grafts in combination 
with rolipram and cAMP administration in a rat contusion model.86 The results have shown 
enhanced axonal sparing and myelination, as seen in Figure 3, with additional significant 
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locomotor improvements. In another study, co-grafting of glia-restricted precursor cells and SCs 
resulted in synergistic actions, with robust oligodendrocyte differentiation, consequent improved 
axonal myelination and recovery of function following SCI.87 The other glia-derived cell type being 
considered in SCI cell therapies is OEC transplantation. OECs migrate along axons to support 
their growth and survival in the olfactory epithelium, thus providing permissive conditions for 
repair.88 Transplantation of OECs into spinal cord transected rats has shown to ameliorate 
autonomic dysreflexia symptoms.89 Additionally, in a clinical trial involving 6 patients with chronic 
complete SCI resulted in improvements in neurological function with no further clinical 
complications following autologous OEC transplantation.90 For more detailed information, SC and 
OEC transplantation following SCI has been recently reviewed and explored elsewhere.91,92 
 
 
Figure 3 – Photomicrographs of transverse sections of rat spinal cords 11 weeks after contusion injury. 
Pictured are: a) control; b) SC transplantation; and c) SC transplantation combined with rolipram and db-
cAMP. Scale bar = 250 µm. Higher magnification images (d-f) illustrate differences in spared central 
myelinated axon density. Scale bar = 50 µm. Higher magnifications (g-i) demonstrate differences in 
peripheral myelinated axon density within the site of injury and transplant. Scale bar = 50 µm.86  
 
Stem cells are also under extensive evaluation, regarding transplantation into the injured cord. 
However, more profound evaluations need to be performed when using stem cells, due to the 
potential risk of tumor formation or abnormal circuit arrangement.93 Nevertheless, the potential 
benefits linked to these cells ability to self-renew and differentiate into different cell types, makes 
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them attractive for therapeutic use in neural regeneration strategies. Human embryonic stem cell 
(ESC)-derived oligodendrocyte and motor neuron progenitor cells transplanted into spinal 
transected rats have induced locomotor recovery, along with survival, migration and 
differentiation of the stem cells into mature oligodendrocytes and neurons.94 Similar results were 
described by Kerr et al. transplanting human ESCs in a contusion model, with extensive survival 
and migration of the stem cells from the lesion site to surrounding areas, and successful 
integration of newly differentiated oligodendrocytes into the spinal cord.95 NSCs, in turn, are more 
committed than ESCs while still having the ability to differentiate into neurons, oligodendrocytes 
and astrocytes. Moreover, these are the naturally occurring stem cells of the nervous system and 
can be efficiently propagated in vitro.96 NSCs embedded in fibrin matrices containing growth 
factor cocktails and implanted in the SCI transection site have successfully differentiated into 
functional neurons, inducing functional recovery.97 In another study, sub-acute NSC 
transplantation in severely contused mice not only has led to locomotor recovery, but it has 
shown that inflammation was being re-programmed by interaction of NSC with macrophages.98 
Finally, the recently described iPSCs are also being evaluated for therapeutic use in 
neurotraumatic conditions promising additional sources of autologous cells for transplantation.99 
iPSCs are pluripotent stem cells that were obtained from fibroblasts in a retrovirus-mediated gene 
transfer.100 They do not entail ethical or immunological concerns, that can be associated to the 
use of ESCs or NSCs, and some authors believe they will become the preferred cell source for 
regenerative medicine.101 Human iPSCs-derived neurospheres have proven to differentiate in all 
neural lineages, as well as increased axonal re-growth, angiogenesis and myelination in the 
injured mice spinal cord .102 
A common issue with cell transplantation into the injured cord is the extremely inhibitory 
environment for survival and cell proliferation. Thus, cell transplantation should be considered in 
conjunction with complimentary strategies, such as the administration of therapeutic 
biomolecules that modulate the lesion area providing more permissive conditions for cell survival 
and consequent tissue repair. 
 
4.2. Biomolecular therapies to enhance regeneration 
 
Biomolecular therapies to regenerate the spinal cord focus on the supply of biochemical cues 
that influence cell behavior so as to overcome the growth inhibitory nature of the injured spine. 
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This can be achieved with the delivery of growth promoting ECM molecules, adhesion molecules 
and trophic factors.82,103 Examples of ECM molecules are collagen, laminin and fibronectin, all 
commonly used in vitro for the promotion of neural cell adhesion. In association with other 
compounds or constructs, adhesion molecules can help achieve better integration in the host 
neural tissue. Yoo et al. developed an engineered human neural cell line expressing L1, a 
regenerative conducive adhesion molecule and tested its implantation in an acute compression 
injury in mice.104 Treated animals have shown locomotor improvements, lower CSPG expression 
and migration of cells in the target tissue. A similar approach was examined with transduced SCs 
expressing L1, and the transplanted mice have exhibited faster locomotor recovery that was 
attributed to enhanced myelination and increased serotonergic fiber sprouting.105 Other 
biomolecules act in the soluble form and influence neural cells activating secondary messenger 
pathways. Neurotrophic factor adequate spatial and temporal expression patterns have shown to 
contribute to successful regeneration (as seen in the peripheral nervous system),106 and 
numerous studies are exploiting the use of these molecules to achieve effective repair in the 
CNS.107 Nerve growth factor (NGF) is the most studied trophic factor and is up-regulated following 
injury.108 Along with brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) they bind 
to surface receptors activating intracellular signaling cascades, such as cAMP. Single exogenous 
administration of NGF has demonstrated increased regeneration in CNS, however it also induced 
significant sprouting of uninjured axons which lead to chronic pain symptoms and inappropriate 
reflexes.109 Similar studies with BDNF proved to be inconclusive, and corroborated that a local and 
high dosage administration of the factor is needed for regeneration to occur.110,111 A multifunctional 
NT-3/D15A neurotrophin has been recently created and combined with SC transplantation 
revealing enhanced SC survival, as well as sensory and supra-spinal fiber extension.112 Thus, 
combined administration of neurotrophic factors seems to be the best approach assembling the 
varied neural responses as it can promote simultaneously: nerve outgrowth, survival and 
plasticity; spinal cord and peripheral nerve regeneration; dendritic arborization and synapse 
formation.113 Nonetheless, a critical point is the controlled delivery of these compounds, since 
these natural cues usually are presented in neural tissue in specific spatial and temporal 
distributions. Biodegradable polymers processed as micro- and nanoparticle systems can be 
useful carriers due to their versatile properties that can be designed to accomplish precise 
spatiotemporal control over drug release, and are one of the recent advanced tissue engineering 
strategies for neural repair.114 
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4.3. Advanced regenerative strategies 
 
Advanced tissue engineering strategies rely on trying to mimic the natural repair and regeneration 
in the organism, focusing on creating complex guidance channels and/or combining multiple 
stimuli in a single therapy. Physical, chemical and electrical guidance cues are essential to neural 
cells during development, and these are being considered in tissue engineering strategies for 
neuronal repair.115 Guidance channels are one of the strategies and have been produced using 
several different techniques, aiming at creating intricate structures that accurately imitate the 
nerve architecture. Prang et al. developed an alginate-based anisotropic hydrogel that has elicited 
oriented axon re-growth and appropriate reinnervation in organotypic cultures.116 Chitosan 
scaffolds seeded with NSCs have also been tested and implanted in spinal cord transected rats 
revealing NSCs survival and host axon re-growth.117 Silva et al. engineered a hybrid scaffold 
tubular structure composed of a starch/poly-ɛ-caprolactone (SPCL) surrounding a gellan gum 
hydrogel and shown efficient integration of the scaffold in a rat hemisection model, with no 
inflammatory reaction.118 Other recent constructs made of poly-L-lactic acid (PLLA) and polylactic-
co-glycolic acid (PLGA) were cultured with olfactory bulb derived cells and have shown up-
regulation of NGF and BDNF, along with stimulation of endothelial cell networks.119 Several other 
types of conduits have been produced for nerve repair, and these have been reviewed 
elsewhere.120,121 
Refined multifunctional drug delivery systems (DDS) are another recently explored advanced 
tissue engineering strategy to overcome the current impenetrability of SCI therapy.122 
Nanoparticle-based systems are being suggested for use as DDS due to the possibility to 
engineer these molecules, fine-tuning its properties for more effective delivery of therapeutics to 
CNS.123 In the next section we will review the more recent reports on the use of nanocarriers for 
SCI drug delivery. 
 
5. Nanocarriers for the effective delivery of neurotherapeutics 
 
In face of the present constraints and challenges in delivering drugs to the nervous tissue, there 
is an evident need to pursue more sophisticated and thus efficient DDS. Nanotechnology, as the 
scientific field dealing with the synthesis, characterization and application of materials comprised 
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within dimensions from few to about 100 nanometers, is promising unique benefits in biomedical 
applications for CNS.124 Ranging from improved means of diagnostics and imaging to targeted 
therapies, nanomedicine applied in neuroscience is a growing field in research. There are several 
advantages that nanomaterials present for use as drug carriers in regenerative strategies, 
namely: (i) increased drug bioavailability, with extended circulation times; (ii) the possibility to 
overcome the blood-CNS barriers; and (iii) the possibility to be functionalized, adding targeting, 
imaging or therapeutic features to the nanoparticle systems (Figure 4); while making use of 
traditional routes of administration, as intravenous injection.125 Moreover, some nanoparticles still 
present intrinsic therapeutic features, such as reactive oxygen species scavenging,126 anti-
angiogenic properties,127 peroxidase-like activity,128 and other interesting qualities that can be used 
for therapeutic purposes. Additionally, the design of successful nanocarriers for SCI will allow the 
use of current classical drugs in more effective manners, directing its actions to the desired sites. 
 
 
Figure 4 – Illustrative example of a dendrimer-based multifunctional nanoparticle system. 
 
 
There is therefore an immense set of nanoparticles recently proposed for use as nanocarriers for 
therapeutic applications, from classical linear polymers to novel spherical molecules.129  
Nanoparticles can be made from various materials, including proteins, peptides, polymers, lipids, 
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metals and carbon, among others.130 The most relevant structures have the ability to be 
functionalized with targeting moieties, therapeutic and/or contrast agents. The developed 
nanoparticles for drug delivery in the CNS will be addressed, and the most recent examples of 
use in SCI related applications are provided in Table 2. 
 
Table 2 – Recent nanomedicine examples for drug/gene delivery applications in the injured CNS. 
Nanocarrier type CNS injury model Administration route Main results 
Liposomes    
Hydroxycamptothecin-
loaded liposomes 
Yang et al.131 
L4-L6 laminectomies with 
L5 disc injury on adult 
New Zealand white rabbits. 
Local administration Reduced fibrosis and 
epidural adhesion. 
PEG-TAT modified 
liposomes 
Liu et al.132 
T10 severe contusion 
injury in Wistar rats. 
Systemic (intravenous, 
tail) 
Modified liposomes cross 
the BSCB and accumulate 
at lesion site. 
Clodronate-loaded 
liposomes 
Ianotti et al.133 
T8 moderate contusion in 
adult Sprague-Dawley rats. 
Systemic 
(intraperitoneal) 
Enhanced neuroprotection, 
tissue sparing and hindlimb 
functional recovery. 
DNA-loaded mesoporous 
silica-supported lipid 
bilayers 
Dengler et al.134 
 
Chronic constriction injury 
to the sciatic nerve of adult 
Sprague-Dawley rats 
Local (intrathecal) Functional suppression of 
pain-related behavior 
(successful spinal gene 
delivery). 
Polymeric 
nanoparticles 
   
Chitosan nanoparticles 
Cho et al. 135 
Mid-thoracic 
crush/compression injury 
in adult Hartley guinea 
pigs 
Systemic 
(subcutaneous) 
Restoration of the nerve 
impulse transmission; 
membrane sealing 
properties. 
Methylprednisolone-
encapsulated PLGA-based 
nanoparticles 
Kimet al.136 
T9-10 thoracic dorsal 
hemisection injury in adult 
Sprague-Dawley rats 
Local (topical delivery) Lesion volume reduction 
and improved functional 
outcomes (grid and beam 
walking). 
BSA or GDNF-loaded PLGA 
nanoparticles 
Wang et al.137 
T9-10 moderate and 
severe injuries in adult 
Sprague-Dawley rats 
Local (intraspinal) Improved neuronal survival 
and hindlimb locomotion. 
PEGylated silica 
nanoparticles 
Chen et al.138 
Cho et al.139 
Ex vivo compression injury 
in adult Hartley guinea pig 
 
In vivo mid-thoracic crush 
injury in adult Hartley 
guinea pig 
 
 
 
Systemic 
(subcutaneous) 
Selective targeting of injured 
tissue 
Specific targeting of 
damaged tissue 
Reduction in ROS 
production and lipid 
peroxidation 
Nerve impulse re-
conduction 
Chitosan-DNA/ hyaluronic 
acid nanoparticles 
Gwak et al.140 
 
In vitro 
NSC cultures 
Organotypic SC slices 
 
 
Low cytotoxicity and high 
transgene expression 
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Nanocarrier type CNS injury model Administration route Main results 
Poly(methyl methacrylate) 
nanoparticles 
Rossi et al.141 
In vivo T11 laminectomy in 
C57BL/6 mice 
Local (embedded in 
agarose hydrogel) 
Sustained and tunable drug 
release 
FGF2-loaded PLGA 
nanoparticles 
Kang et al.142  
T2 clip compression injury 
in Sprague-Dawley rats 
Local (embedded in 
HAMC hydrogel) 
Enhanced blood vessel 
density in the lesioned area  
SOD and NR1 antibody 
conjugated PBCA 
nanoparticles 
Reukov et al.143 
In vitro primary neuronal 
cultures 
 
 
Control of the composition 
and activity of the NP 
conjugates 
Neuroprotection of the 
neuronal cultures 
Prostaglandin E1-loaded 
PEG-PDLLA nanoparticles 
Takenaga et al.144  
T10 severe contusion 
injury in adult Sprague-
Dawley rats 
Systemic (intravenous) Improved neuroprotection 
and anti-apoptotic action; 
Functional recovery. 
Dendrimers    
Methylprednisolone-loaded 
CMCht/PAMAM dendrimers 
Cerqueira et al.145 
In vitro glia cultures 
In vivo T8 lateral 
hemisection in adult Wistar 
rats 
 
Local (intraspinal) 
Microglia proliferation 
modulation; 
Locomotor improvement 
Polyphenylenevinylene(PPV)-
PAMAM dendrimers 
Rodrigo et al.146 
In vitro primary rat 
cerebellar neuronal 
cultures 
 
 
Non toxic 
Efficient siRNA delivery 
(cofilin-1 gene silencing) 
Anti-H1F1-α siRNA 
carbosilane dendrimers 
Posadas et al.147 
In vitro primary rat cortical 
neuronal cultures 
 
 
High transfection levels 
Selective H1F1 synthesis 
blocking 
Neuroprotective in hypoxia 
conditions 
pBDNF-IRES-hrGFP PAMAM 
dendrimers  
Shakhbazau et al.148 
In vitro human MSCs  
 
Successful transfection and 
expression of BDNF 
Magnetic 
nanoparticles 
   
Iron oxide nanoparticles 
Pal et al.149 
In vitro GMB-U87 cell line 
In vivo T11 complete 
transection in adult Wistar 
rats 
 
Local (embedded in 
agarose hydrogel) 
Low cytotoxicity 
Antioxidant and 
neuroprotective properties 
Lesion volume reduction 
and signifficant functional 
recovery 
Aminosilane-coated iron 
oxide nanoparticles 
Zhizhi et al.150 
In vitro Brain-derived 
microvessel endothelial 
cell line (bEnd.3) 
Primary cortical neurons 
and astrocytes 
 
 
Low toxicity 
Intracellular accumulation 
High biocompatibility 
Superparamagnetic iron 
oxide nanoparticles 
Vanecek et al.151 
 
In vitro MSC cultures 
In vivo T8-9 ballon 
compression lesion in 
adult Wistar rats 
Local (intrathecal, 
nanoparticle-labeled 
MSC transplantation) 
Efficient MSC labeling 
Targeting of the lesion site 
 
Commercial magnetic 
nanoparticles (Chemicell) 
Pinkernelle et al.152  
In vitro cerebellar primary 
cultures 
SC/ fibroblast cultures 
PC12 cell line 
Organotypic co-culture of 
spinal cord and peripheral 
nerve graft 
 
 
Preferential uptake by 
microglia cells 
Differential uptake in PC12 
cells and primary neurons 
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Nanocarrier type CNS injury model Administration route Main results 
Superparamagnetic iron 
oxide nanoparticles 
Lei et al.153  
Spinal cord NSCs cultures 
 
 
 
Successful labeling of NGF-
transfected NSCs 
Micelles    
mPEG-PDLLA micelle 
nanoparticles 
Shi et al.154  
Ex vivo spinal cord crush 
model 
T10 compression injury 
adult Long-Evans rats 
Systemic (intravenous, 
tail) 
No cytotoxicity 
Decreased lesion volume 
and macrophage infiltration 
Improved locomotor 
recovery  
Methylprednisolone-loaded 
PEO-PPO-PEO triblock 
copolymer micelles 
Chen et al.155 
New Zealand adult rabbits 
T10 severe contusion 
injury in adult mice 
Systemic (intravenous) Increased bioavailability 
Anti-apoptotic effects 
Colloidal    
NogoR/ Fc-conjugated gold 
nanoparticles 
Wang et al.156 
In vitro  DRG cultures 
In vivo T10 dorsal 
hemisection injury in 
Sprague-Dawley rats 
 
 
Stimulation of anti-NgR 
production; 
Inhibition of myelin 
inhibitors, promotion of 
axon growth, tissue 
protection and functional 
recovery. 
No detectable toxicity. 
Carbon-based NP    
PEG-functionalized single-
walled carbon nanotubes 
Roman et al.157 
T9 complete transection 
injury in adult Sprague-
Dawley rats 
Local Decreased lesion volume 
Enhanced neurofilament 
and CST positive fibers 
Modest hidlimb motor 
recovery 
 
 
 
Liposomes are unilamellar or multilammelar phospholipid bilayer vesicles comprising an aqueous 
inner core, and have sizes usually around 50 to 100 nm.158 They can be engineered controlling 
lipid composition to possess more fluid or rigid properties, positive or negative net charge, and 
can be further surface functionalized with targeting molecules.159 Due to their similarity to lipid 
membranes, liposomes have remarkable cell penetration and diffusion properties. They have 
been recently examined for use in the management of oxidative stress-induced diseases, by 
intravenous administration of N-acetylcysteyne (NAC) containing dipalmitoylphosphatidylcholine 
(DPPC) liposomes, and no toxicity has been associated to the treatment.160 In another strategy, 
implantation of tacrolimus (TAC) liposomal pellets has been presented as an effective 
immunosupressive DDS that allowed long-term survival of human NSC grafts in healthy and SCI 
rats.161 As nanocarriers for the injured spinal cord, liposomes have been tested both as drug or 
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DNA delivery agents in animal models of the injury. Local administration of hydroxycamptothecin 
in laminectomized rabbits has significantly reduced the subsequent fibrosis and epidural 
adhesion.131 Iannotti et al., in turn, have investigated the effect of systemic administration of 
clodronate-loaded liposomes in contused rats and verified that the treated animals presented 
improved tissue sparing and limb functional recovery, due to enhanced neuroprotection.133 
Additionally, functionalization of liposomes with the cell penetrating peptide TAT (Figure 5) has 
allowed efficient transport of these nanocarriers along the BSCB.162 Moreover, this TAT-liposomes 
tend to accumulate at the lesion site which can be helpful in therapeutic applications.132 Finally, 
intrathecal injection of DNA-loaded loaded liposomes in a sciatic nerve constriction model has 
shown suppression of pain-relating behavior in rats, proving successful gene delivery.134 
 
 
Figure 5 – A. Schematic illustration of the TAT-PEG liposomes/magnetic NPs used by Wang et al. B. A 
transmission electron microscopy (TEM) image shows the nanostructure of the TAT-PEG liposomes/ 
magnetic NPs.162 
 
  
Polymeric nanoparticles have been produced from a variety of materials, either natural-based or 
synthetic materials. Natural-based nanoparticles are mainly derived from proteins (e.g., silk,163 
collagen,164 and albumin165) or polysaccharides (e.g., chitosan,166 alginate,167 and heparin168). The 
use of natural-based nanoparticles is based on the lower immunogenicity of these molecules that 
leads to enhanced biocompatibility, associated with the possibility of nanoparticle biodegradation 
and clearance by the organism. However, the increasing control in the synthesis of polymers is 
allowing the design of more sophisticated systems, with the ability to mimic some of the natural 
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biopolymers.169 Some of the most common synthetic polymers under investigation for their 
therapeutic properties are poly(ethylene glycol) (PEG), poly(lactic acid) (PLA), and poly (lactic 
acid-glycolic acid) (PLGA).170 PEG is a polyether that is very often covalently attached to the 
surface of nanoparticles since PEGylation grafting masks the nanoparticle from the host immune 
system, reducing potential immunogenicity, and also increases the nanoparticle hydrodynamic 
size which confers longer circulation times to the molecules.171 Systemic administration of 
PEGylated silica nanoparticles in spinal cord crushed guinea pig models, has revealed low 
immunogenicity, as well as preferential targeting for the damaged tissue, with further reduced 
ROS production and lipid peroxidation.139 Drug encapsulated synthetic nanoparticles have also 
been tested in animal models of SCI. Methylprednisolone and GDNF were incorporated in PLGA 
nanoparticles and administered locally in the lesion site, as represented in Figure 6, both 
resulting in improved functional recovery.136 137 A general approach that has been recently tested 
in nanoparticle drug delivery to the spinal cord is the embedding of the trophic-factor loaded 
nanoparticles in hydrogels and implantation of the material in the lesion area, since most 
hydrogels can be produced as injectable materials.172 Hydrogels are biodegradable water-swollen 
polymers that can be designed with tissue-like properties.173 These systems can be natural or 
synthetic-based and used for the controlled and sustained release of factors locally in vivo. Rossi 
et al. have tested the embedding of poly(methyl methacrylate) (PMMA) nanoparticles in an 
agarose gel and following implantation in mice subjected to a laminectomy, the tunable and 
sustained drug release in the injury site has been confirmed.141 A different study with growth 
factor FGF-2-loaded PLGA nanoparticles included in a hyaluronan/methyl cellulose (HAMC) 
hydrogel has revealed enhanced blood vessel density in a rat compression injury model, 
suggesting beneficial effects of the FGF-2 release.142 As for natural-based polymeric nanoparticles, 
chitosan nanoparticles have been widely used for these applications.174 DNA-loaded 
chitosan/hyaluronan nanoparticles have been tested in NSC cultures and organotypic spinal cord 
slices, revealing in both cases low cytotoxicity and high transgene expression.140 In in vivo 
compression models, Chen et al. have also described restoration of nerve impulse transmission 
and membrane sealing occurrence following chitosan nanoparticle administration.135 
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Figure 6 - Methylprednisolone-encapsulating PLGA nanoparticles (MP-NP) for hydrogel inclusion and SCI 
implantation. A. A SEM image of the lyophilized MP-NPs. Scale bar = 1 μm. B. Schematic of topical and 
local delivery of the MP-NPs onto dorsal hemisection lesioned spinal cord.136  
 
Magnetic nanoparticles are spherical nanocrystals of about 10 to 20 nm with an iron core and 
they have been traditionally used for imaging, due to their intrinsic magnetic properties.175 The 
recent possibilities of nanoparticle functionalization have also applied to magnetic nanoparticles 
thus broadening its range of applications, namely as targeted DDS. Pal et al. have investigated 
the potential of iron oxide magnetic nanoparticles in vitro and in spinal cord complete transected 
rats, embedding the nanoparticles in an agarose gel.149 The authors have reported interesting 
intrinsic antioxidant and neuroprotective properties, associated with low toxicity profiles and 
lesion volume reduction. Furthermore, significant functional recovery has also been reported from 
the same study, supporting the therapeutic potential of these magnetic nanoparticles. Other 
studies, using aminosilane-coated iron oxide nanoparticles and super-paramagnetic nanoparticles 
(Figure 7) have also demonstrated efficient targeting of the lesion and high biocompatibility in 
vitro in endothelial and cortical cell cultures.150,151 
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Figure 7 - Magnetic resonance signal of superparamagnetic iron oxide NP-labeled MSCs in SCI animals: 
in a magnet group after intrathecal application (A), in contrast to the non-magnet group (D). Intense 
Prussian blue staining (B) co-localized with the GFP signal (C) in the area under the magnet. Cell nuclei 
are stained with DAPI (blue) (C and F).151 Scale bars = 100 μm. 
 
One of the most recently developed nanoparticle types are dendrimers, which possess unique 
branched and spherical architecture, and form a new class of polymers after the classical linear, 
crosslinked and branched polymers.176 Dendrimers can be synthesized in a defined manner, with 
precise control over its molecular weight, branching structure and composition, while allowing 
several additional surface modifications.177 Due to its structural similarities with proteins, 
dendrimers are sometimes referred to as “artificial proteins”. Their multiple functionalization 
possibilities, associated with high drug payloads and monodispersity are making them attractive 
molecules for use in biomedical and pharmaceutical applications.178 For CNS applications, 
dendrimers have mainly been proposed as gene delivery carriers. For instance, siRNAs have 
been incorporated in polyphenylenevinylene (PPV)-poly(amidoamine) (PAMAM)  and carbosilane 
dendrimers and tested in primary neuron cultures with successful gene silencing and no 
associated cytotoxicity.146,147 Shakhbazau et al., in turn, have coupled a BDNF plasmid to PAMAM 
dendrimers and tested the transfection rates in human bone marrow MSC cultures, envisioning a 
BDNF-secreting MSC transplantation strategy following neural system injuries.148 The results have 
indicated successful transfection and expression of the neurotrophic factor, suggesting a safer 
method than viral approaches to engineer autologous stem cells to produce relevant factors. 
Oliveira et al., have recently focused on the application of a non-toxic carboxymethylchitosan 
(CMCht) grafted PAMAM dendrimer (Figure 8) for neurotrauma therapies as an intracellular drug 
nanocarrier.179 The successful incorporation of MP into the nanoparticles has proven to be 
beneficial following hemisection in rat models, originating functional improvements.145  
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Figure 8 – A. Structural representation of MP incorporation and FITC conjugation to CMCht/PAMAM 
dendrimer nanoparticles. B. Intracellular retention of FITC-labeled MP-loaded CMCht/PAMAM dendrimer 
nanoparticles in primary glial cultures.145 
 
Moreover, a multifunctional dendrimer has also been designed and produced coupling the MP-
loaded dendrimers with an antibody that conferred altered uptake in primary glial cultures.180 With 
this strategy, the enhanced use of a classical drug in SCI is proposed, maximizing its beneficial 
actions in glial cells following injury. Moreover, a targeted delivery to the injury site is expected to 
eliminate the deleterious side effects provoked by systemic high dosage administration. 
As herein presented, significant advances in therapeutics are expected to continue to occur 
derived from nanotechnology progress; nonetheless, particular attention should also be given to 
the toxicology of nanoparticles. When materials are used as nanoformulations, may present 
different toxicological profiles than the bulk materials.181 Although routine assays are currently 
performed evaluating in vitro and in vivo nanoparticle toxicity, and emphasizing on 
pharmacokinetics and distribution, long-term studies should also be considered to assess 
potential chronic toxicity.  
 
6. Conclusions and future perspectives 
 
The advent of nanotechnology brought a whole new range of possibilities in biomedical 
engineering, bringing improved means of therapeutics, imaging and diagnostics, which can even 
be combined in a single system. The possibility to design nano-polymers to attain desired 
properties and functions and be able to enter the organism, execute a determined action and exit 
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whenever the task is completed is making R. Feynman suggestion of “swallowing the surgeon” a 
reality. The complexities of the events that follow SCI, both at the cellular and molecular levels, 
associated with the presence of BSCB, have been hindering the successful establishment of an 
effective treatment for SCI. However, tissue engineering and nanotechnology recent advances are 
enabling the development of more complex approaches that are bringing new hopes for SCI 
repair. Most of the nanoparticle-based systems that have been herein described enclose multiple 
functionalities, such as: (i) drug/gene incorporation; (ii) surface grafting to confer enhanced 
biocompatibility, penetration and/or targeting; and (iii) imaging properties. For SCI applications, 
nanoparticles have been recently pointed out as systems that have the potential to effectively act 
on the modulation of the harsh secondary injury environment, providing a more suitable 
environment for successful nerve regeneration and tissue repair to occur. 
Given its intrinsic properties, magnetic nanoparticles have been mainly investigated as imaging 
agents contributing to the identification and in vivo tracking of relevant cells with demonstrated 
therapeutic potential. Liposomes, as drug and gene nanocarriers, have shown some interesting 
improvements in SCI animal models, both with local or systemic administrations. 
Notwithstanding, a more recent class of nanoparticles has brought additional advantageous 
properties for theranostics prospective uses. Dendrimers display superior drug payloads and 
control over its structure, along with further functionalization possibilities. The use of a PAMAM 
dendrimer grafted with CMCht has shown superior loading capability and therapeutic properties 
when loaded with MP. Additionally, high transfection efficiency has also been described using 
PAMAM dendrimers. Conjugation of multiple functionalization in the same nanoparticle system, 
have tremendous potential for strategies envisioning combined actions in damaged areas. For 
instance, inclusion of a cocktail of relevant factors in a nanoparticle system targeting the 
modulation of glial cell activity or transplanted cells, in a specific and differential manner, may 
finally bring exciting and reasonable hopes in the management of such a complex ailment as SCI. 
Although more exhaustive investigations are needed regarding nanoparticle administration for SCI 
repair, namely analysis of intracellular trafficking and clearance routes, as well as long-term 
toxicity studies, these newly developed strategies are bringing promising hopes for the 
development of an effective therapy for neurotrauma.  
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CHAPTER II 
Materials and methods 
The main aim of this chapter is to describe the experimental work and protocols used in the 
scope of this thesis and related to the obtained results, which will be provided in more detail in 
Section 3. Along with Chapter I, it aims to provide the reader a more comprehensive overview of 
the experimental and analytical tools used, as well as the rationale behind its use. 
 
1. Materials 
1.1. Poly(amido)amine dendrimers 
Poly(amido)amine (PAMAM) dendrimers are the most common class of dendrimers and are used 
nowadays for several biotechnology applications.1 Dendrimers were first described in 1978, 
introducing a new class of nanoscale synthetic polymers with branched spherical architectures, 
inspired in nature (dendron is the greek word for tree).2 These molecules present an extremely 
precise and controlled structure, and therefore have tuneable sizes and molecular weights, with 
further functionalization possibilities. 
 
Figure 1 - Structures of generations 1.5 to 3 poly(amidoamine) dendrimers.  
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The typical dendrimer structure comprises three main parts: the inner core that ramifies in 
branching units and eventually ends in external capping groups.3 To each layer of the branching 
units it is attributed the designation of generation (G). The PAMAM dendrimers consist of an alkyl-
diamine core with tertiary amine branching units. It is commercially available and the PAMAM 
dendrimers used throughout this work were obtained from Sigma, USA. 
 
1.2. Chitosan and its derivative carboxymethylchitosan 
 
Chitin and chitosan (Cht) are interesting macromolecules for biomedical uses; however, they 
present some limitations due to its poor water solubility. Some chemical modifications in the 
chitosan structure can be performed in order to overcome this, and taking advantage of its 
reactive functional groups (e.g., amine -NH2 and hydroxyl -OH) the degradation profile can be 
controlled, thus broadening its range of applications.4 Modification of Cht structure has been 
done introducing acetyl, carboxymethyl, sulfuryl or phosphoryl groups, among others.5 
Carboxymethylchitosan (CMCht) is a water-soluble biomacromolecule derived from deacetylation 
and insertion of carboxylic groups in Cht (Figure 2). CMCht is soluble in a wide range of pH and 
its properties, namely low toxicity and antimicrobial activity, are attractive in medical and 
pharmaceutical areas, mainly for the controlled release of drugs.5 
 
Figure 2 - Schematic representation of chitosan (A), and carboxymethylchitosan (B) molecular structure. 
 
For the purpose of this thesis, reagent grade chitosan particles with a degree of deacetylation 
(DD) of ≈91% were used for the preparation of CMCht. The methodology used has been 
previously reported by Chen et al.6 Succinctly, chitosan was dissolved in 40% sodium hydroxide 
(NaOH, Sigma, Germany) solution at room temperature for 1 hour. Then, monocloroacetic acid 
(ClCH2COOH, Sigma, Germany) was added into the reaction vessel drop-wise and let react for 2 
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hours, in a water bath at 60ºC. The reaction was stopped by adding 70% ethanol and the 
resulting pellet ﬁltered and rinsed in sequential 70 to 90% ethanol. Finally, the H-form of CMCht 
was obtained by re-suspending the filtrate in 80% ethanol solution and 37% hydrochloric acid 
(HCl, Sigma, Germany) for 30 minutes, under agitation. New filtration was performed followed by 
de-hydration. CMCht was obtained by freeze-drying at -80ºC (Telstar-Cryodos -80, Spain). CMCht 
with a DD of 80% and a degree of substitution (DS) of 47% was used for the surface modification 
of the dendrimers, as previously reported.7 
 
1.3. Methylprednisolone 
 
Methylprednisolone (MP) is a synthetic corticosteroid drug clinically used for its potent anti-
inflammatory and antioxidant properties.8 MP is currently recommended for use in a variety of 
CNS disorders involving white matter injuries, such as spinal cord injury (SCI) and multiple 
sclerosis (MS).9 Nonetheless, its use has been shown to be highly unspecific, leading to a series 
of undesired side effects in patients following intravenous administration, such as gastric 
bleedings and pneumonia.10 Therefore, the blurred balance between the benefits and drawbacks 
of MP administration has led some clinicians to abandon its use. In fact, its precise mechanisms 
of action are still being uncovered and it is becoming clearer that according to the target cell MP 
exerts differential effects.11 
 
Figure 3 - Schematic representation of the methylprednisolone molecule. 
 
1.4. Reagents 
 
Chemicals used for the synthesis and purification of CMCht, CMCht/PAMAM dendrimer 
nanoparticles as well as their processing and characterization, were bought from the following 
companies: Fluka (Slovakia), Merck (Germany), Panreac (Spain), Pronalab (Portugal), Riedel-de 
Haën (Germany) and Sigma (Germany). 
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2. Nanoparticle synthesis and functionalization  
 
2.1. Dendrimer nanoparticle synthesis: overview 
 
Dendrimer synthesis has been suggested through two alternative methodologies: the divergent 
and the convergent synthesis. The divergent method has been described by Tomalia et al.,12 and 
it involves the in situ assembly of each branching unit in a step-by-step manner around the 
central core (Figure 4A). In the convergent approach, developed by Fréchet and colleagues, the 
building blocks are first prepared (as dendrons) and afterwards put together from the outside to 
the core (Figure 4b).13 
 
A. 
 
 
 
B. 
 
Figure 4 – Schematic representation of the divergent (A) and convergent (B) synthesis approaches.  
 
In this thesis, the dendrimer nanoparticle systems were obtained following the divergent route, 
expanding a PAMAM G1.5 dendrimer to a PAMAM G3 molecule.14 The drug delivery systems 
(DDS) were herein produced for applications in CNS tissue repair, namely for spinal cord injury 
drug delivery. 
 
2.2. Carboxymethylchitosan/poly(amido)amine dendrimer nanoparticles 
 
In the present thesis we applied a nanoparticle system with novel capabilities and performance 
for CNS drug delivery purposes. Investigation of this system applicability should address 
concurrently: (i) the prevention of opsonization or early NP clearance; (ii) the ability to enter cells 
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and cross biological barriers, such as the BBB; (iii) intracellular trafficking of the nanostructures; 
(iv) toxicity assessment, both in vitro and in vivo; (v) in vivo biodistribution; and (vi) the 
therapeutic activity of the DDS. The techniques herein described were used with the aim of 
evaluating these parameters, allowing a relevant and complete understanding of the developed 
DDS. In the herein presented approach, surface grafted amine-terminated PAMAM dendrimers 
with water-soluble CMCht were produced in order to neutralize the amine groups of PAMAM, 
which have been described to be accountable for some toxicity.15,16 
 
2.3 CMCht/PAMAM dendrimer nanoparticle synthesis 
 
For the surface modification of the PAMAM dendrimers, CMCht with a DD of 80% and DS of 47% 
was used. Starburst® poly(amido)amine-carboxylic terminated dendrimers (PAMAM-CT) 
(generation 1.5, 20% (w/v)) in a methanolic solution with an ethylenediamine core were 
purchased (Sigma, Germany). CMCht/PAMAM nanoparticles were prepared in a step-by-step 
method starting with the increase of the PAMAM-CT G 1.5 to a G 3 dendrimer. To achieve this, 
the methanol was evaporated from the PAMAM dendrimers under nitrogen gas to completely 
remove it. The remaining compound was re-dissolved in ultra-pure water to a final concentration 
of 10 mg.mL-1, and the pH was adjusted with HCl to 6.5. Afterwards, 1-ethyl-3(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC, Fluka, Slovakia) was added to the 
solution to modify the carboxylate residues. The reaction was let occur for 30 minutes at room 
temperature (RT) and under agitation. Following this, ethylenediamine (EDA, Sigma, Germany) 
was added and let react for 4 hours. The exceeding EDC was removed by dialysis in ultrapure 
water using a cellulose tubing (benzoylated for separating compounds with a molecular weight of 
≤1,200, Sigma, Germany). The obtained amine-terminated PAMAM dendrimers (PAMAM-AT) 
were mixed with methanol (Sigma, Germany) and methyl methacrylate (Fluka, Germany) and 
kept under agitation in a water bath at 50ºC for 24 hours, to perform alkylation of its primary 
amines (Michael addition).12 Finally, in order to perform a condensation reaction between the 
CMCht and the PAMAM groups, hydrochloric acid (HCl, Panreac, Portugal) and trifluoroacetic 
acid (TFA, Sigma, Germany) were added to the solution. Meanwhile, 1 g of CMCht was dissolved 
in 50 mL of water. The PAMAM methyl esther terminated dendrimers were dissolved in a 20/80 
water/methanol solution and the CMCht was added and kept under agitation for 72 hours, after 
which the CMCht/ PAMAM dendrimer nanoparticles with carboxylic-terminated groups were 
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obtained. The nanoparticles were then precipitated with the addition of an appropriate volume of 
a saturated sodium carbonate (Na2CO3, Sigma, Germany) solution and acetone (Pronalab, 
Portugal). CMCht/PAMAM dendrimer nanoparticles were obtained by freezing the solution at -
80°C and freeze-drying (Telstar-Cryodos -80, Spain) for 5 days, until the solvent was completely 
removed. 
 
2.4. Incorporation of methylprednisolone into CMCht/PAMAM dendrimer nanoparticles 
 
The corticosteroid MP was physically incorporated into the CMCht/PAMAM dendrimer 
nanoparticle branches. Firstly, CMCht/PAMAM dendrimer nanoparticles were mixed with an 
ethanolic MP solution in a final concentration of 5x10-4 M (w/w) under agitation. The mixture was 
then added to precipitation media consisting of a saturated Na2CO3 (Sigma, Germany) and 
acetone (Pronalab, Portugal) solution, under vigorous agitation. Precipitates were collected by 
filtration and dispersed in ultrapure water for dialysis against ultrapure water (cellulose tubing, 
benzoylated for separating compounds with a molecular weight of ≤1,200, Sigma, Germany) 
during 48 hours. MP-loaded CMCht/PAMAM dendrimer nanoparticles were obtained by freezing 
the solution at -80°C and freeze-drying (Telstar-Cryodos -80, Spain) until the solvent was 
completely removed. 
 
2.5. Labeling CMCht/PAMAM dendrimer nanoparticles with fluorescein isothiocyanate  
 
In order to track the intracellular localization of the NPs, conjugation with a fluorescent probe was 
performed. A derivative of fluorescein was used to label the NPs, fluorescein isothiocyanate 
(FITC, Sigma, Germany). FITC-labeled dendrimer nanoparticle conjugates were prepared by 
covalently bonding the amine group of CMCht and the isothiocyanate group from FITC. To 
perform the reaction, a 10 mg.mL-1 FITC solution was prepared in dimethyl sulfoxide anhydrous 
(DMSO, Riedel-de Haen, Germany) in the dark. Concurrently, a 10 mg.mL-1 CMCht/PAMAM 
dendrimer nanoparticle solution was prepared in a carbonate/bicarbonate coupling buffer (pH 
9.2) and 50 L of FITC/DMSO solution were added per each mL of CMCht/PAMAM dendrimer 
nanoparticle buffered solution, under agitation. The resulting solution was kept in the dark at 4ºC 
for 8 hours. The obtained FITC-labeled CMCht/PAMAM dendrimer nanoparticle solution was then 
dialyzed against ultra-pure water (cellulose tubing, benzoylated for separating compounds with a 
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molecular weight of ≤1,200, Sigma, Germany) for 48 hours in order to remove unbonded FITC 
molecules. The final product was obtained by freezing the solution at -80°C and freeze-drying 
(Telstar-Cryodos -80, Spain) for 5 days, until the solvent was completely removed. 
 
 
Figure 5 - Chemical structure of the FITC molecule. 
 
2.6. Surface functionalization with CD11b antibody 
 
One of the most exciting features of nanoparticles in drug delivery is the possibility to design a 
DDS that can act specifically in a certain cell type or tissue, for instance. The drug delivery 
efficiency would subsequently be maximized while unwanted side reactions in other tissues would 
be significantly lessened.17 To assess the possibility of functionalization of CMCht/PAMAM 
dendrimer NPs with a targeting agent that might confer altered uptake, we performed a 
crosslinking reaction with an antibody. Along with other moieties, such as low molecular weight 
molecules, peptides, proteins, polysaccharides, DNA and plasmids, antibodies have been 
suggested to confer selectivity in NP uptake.18 Antibodies, also known as immunoglobulins (Ig), 
are recognition proteins used as part of the immune system to specifically identify and neutralize 
foreign bodies in the organism. Antibodies identify a distinctive part of the foreign body, called 
antigen, to which they bind with high affinity (Figure 8). 
 
Figure 6 - Structural representation of an antibody and its main parts. 
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In order to conjugate anti-mouse CD11b antibody (BD Biosciences, USA) which identifies 
microglial cells to the dendrimer nanoparticles a crosslinking reaction was performed.19 A 20 
mg.mL-1 solution of nanoparticles in phosphate buffered saline (PBS, pH 7.4) was mixed with 1 
mg.mL-1 of 1-ethyl-3(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC, Fluka, Slovakia) 
and let react for 30 minutes at RT. The remaining solution was dialysed against ultrapure water 
(cellulose tubing, benzoylated for separating compounds with a molecular weight of ≤1,200, 
Sigma, Germany) for 24 hours to remove the excess EDC. Afterwards, the pH was corrected to 
7.4 and the 4 nmol of CD11b antibody were added under agitation. The crosslinking reaction 
was let occur for 1 hour, after which the solution was frozen at -80ºC and freeze-dried (Telstar-
Cryodos-80, Spain) for 5 days, until the solvent was completely removed. 
 
3. Physicochemical characterization techniques 
 
3.1. Scanning-transmission electron microscopy 
 
The morphology and average diameter distribution of NPs were investigated under a scanning-
transmission electron microscope (Nova™ NanoSEM 50 series, FEI Company, The Netherlands). 
Conventional electron microscopy allows examination of the samples via a beam of electrons that 
either scan the surface of the sample (scanning electron microscope, SEM) or are transmitted 
through it (transmission electron microscope, TEM) providing high magnification detailed images 
of its morphology.20 Novel advanced electron microscopy techniques, especially scanning 
transmission electron microscopy (STEM) techniques are becoming indispensable for 
characterizing nanosystems. STEM microscopes present higher versatility, with atomic resolution 
imaging, diffraction patterns and spectroscopy data being obtained simultaneously or sequentially 
by this method from the same region of the specimen.21 STEM is therefore considered one of the 
most powerful microscopy techniques for use in the physicochemical characterization of 
nanosystems. To have high resolution images of the nanoparticles produced during this work, 
lyophilized NPs were dispersed in ultrapure water to a final concentration of 1 mg.mL -1, stained 
with 1% phosphotungstic acid and placed on copper grids for further observation. 
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3.2. Fourier-transform infra-red spectroscopy 
 
Fourier-transform infra-red (FTIR) analysis allows to determine the presence of functional groups 
in organic molecules in a non destructive manner by registering the vibrational spectra of the 
compounds.22 It is a spectroscopic technique in which a beam containing the selected 
frequencies is pointed out to a pellet containing the specimen and a measure of the absorption at 
each frequency is made, resulting in specific spectra for each compound analyzed.23 To validate 
the synthesis of CMCht/PAMAM dendrimer NPs, as well as the MP incorporation and antibody 
bonding, the obtained spectra for each sample were analyzed. Transparent potassium bromide 
(KBr) pellets were prepared by mixing in the sample in KBr, and the analysis was performed 
using a Perkin-Elmer spectroscope (Perkin-Elmer 1600 series equipment). All transmission 
spectra were recorded in the region of 4400-450 cm-1, using a minimum of 32 scans and a 2 cm-
1 resolution. 
 
3.3. Nuclear magnetic resonance spectroscopy 
 
Nuclear magnetic resonance (NMR) is a physical phenomenon that occurs when the nuclei of 
certain atoms absorb and re-emit electromagnetic radiation.24 Some nuclei experience this 
phenomenon depending upon whether they possess a property called spin. 1H NMR is the 
application of nuclear magnetic resonance spectroscopy with respect to hydrogen nuclei within 
the molecules of a compound and allows the resolution of the structure of organic compounds. 
Unlike other NP characterization techniques, such as electron microscopy, it does not require 
sample preparation with the risk of causing artifacts or sample deterioration.25 Moreover, NMR 
spectroscopy renders simultaneous information on the chemical composition as well as the 
molecular mobility of components in a complex non-homogenous mixture. In this thesis, 1H NMR 
analysis of the CMCht/PAMAM, MP-loaded CMCht/PAMAM, FITC-labeled CMCht/PAMAM and 
CD11b antibody-conjugated CMCht/PAMAM dendrimer NPs was carried out in order to confirm 
the performed functionalization. For this purpose, NPs were dissolved in deuterated water (D2O) 
and the 1H NMR spectra were obtained in a Varian Unity Plus spectrometer at 300 MHz and 
20ºC. The one-dimensional 1H spectra were acquired using a 45° pulse, a spectral width of 6.3 
kHz and an acquisition time of 2.001 seconds.  
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3.4. Zeta potential and particle size analysis 
 
Zeta potential and particle size of the CMCht/PAMAM dendrimer nanoparticles and MP-loaded 
CMCht/PAMAM dendrimer nanoparticles were measured in a particle size analyzer (Zetasizer 
Nano ZS, Malvern Instruments, UK). The zeta potential is calculated by determining the 
electrophoretic mobility, which is obtained by performing an electrophoresis experiment on the 
sample and measuring the velocity of the particles using a Laser Doppler Velocimetry (LDV).26 
Zeta potential has proven to be a central index which reflects the intensity of repulsive forces 
among the NPs, and consequently its stability when dispersed in solution.27 Studies have shown 
that zeta potential depends on the chemical composition of the NPs, the surrounding solvent, the 
pH of the media and the ions in the suspension.28 Electrophoretic determinations of zeta potential 
were investigated using the universal ‘dip’ cell, at pH 5.0; 7.4 and 10.0, in citrate buffer, 
phosphate buffered saline (PBS) and bicarbonate buffer solutions, respectively. 
Using the same equipment, diameter determinations were made using dynamic light scattering 
(DLS). DLS utilizes time variation of scattered light from suspended particles under Brownian 
motion to obtain their hydrodynamic size.29 It is a reliable technique that has been used to 
measure macromolecules and small particles in dilute suspensions. Thus, for the present study, 
particle size analyses were performed using the DLS technique. The analyses were carried out in 
different aqueous solutions (PBS pH 7.4; citrate buffer pH 5.0; and bicarbonate buffer pH 10.0) 
with low concentration of nanoparticles and using disposable sizing cuvettes. 
 
3.5. High performance liquid chromatography 
 
High performance liquid chromatography (HPLC) is an analytical technique used to identify, 
quantify and purify the individual components of a solution. The compounds are separated 
passing through a column at different rates due to differential affinity and interaction of the 
mobile phase (comprising the sample) and the stationary phase of the column.30 The MP release 
from the NPs was quantified using HPLC (Knauer Smartline, Germany), with an UV detector set 
at 250 nm. The mobile phase consisted of acetonitrile:ammonium phosphate buffer (0.1 M, pH 
4.6) (50:50 v/v) at a flow rate of 1 mL.min-1. MP release was studied after dissolution of 10 mg 
of MP-loaded CMCht/PAMAM dendrimer nanoparticles in 10 mL of PBS (pH 7.4, Sigma, USA) 
solution. Simultaneously, the absence or presence of 15% fetal bovine serum (FBS) was also 
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tested in order to assess protein interaction in the drug release rates. To avoid external biological 
contaminations sodium azide 0.01% (w/v) (Sigma, Germany) was added to the buffer solutions. 
The in vitro release studies were performed at 37C and 60 rpm for times ranging from 1 hour to 
14 days. At set time intervals, 1 mL of sample was collected for analysis and the same volume 
replaced by the respective buffer solution. Prior analysis, samples were centrifuged at 2,000 rpm 
for 10 minutes. A solution with sample:acetonitrile:ammonium phosphate buffer (50:25:25, v/v) 
was prepared for further analysis. A C18 analytical column (Atlantis T3, Waters, USA) was used. 
The MP retention time was approximately 3 minutes. A calibration curve was acquired preparing 
relevant standard solutions. 
 
4. Primary cell isolation and culture establishment 
 
Cell culture studies are a fundamental step in biotechnological product evaluation before in vivo 
testing, particularly if biomedical applications are envisioned. Frequently, in vitro studies in cell 
culture models of neuropathologies are used to test possible therapies, namely for brain tumor,31 
neurotrauma,32 and neurodegeneration.33 Particular focus has also been given recently to 
modelling the BBB in vitro cell trafficking and substance permeability studies.34 In this thesis, 
fresh primary cultures were used in an attempt to more closely mimic the in vivo conditions and 
generate physiologically relevant data. In order to assess the NP effect on cell viability and its 
uptake profile, mixed glial cell cultures were established. Further purification of these cultures 
was executed to obtain pure microglia and astrocyte cultures, allowing the assessment of 
intracellular MP action and NP intracellular trafficking, respectively. Additionally, Schwann cell 
(SC) and dorsal root ganglia neuron (DRGN) cultures were done to verify the NPs effect on the 
SCs ability to myelinate DRGN axons. All the cultures were derived from Wistar or Fischer rats. 
Animal handling and experiments were conducted in accordance with the guidelines for the care 
and handling of laboratory animals in the Directive 2010/63/EU of the European Parliament and 
Council. 
 
4.1. Primary cultures of cortical glial cells 
 
Cortical glial cells were isolated from P4 newborn Wistar rats. Upon careful dissection to remove 
the skin and the skull, the cortices were collected and maintained in ice-cold Hanks’ balanced 
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salt solution (HBSS, Gibco, USA) to be mechanically dissected. Afterwards, the cortical fragments 
were incubated in an enzymatic medium of 30 mg.mL-1 DNAse solution (Sigma, Germany) with 
0.25% trypsin (Sigma, Germany) in Ca2+/Mg2+ free HBSS solution for 30 minutes at 37ºC. The 
trypsin reaction was blocked adding 40% foetal bovine serum (FBS, Gibco, USA) and the resulting 
tissue was centrifuged at 800 rpm for 2 minutes. Glial cells were then plated out on coverslips 
previously coated with poly-L-lysine (Sigma, USA) at a density of 4x104 cells.cm-2. Cells were 
maintained for one week at 37ºC in 5% CO2, in Dulbecco’s modified Eagle’s medium (DMEM, 
Gibco, USA) supplemented with 1% antibiotic (A/B) and 10% fetal bovine serum (FBS, Gibco, 
USA) with periodical media renewal. All the procedure was performed under aseptic conditions. 
These mixed cultures are constituted mainly by astrocytes, followed by microglia and 
oligodendrocytes. Therefore, these cell types are representative of the environment that 
surrounds neurons in the CNS. The glial cultures were used to assess the NP influence in these 
cells viability and also to have an uptake profile of the NP in each cell type. 
 
 
Figure 7 - Primary cultures of cortical glial cells. Immunocytochemistry was done for astrocytes (GFAP), 
microglia (CD11b) and oligodendrocytes (O4), respectively. 
 
4.2. Primary cultures of microglial cells 
 
Microglia cultures were purified from the mixed glial cell cultures. A physical separation is on the 
basis of this isolation procedure, since microglial cells are known to grow on top of astrocytes 
and can be isolated by physical separation without trypsinization. Consequently, after the 
isolation procedure glial cells were plated out at a density of 1×106 cells.cm-2 in polystyrene T75 
flasks (Thermo Scientific, USA) previously coated with poly-L-lysine (Sigma, USA). The glial 
primary cultures were kept at 37ºC in 5% CO2, in DMEM (Gibco, USA) supplemented with 1% A/B 
and 10% FBS (Gibco, USA) for two weeks, with periodical media renewal. After this period, the 
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cell flasks were agitated in an orbital shaker at 240 rpm during 4 hours at 37ºC. Following this, 
the medium containing detached microglia cells was collected, centrifuged at 800 rpm for 5 
minutes and the pellet re-suspended in DMEM medium (Gibco, USA) and plated out at a density 
of 4×104 cells.cm-2. Microglial cell primary cultures were then maintained at 37ºC in a 5% CO2 
atmosphere, in DMEM medium (Gibco, USA) supplemented with 10% FBS (Gibco, USA) and 1% 
A/B (Sigma, USA) for 3 days for further testing. All the procedure was performed under aseptic 
conditions. The purity of these cultures was verified by immunocytochemistry with CD11b 
antibody and proved to be superior to 95%. The microglial cell cultures were herein used to 
assess the intracellular action of MP, while being intracellularly released from the NPs. 
 
4.3. Primary cultures of astrocytes 
 
For astrocyte isolation, the same concept of microglial isolation was on the basis of astrocyte 
purification. After microglial cell detachment and discarding pure cultures of astrocytes were 
obtained. The isolated glial cells were plated out at a density of 1×106 cells.cm-2 in polystyrene T75 
flasks (Thermo Scientific, USA) previously coated with poly-L-lysine (Sigma, USA), and kept at 
37ºC in 5% CO2. The cultures were maintained in DMEM (Gibco, USA) supplemented with 1% A/B 
and 10% FBS (Gibco, USA) for two weeks, with periodical media renewal. After this period, the 
cell flasks were agitated in an orbital shaker at 240 rpm during 4 hours at 37ºC, after which the 
media was discarded. The remaining cells from the agitation procedure were grown in high 
glucose DMEM and supplemented with 10% FBS (Gibco, USA), 2 mM L-glutamine (Sigma, 
Germany), 1 mM sodium pyruvate (Sigma, Germany) and penicillin/streptomycin (Sigma, 
Germany). The cultures were kept at 37°C and 95% air and 5% CO2. The astrocytes were then 
sub-cultured onto 22 mm diameter poly-L-lysine (Sigma, USA) coated glass coverslips at low 
densities. All the procedure was performed under aseptic conditions. These cells were used in 
electrophysiological membrane capacitance readings for investigation of endocytosis/exocytosis 
frequency following NP incubation. Moreover, confocal imaging of live astrocytes was also 
performed. 
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4.4. Primary cultures of Schwann cells 
 
Schwann cells (Figure 8) were obtained from sciatic nerves of adult female Fischer rats. Upon 
dissection, the sciatic nerves were cut into small 1-2 mm pieces and incubated in DMEM-F12 
(Gibco, USA) with 10% FBS (Gibco, USA) and 1% A/B (Gibco, USA) onto uncoated culture dishes. 
The cultures were kept at 37°C and 95% air and 5% CO2. Every week the nerve segments were 
transferred to new 35 mm dishes until, after 3 weeks in culture, the nerve segments, essentially 
depleted from fibroblasts, were mechanically and enzymatically dissociated with collagenase 
solution (320 U, Sigma, Germany) containing 5 U.mL-1 DNase (Worthington, UK).  
 
Figure 8 - Primary cultures of rat Schwann cells, with the nuclei stained with Hoescht (blue), 
and SCs labeled with GFAP (red) (10x). Scale bar represents 100 µm. 
 
Cells were then transferred to new dishes for SC expansion in the presence of mitogens: 20 
µg/mL bovine pituitary extract (Gibco, USA) and 2 µM forskolin (Sigma, Germany). SC purity was 
between 95 and 98%. All the procedure was performed under aseptic conditions. The obtained 
SCs were used for NP biocompatibility assessment and also for co-culturing with DRGN to 
evaluate the SC myelinating capacity in the presence of NPs. 
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4.5 Dorsal root ganglia neurons 
 
The DRGs were dissected from embryonic day 15 Fischer rats and incubated in trypsin 
(Worthington Biochemical Corporation, USA). Trypsin activity was stopped by the addition of L-15 
medium (Sigma, Germany) containing 10% FBS (Gibco, USA). The suspension was centrifuged 
and the pellet was re-suspended in serum-containing medium. Mechanical dissociation was done 
with a pipette until the neurons were dispersed and the volume increased to 5 mL. The cell 
suspension was mixed and centrifuged, and the pellet re-suspended in NLA medium containing: 
neurobasal medium (Invitrogen, USA), B27 neural supplement (Invitrogen, USA) and 10 ng/mL 
nerve growth factor (Invitrogen, USA). One drop of DRGN suspension in NLA medium was plated 
in the middle of dry, ammoniated collagen-coated dishes. Approximately 5,000 to 7,000 neurons 
were plated per culture. After the cells attached to the collagen overnight, the cultures were filled 
and subsequently treated with NLA medium containing fluorodeoxyuridine (FUDR, Sigma, 
Germany) on days 2 to 4, 6 to 8, and 10 to 12 to eliminate non-neuronal cells. After this anti-
mitotic treatment, the resulting DRGN cultures were maintained on NLA medium for at least 1 
week to ensure that no residual FUDR remained when SCs were added. The cultures were kept 
at 37°C and 95% air and 5% CO2, and all the procedures were performed under aseptic 
conditions. 
 
5. In vitro biological testing 
 
5.1. Metabolic activity assay 
 
The colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) viability test was performed to determine the potential cytotoxicity of MP-loaded 
CMCht/PAMAM dendrimer nanoparticles when incubated with glial cells. This assay has been 
widely used to measure cellular viability and it is based on the bioreduction of the MTS substrate 
into a brown formazan compound by dehydrogenase enzymes in metabolically active cells.35 Glial 
cells were incubated with 200 µg.mL-1 MP-loaded CMCht/PAMAM dendrimer nanoparticles for a 
week with periodical renewal every 48 hours. Then, the cells were placed in serum-free culture 
medium containing MTS in a 5:1 ratio and incubated in a humidified atmosphere at 37ºC and 5% 
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CO2. After three hours of incubation 100 L of solution from each well were transferred to a 96-
well plate and the optical density for triplicates of each sample was determined at 490 nm. 
 
5.2. Cell proliferation assay 
 
The 5-bromo-2’-deoxyuridine (BrdU) assay (Roche, Switzerland) was used for DNA quantification 
as a measure of cell proliferation. Cell replication is commonly assessed analysing thymidine (3H) 
incorporation into DNA.36 BrdU is the equivalent non-radioactive method that evaluates DNA 
synthesis and cell proliferation. This ELISA-based assay measures the amount of BrdU 
incorporated into newly synthesized DNA of replicating cells. To perform the test, BrdU was 
added to the cell cultures for 24 hours and the cells were then fixed and its DNA denatured in a 
single step with FixDenat (Roche, Switzerland), after which the anti-BrdU peroxidase antibody 
(Roche, Switzerland) was added. The formed immune complexes were detected quantifying the 
substrate reaction product in a multiplate reader (BioRad) set at 370 nm (reference filter at 492 
nm). 
 
5.3. Assessment of FITC-labeled CMCht/PAMAM dendrimer nanoparticle internalization 
 
In this thesis, the internalization of the FITC-labeled MP-loaded CMCht/PAMAM dendrimer 
nanoparticles was investigated in glia and Schwann cell cultures, both by fluorescence and 
confocal microscopy analyses. The glial cultures were incubated with 200 µg.mL-1 of FITC-labeled 
MP-loaded CMCht/PAMAM dendrimer nanoparticles for periods of 1, 3, 12, 18 and 24 hours 
(n=3/ time point). After each incubation time, the cells were washed in 0.1 M PBS and fixed in a 
4% paraformaldehyde solution for 30 minutes. The nuclei were stained with 4',6-diamidino-2-
phenylindole (DAPI, Invitrogen, USA), for the assessment of possible morphological changes. 
Immunocytochemistry was performed in order to co-localize the NPs within the cells with the 
following primary antibodies: rabbit GFAP antibody (Dako, Denmark, 1:500, v/v) for astrocytes 
recognition; mouse CD11b antibody (BD Biosciences Pharmingen, USA, 1:100, v/v) was used in 
microglial cells identification; and mouse O4 antibody (R&D Systems, 1:50, v/v) for 
oligodendrocytes detection. The FITC-labeled MP-loaded CMCht/PAMAM dendrimer 
nanoparticles internalization levels for each cell population were determined according to 
Equation (1) (n=3, 3 random fields/coverslip): 
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Equation (1):  100
Tc
Pc
I  
I: percentage of internalization; 
Pc: number of positive cells for FITC-labeled MP-loaded CMCht/PAMAM dendrimer nanoparticles; 
Tc: total number of each cell type. 
 
For Schwann cell (SCs) cultures, 200 µg.mL-1 FITC-labeled MP-loaded CMCht/PAMAM dendrimer 
nanoparticles were incubated for periods of 3, 6, 16 and 24 hours. The samples for fluorescence 
microscopy were then washed with 1 mL of PBS, and cells fixed with 4% PFA for 10 minutes at 
4ºC followed by washing each well twice with PBS. After that SCs were incubated with 0.5 mL of 
PBS containing Hoechst 33258 (Invitrogen, USA) for cell nuclei staining. Immunocytochemistry 
was performed in order to co-localize the NPs within SCs with the primary antibody rabbit S100 
antibody (Dako, Denmark, 1:500, v/v). The FITC-labeled MP-loaded CMCht/PAMAM dendrimer 
nanoparticles internalization levels for each cell population were determined according to 
Equation (1) (n=3, 3 random fields/coverslip). 
 
5.4. Immunocytochemistry 
 
Imunocytochemistry is a method for determining the presence, subcellular localization and 
relative abundance of a specific antigen in cultured cells. For internalization studies using glial 
cells and SCs, immunocytochemistry studies were performed in the scope of this thesis. The 
cells were fixed in 4% PFA for 30 minutes, permeabilized by incubation with 100% triton-X for 4 
minutes and washed 3 times in PBS. Cells were then blocked with 10% FBS (Gibco, USA), 
followed by incubation with the following primary antibodies: rabbit anti-rat glial fibrillary acid 
protein (GFAP) (Dako, Denmark, 1:500) for astrocytes, mouse anti-CD11b (BD Biosciences 
Pharmigen, USA, 1:100) for microglial cells and mouse anti-O4 (R&D systems, USA, 1:50) for 
oligodendrocytes and rabbit anti-S100 (Dako, Denmark, 1:500) for SCs. Cells were then washed 
in PBS and incubated with the secondary antibodies: Alexa Fluor 594 goat anti-mouse 
immunoglobulin G (IgG) and Alexa Fluor goat anti-rabbit 594 (Molecular Probes, USA). The 
primary antibody was omitted to produce negative controls. Samples were further observed under 
an Olympus BX-61 Fluorescence Microscope (Olympus, Germany). Levels of FITC-labeled 
CMCht/PAMAM dendrimer nanoparticles internalization by the different cell populations were 
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quantified by determining the ratio between the number of positive cells for FITC-labeled 
CMCht/PAMAM internalization and the total number of cells. 
 
5.5 Myelination in Schwann cell and dorsal root ganglia neuron co-cultures 
 
For myelination experiments, co-cultures were prepared by adding 50,000 SC to purified DRGN 
cultures. The DRGN cultures and the co-cultures, represented in Figure 9, were fed every 2–3 
days with NLA medium for 2 weeks at 37°C and 95% air and 5% CO2. For the induction of 
myelination, NLA medium containing ascorbic acid (Sigma, Germany) was added to the co-
cultures. All cultures were then maintained for an additional 2 week period, with replacement of 
the appropriate medium every 2–3 days. 
 
Figure 9 - Co-cultures of primary rat Schwann cells and dorsal root ganglia neurons 
(Sudan black staining). Scale bar = 100 µm. 
 
To quantify the myelination of axons two methods were used: immunocytochemistry and Sudan 
black staining. Immunocytochemistry procedure was done as already described (see 5.4) using 
mouse anti-myelin basic protein (MBP) SMI 94 (Sternberger Monoclonals, Inc., USA, 1:1000) or 
mouse anti-neurofilament SMI 31 (Sternberger Monoclonals, Inc., USA, 1:1000). Concomitantly, 
Sudan black was used to stain the myelin for bright field microscopy observation. Sudan black is 
a non-fluorescent lysocrome dye used for lipid staining, such as myelin, resulting in a blue-black 
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labeling.37 To prepare the cell cultures for Sudan black staining, cells were fixed for at least 15 
minutes in 4% PFA, rinsed in 0.1 M PBS and further fixed in 0.1% osmium tetroxide (OsO4) for 1 
hour. The cultures were then dehydrated in sequential 25%, 50% and 70% ethanol solutions for 5 
minutes each. A 0.5% Sudan black in 70% ethanol solution was prepared and filtered before 
staining for 1 hr. The cultures were rehydrated in the following solutions sequentially: ethanol 
70% for 1 minute; 50% ethanol for 5 minutes; and 25% ethanol for 5 minutes. The cultures were 
finally rinsed in 0.1 M PBS and mounted for further observation and counting. Myelinated axons 
were counted using a square grid eyepiece during three scans across the coverslip. The number 
of Sudan black-stained myelin sheaths crossing the scan line was counted. 
 
6. Investigation of the mechanism of FITC-labeled MP-loaded CMCht/PAMAM 
dendrimer nanoparticle intracellular trafficking 
 
For the investigation of the mechanisms by which dendrimer nanoparticles are internalized by 
cells, two different techniques were used complimentarily, i.e. patch-clamp membrane 
capacitance electrophysiological recording and confocal live astrocyte imaging. For endocytotic 
vesicle examination labeled dextrans were incubated in the astrocyte cultures, while for exocytotic 
vesicle observation astrocytes were transfected with neuropeptide-Y (NPY) plasmid for further 
visualization. 
 
6.1. Electrophysiological analysis 
 
Electrophysiology techniques allow the study of the electrical properties of cells and tissues, 
involving the placement of electrodes into the biological preparations to measure the flow of ions. 
In this thesis we used the patch-clamp technique in the cell-attached mode, where a micropipette 
approaches the cell membrane in order to form a “patch” by suction and a microelectrode 
records the cell membrane ion flow. This approach allows the monitoring of discrete alterations 
in the membrane capacitance (Cm) that reflect unitary endocytotic and exocytotic events and 
allow its quantification, as well as vesicle diameter and fusion pore opening time. The equipment 
used to analyze and record the membrane response is represented in Figure 10. In order to 
perform the electrophysiological readings, astrocyte coverslips were bathed in extracellular 
solution (ECS) containing: 130 mM NaCl, 5 mM KCl, 1 mM MgCl, 2 mM CaCl2, 10 mM Na-
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HEPES and 10 mM D-glucose at pH 7.4. The fire-polished 3–4 MΩ glass patch-clamp pipettes 
were coated with Sylgard resin and the recordings were all performed in a SWAM IIB (Celica, 
Ljubljana, Slovenia).38 Single astrocytes revealing the typical star-like morphology were chosen for 
the patch-clamp analysis. To stimulate exocytosis ATP was added to the extracellular solution. 
The secretory activity of single cells was measured from the membrane capacitance (Cm). Off-
line data analysis was performed using the software MATLAB (MathWorks Inc.). Quantification of 
the number of events was determined from the obtained recordings. 
 
 
Figure 10 - Apparatus used for the electrophysiological recordings. a. Schematic representation of the 
circuit. b. Patch-clamp amplifier, low-pass filter and auxiliary oscilloscopes used. 38  
 
 
6.2. Endocytotic and exocytotic vesicle labeling 
 
Co-localization studies in live astrocytes were performed in order to identify both the endocytotic 
and exocytotic vesicles involved in the nanoparticle cellular dynamics, namely its intracellular 
trafficking. For endocytotic vesicle labeling, low dense astrocyte cultures were incubated with 
Alexa Fluor® 546 Dextran (Molecular Probes, USA) for 1.5 hours and thoroughly washed in ECS 
prior to observation. To observe the exocytotic vesicles sub-confluent astrocyte cultures were 
used and transfected with the plasmid DNA encoding Neuropeptide Y (NPY) tagged with mCherry 
fluorescent protein (NPY-mCherry, a kind gift from Dr. Ronald W. Holz, University of Michigan, 
USA). Briefly, the cells to be transfected were incubated in lipofection media (DMEM, 1 mM 
sodium piruvate, 2 mM L-glutamine) and mixed with transfecting reagent (Fugene, Promega, 
USA) with 1 µg of plasmid DNA for 15 minutes, at 37ºC. After that, culture medium was added 
and supplemented with 3% UltraSerG serum (Life Technologies, USA) and the cells were 
observed past 24 hours of incubation. 
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6.3. Confocal microscopy imaging of live astrocytes 
 
Confocal imaging of live astrocytes following incubation with fluorescently labeled NPs along with 
vesicle staining enabled to track possible co-localization of NPs and vesicles, validating NP 
intracellular vesicle transport. Confocal imaging microscopy overcomes some of the limitations of 
conventional wide-field fluorescence microscopy by increasing resolution and contrast by making 
use of point illumination and a spatial pinhole to eliminate out-of-focus light outside the focal 
plane. The images were acquired with a confocal inverted microscope (Zeiss LSM META 510, 
Germany) equipped with a 63.2× oil-immersion objective. FITC molecules bonded to the NPs 
were excited by the 488-nm line of the argon laser and the emission light was collected through 
the bandpass filter (505–530 nm). Alexa Fluor 546 labeling the vesicles was excited with the 
He/Ne laser (543 nm) and the emission light was filtered with the long-pass filter, with the cutoff 
below 560 nm. To eliminate possible bleed through, the green and red emission fluorescence 
were acquired sequentially. Time series images were recorded in 20 seconds intervals during 45 
minutes. All the recordings were performed in 300 mOsm ECS. 
 
6.4. Fluorescence quantification of co-localization of internalized nanoparticles with 
vesicles 
 
Co-localization spots refer to the observation of the spatial overlap between two different 
fluorescent labels each having separate emission wavelengths, to define if the different targets 
are located in the same area of the cell or very near to one another. Relative co-localization of 
FITC-labeled NPs with Alexa Fluor® 546 Dextran or NPY-mCherry was quantified using ColocAna 
software (Celica, Slovenia). The co-localization was calculated as a percentage of co-localized 
pixels versus all pixels of the respective labeled protein. The threshold intensity for the co-
localized pixel count was 20% of the maximal fluorescence. 
 
7. In vivo studies 
 
In vivo studies presented in this thesis including animal handling and all the experiments were 
conducted in accordance with the guidelines for the care and handling of laboratory animals in 
the Directive 2010/63/EU of the European Parliament and Council. To have a more relevant 
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response on the effect of MP-loaded CMCht/PAMAM dendrimer NPs administration in vivo 
studies were performed. Firstly, NPs were administered in healthy Wistar rats to have insights on 
its diffusion and distribution in the brain tissue. Secondly, a spinal cord injury (SCI) animal model 
was established in order to test the possible therapeutic effects of the drug-loaded NPs following 
injury. 
 
7.1. Animals 
 
Eight and ten week-old male Wistar rats (Charles River, Spain) were used for the therapeutic and 
biodistribution studies, respectively. The animals were housed in light and temperature controlled 
rooms and fed with the recommended standard diet. The Animal Care Committee of the research 
Institute approved the animal protocols in accordance with standardized Animal Care 
Guidelines.39 Following surgery the animals were kept under heat lamps and received vitamins 
and antibiotics, to prevent infections. Bladder evacuation was done manually whenever 
necessary. Throughout the recovery period the animals were examined for symptoms of illness or 
adverse reaction to the treatment. 
 
7.2. Intracisternal administration of MP-loaded CMCht/PAMAM dendrimer nanoparticles 
 
Administration of the NPs directly in the CSF of the animals was done in order to assess its 
biodistribution in the brain. All experiments were carried out using male ten week-old Wistar rats 
(Charles River, Spain). Before the surgery, the animals were anesthetized by intraperitoneal 
injection of 150 mg.Kg-1 ketamine hydrochloride (Dorbene Vet, Laboratorios SYVA SA, Spain) and 
0.3 mg.Kg-1 medetomidine (Imalgen, Merial, France). The animals were placed in a stereotaxic 
frame with the head curved 45° downwards and the dorsal base of the skull was shaved and 
soaked with ethanol and chlorohexidin (AGB, UK). An occipital-cerebral midline incision was 
made with a blade and the muscles retracted until the meninges were visible. A small amount of 
CSF was withdrawn from the cistern magna and afterwards 15 µL of solution were injected with a 
Hamilton syringe (Hamilton, Switzerland). Following surgery, rats received analgesic (Butorphanol 
tartrate, 1 mg.mL-1, Fort Dodge, Spain) and antibiotic (Enrofloxacine, 1 mg.mL-1, Bayer, Germany) 
and were kept for 72 hours. 
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7.3. Spinal cord injury surgery 
 
To have an insight of the possible therapeutic effects of MP-loaded CMCht/PAMAM dendrimer 
NPs, local administration of the nanocarriers was performed following thoracic hemisection of the 
cord. Eight week-old male Wistar rats (Charles River, Spain) were anesthetized by intraperitoneal 
injection of 150 mg.Kg-1 ketamine hydrochloride (Dorbene Vet, Laboratorios SYVA SA, Spain) and 
0.3 mg.Kg-1 medetomidine (Imalgen, Merial, France). The surgical area was shaved and soaked 
with ethanol and chlorohexidin (AGB, UK). A laminectomy at T8-T9 level was performed to expose 
the spinal cord. After that, a unilateral defect was made on the cord by removing approximately 2 
mm of the tissue. Immediately after the lesion, 5 µL of solution was injected circa 1 mm rostral 
and 1 mm caudal to the lesion (the content of the solution varied according to the experimental 
group). All solutions were prepared in 5 mg. mL-1 stocks. To stabilize the vertebral column in the 
lesion area, a semi-tubular starch/polycaprolactone (SPCL) scaffold was implanted in alignment 
with the vertebrae in all the animals.40 The muscles and skin were separately sutured with Vicryl 
sutures (Johnson and Johnson, USA) and disinfection was carried out with chlorohexidin (AGB, 
UK). The animals were maintained for 4 weeks. 
 
7.4. Basso, Beattie and Bresnahan locomotor test 
 
The locomotor behavior of the animals was assessed using the Basso, Beattie and Bresnahan 
(BBB) locomotor rating scale.41 The test was performed weekly after the surgery, for a month. The 
BBB test consists on a 21 point scale to evaluate the hindlimb motor recovery following a 
thoracic spinal injury. A BBB score of 0 indicates no hindlimb movement. From 1 to 8 the scores 
designate some joint movement, still with no weight support. BBB scores from 9 to 20 already 
demonstrate the animal ability to support weight and use the limbs for locomotion, although in 
the presence of some abnormalities such as the lack of coordination. Finally, a BBB score of 21 
corresponds to the locomotion profile of a normal healthy rat (Table 1). To evaluate the rat 
locomotion, animals were allowed to move freely in the open-field arena and scored during a 
4 minute period for their ability to use their hindlimbs by two independent blinded observers. 
Joint movements, paw placement, weight support, and fore/hindlimb coordination were judged 
according to the 21-point BBB locomotion scale. Scores obtained by 2 independent observers 
were averaged for the left hindlimb.  
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Table 1. Basso, Beattie and Bresnahan locomotor rating scale.41 
 
Score Operational Definition 
0 No observable hindlimb (HL) movement 
1 Slight movement of one or two joints (ankle, hip or knee) of the HL 
2 Extensive movement of one joint OR extensive movement in one joint and slight movement in on other joint 
3 Extensive movement in two joints 
4 Slight movement of all three joints 
5 Slight movement of all two joints and extensive movement of the third 
6 Extensive movement of two joints and slight movement of the third 
7 Extensive movement of all three joints 
8 Sweeping with no weight support OR plantar placement of the paw with no weight support 
9 
Plantar placement of the paw with weight support in stance only (i.e., when stationary) OR occasional, 
frequent, or consistent weight supported dorsal stepping and no plantar stepping 
10 Occasional weight supported plantar steps, no forelimb (FL)-HL coordination 
11 Frequent to consistent weight supported planter steps and no FL-HL coordination 
12 Frequent to consistent weight supported planter steps and occasional FL-HL coordination 
13 Frequent to consistent weight supported planter steps and frequent FL-HL coordination 
14 
Consistent weight supported plantar steps, consistent FL-HL coordination and predominant paw position 
during locomotion is rotated (internally or externally) when it makes initial contact with the surface as well as 
just before it is lifted off at the end of stance OR frequent plantar stepping, consistent FL-HL coordination and 
occasional dorsal stepping 
15 
Consistent plantar stepping and consistent FL-HL coordination and no toe clearance or occasional toe 
clearance during forward limb advancement; predominant paw position is parallel to the body at initial contact 
16 
Consistent plantar stepping and consistent FL-HL coordination during gait and toe clearance occurs frequently 
during forward limb advancement, predominant paw position is parallel at initial contact and rotated at lift-off 
17 
Consistent plantar stepping and consistent FL-HL coordination during gait and toe clearance occurs frequently 
during forward limb advancement, predominant paw position is parallel at initial contact and lift-off 
18 
Consistent plantar stepping and consistent FL-HL coordination during gait and toe clearance occurs 
consistently during forward limb advancement, predominant paw position is parallel at initial contact and 
rotated at lift-off 
19 
Consistent plantar stepping and consistent FL-HL coordination during gait and toe clearance occurs 
consistently during forward limb advancement, predominant paw position is parallel at initial contact and lift-
off, tail is down part or all the time 
20 
Consistent plantar stepping and consistent coordinated gait, consistent toe clearance, predominant paw 
position is parallel at initial contact and lift-off, trunk instability, tail consistently up 
21 Consistent plantar stepping and consistent coordinated gait, consistent toe clearance, predominant paw 
position is parallel throughout stance, consistent trunk stability, tail consistently up 
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8. Histological and western blot analysis 
 
8.1. Tissue preparation for immunohistochemistry 
 
Following the in vivo experiments, once reaching the pre-established time-points animals were 
deeply anesthetized with an intraperitonial injection of sodium pentobarbital. Then, rats were 
perfused through the ascending aorta artery first with 0.9% NaCl saline solution and once the 
blood was cleared from the organism, with 4% PFA in PBS. Brains were collected for NP 
biodistribution studies and dissected to obtain the pre-frontal cortex, hippocampus and 
cerebellum. The tissues were immediately frozen at -80ºC for further analysis. The remaining 
brains were carefully placed in OCT embedding compound (ThermoScientific, USA) and frozen at 
-20ºC for posterior cutting in a cryostat at a thickness of 10 µm. The brain slices were then 
subjected to an immunohistochemical protocol. First the coverslips were covered in PBS (pH 7.4) 
and let stay for 15 minutes. Blocking solution composed of 5% FBS (Gibco, USA) in 0.5% Triton 
was applied to the brain slices for 1 hour at RT. Following that, primary antibodies were 
incubated overnight at 4ºC: rabbit anti-rat glial fibrillary acid protein (GFAP) (Dako, Denmark, 
1:500) for astrocyte labeling. The following day 3 washes in PBS were executed and then 
incubation with the secondary antibody Alexa Fluor goat anti-rabbit 594 (Molecular Probes, USA) 
in blocking solution was done, along with DAPI staining (1:1000, Invitrogen, USA). Samples were 
further observed under a confocal microscope (FV1000; Olympus, Germany). The coverslips 
were once again washed 3 times in PBS and then mounted in Vectashield (ThermoScientific, 
USA). The coverslips were kept at 4ºC until further observation. 
 
8.2. Western blot analysis 
 
For protein expression analysis, three distinct brain areas were carefully dissected: the 
hippocampus (HPC), the pre-frontal cortex (PFC) and the cerebellum (CB). Proteins were 
extracted from the CB, HPC and PFC and homogenized in RIPA buffer (NaCl 0.1 M; 
tris(hydroxymethyl)aminomethane (Tris) pH 8.0, 0.01 M; EDTA pH 8.0, 0.001 M and complete 
protease inhibitor cocktail; Roche, Switzerland). Afterwards, sonication for 30 seconds in 
Laemmli buffer (SDS 4%, Tris pH 8, 0.12 M, glycerol 20% and dithiothreitol 0.2 M) was 
performed. Proteins were then quantified using the Bio-Rad protein assay (Bio-Rad, Hercules, 
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USA). Samples were separated by SDS-PAGE (50 μg/lane) and then transferred into a 
nitrocellulose membrane. Membranes were then stained with Ponceau S (Sigma) to confirm 
transfer efficiency; blocked with 5% skim milk in PBS and probed with anti-glucocorticoid receptor 
(GR) antibody (M-20) (Santa Cruz Biotechnology, USA, dilution 1:1000) at 4°C overnight. 
Membranes were washed and incubated with goat anti-rabbit IgG-HRP (Santa Cruz 
Biotechnology) and diluted to 1:10000. The blot was developed using the SuperSignal West Pico 
Chemiluminescent Substrate (PIERCE, USA) and exposed to X-ray film. Finally, the membranes 
were stripped with 2% SDS and 100 mM β-mercaptoetanol solution, warmed to 50°C for 30 
minutes, thoroughly washed, blocked, re-blotted with mouse anti-alpha-tubulin (Santa 
Cruz Biotechnology) and diluted to 1:5000 to normalize for protein load. 
 
9. Statistical analysis 
  
Statistical evaluation was performed using GraphPad Prism v5.0 for Windows (GraphPad 
Software, USA). Statistical differences amongst groups were assessed either by one way ANOVA 
or two way ANOVA tests, followed by Tukey or the Bonferroni post-hoc tests, respectively. 
Statistical significance was defined as p<0.05 for a 95% confidence interval.  
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CHAPTER III 
Multifunctionalized CMCht/PAMAM dendrimer nanoparticles modulate the cellular 
uptake by astrocytes and oligodendrocytes in primary cultures of glial cells 
 
Abstract  
The efficiency of the treatments involving CNS disorders is commonly diminished by the toxicity, 
reduced stability and lack of targeting of the administered neuroactive compounds. In this study, 
we have successfully multifunctionalized CMCht/PAMAM dendrimer nanoparticles by coupling 
the CD11b antibody and loading MP into the nanoparticles. The modification of the new antibody-
conjugated nanoparticles was confirmed by S-TEM observation and 1H NMR and FTIR 
spectroscopy. Cytotoxicity assays revealed that the conjugates did not affect the viability of both 
primary cultures of glial and microglial cells. Trace analyses of FITC-labeled nanoparticles 
revealed that the uptake of antibody-conjugated nanoparticles was conserved in microglial cells 
but significantly decreased in astrocytes and oligodendrocytes. Thus, this study demonstrates 
that antibody conjugation contributes to a modulation of the internalization of these nanocarriers 
by different cell types, which might be of relevance for specific targeting of CNS cell populations. 
 
 
 
 
This chapter is based on the following publication: 
Susana R. Cerqueira, Bárbara L. Silva, Joaquim M. Oliveira, João F. Mano, Nuno Sousa, António 
J. Salgado, Rui L. Reis, “Multifunctionalized CMCht/PAMAM dendrimer nanoparticles modulate 
the cellular uptake by astrocytes and oligodendrocytes in primary cultures of glial cells”, 
Macromolecular Bioscience (12) 591–597, 2011. 
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1. Introduction 
 
Drug delivery to the central nervous system (CNS) has been a considerable challenge in 
biomedical research in the past decades.1,2 Neurological disorders such as Alzheimer´s and 
Parkinson’s diseases, stroke, multiple sclerosis and also neurotraumatic conditions, such as 
spinal cord injury (SCI), are amongst the main debilitating disorders of our times.3 The unique 
environment and the complexity of the mechanisms involved in these conditions, some of which 
still poorly understood, have hindered the development of new and efficient treatments. The 
systemic administration of neuroactive molecules poses several intrinsic issues, particularly its 
toxicity and reduced stability in the organism.4 Thus, there is an urgent demand not only for more 
detailed knowledge of the pathophysiology of CNS disorders, but also for more specific and 
effective drug delivery strategies.5,6 In addition, the presence of biological barriers such as the 
blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (B-CSF) that can obstruct the 
entry of therapeutic molecules to the nervous tissues, is a common limiting factor in the success 
of treatments.7,8 Nonetheless, one must distinguish diseases that do not affect the BBB integrity 
from those which compromise it.9 In the first case, the major obstacle to an effective cure of the 
disease is the BBB presence itself and its characteristics. However, when this barrier has been 
compromised, for instance, after neurotraumatic events, the delivery of compounds is clearly 
eased.10 In brain and SCI physical damage occurs and the CNS barriers are disrupted opening a 
‘window of opportunity’ for the entry of drugs that can limit the extent of following potential 
secondary damage.10,11 Still, efficient drug delivery to the target cells remains a crucial task for the 
success of these therapies, since most of these drugs are often highly unspecific.12  
The use of nanoparticle-based systems has gained increasing interest in drug delivery with 
exciting prospects.13 These nanoscale materials present unique and advantageous features in 
comparison to the classical drug formulations, regarding its solubility, biodistribution, release 
characteristics and immunogenicity.14 In addition, nanoparticles are amenable to further 
modifications that can provide higher functionalization degrees, namely cell or tissue targeting.15 
Fundamentally, nanoparticle-mediated selective drug delivery would offer a mean to minimize 
delivery to unintended sites, allowing higher doses of drug to be administered when reaching a 
precise target site, thereby lowering peripheral cytoxicity. A critical step in such a strategy is the 
internalization of nanoparticles into specific cells, and a way to overcome it would be the 
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modification of the nanoparticle surface with a ligand, that would be efficiently taken up by target 
cells.16,17 A vast range of nanoparticles is being developed and investigated for specific drug 
delivery purposes although from these only a small percentage is being directed to CNS.18  
A new surface engineered macromolecular carrier was recently proposed to be used in CNS 
applications, showing high internalization levels and no significant cytotoxicity over neurons and 
glial cells.19 Moreover, it has also shown to be non-cytotoxic in vivo, revealing a wide 
biodistribution after intravenous injections, being simultaneously able to cross the B-CSF.20 This 
system was firstly described as a new surface engineered nanoparticle based on a 
polyamidoamine (PAMAM) dendrimer core grafted with the natural polymer 
carboxymethylchitosan (CMCht).21 The sphere-like CMCht/PAMAM dendrimer nanoparticles were 
proposed to be used as targeted drug delivery carriers for the modulation of the cells’ behaviour 
by efficient intracellular uptake upon its functionalization via: (i) drug incorporation; (ii) fluorescent 
labelling; and (iii) ligand conjugation.22 Furthermore, an anti-inflammatory corticosteroid clinically 
used in SCI related cases - methylprednisolone (MP) - has already shown to be efficiently 
incorporated and released from these nanoparticles, leading to important alterations on the 
viability of primary cultures of microglial cells.23 
Therefore, following recent developments of these previous works the aim of this study was to 
achieve a higher functionalization level of the CMCht/PAMAM dendrimer nanoparticles by 
conjugating to the latter a targeting ligand, in order to determine a possible modulation of their 
internalization behaviour in glial cells. From the variety of potential ligands to nanoparticles 
surfaces, monoclonal antibodies are attractive molecules due its high specificity.24 Therefore, the 
MP-loaded CMCht/PAMAM dendrimer nanoparticles were conjugated to the CD11b antibody 
which recognizes specific receptors on microglial cells’ membranes. The multifunctional 
modification of the CMCht/PAMAM dendrimer nanoparticles was confirmed by Fourier transform 
infrared spectroscopy (FTIR) and proton nuclear magnetic resonance (1H NMR). Then, we have 
investigated its effects in the normal viability of glial and microglial cells, in vitro. Finally, an 
assessment and comparison of the two types of nanoparticles uptake in mixed glial cultures was 
done following immunocytochemistry and fluorescence microscopy observation. Results revealed 
that conjugated nanoparticles were not deleterious to both glial and microglial cells. Moreover, 
the internalization profile of the new nanoparticles in a mixed glial culture was indeed altered 
when compared to the unmodified nanoparticles. This study demonstrates that by following the 
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above referred strategy it is possible to modulate the internalization of MP-loaded CMCht/PAMAM 
dendrimer nanoparticles by different glial cell populations, rendering them with a cell targeted 
profile for future CNS applications. 
 
2. Materials and methods 
 
2.1. Dendrimer nanoparticle preparation 
 
2.1.1. CMCht/PAMAM dendrimer nanoparticles synthesis 
 
Carboxymethylchitosan/polyamidoamine dendrimer nanoparticles were produced as previously 
reported by Oliveira et al.21 Starburst® PAMAM-carboxylic acid terminated dendrimer solution 
(PAMAM-CT) (generation 1.5, 20% (w/v)) was purchased (Sigma, Germany). The following 
reactions were carried out: (i) increase in the PAMAM-CT generation; (ii) production of a PAMAM-
methyl esther terminated dendrimer; (iii) condensation reaction between the methyl esther and 
amine groups of PAMAM and CMCht; and (iv) conversion of the non-reacting methyl esther 
groups into carboxylic ones in the CMCht/PAMAM dendrimer nanoparticles. Initially, the 
methanol was removed from the PAMAM-CT dendrimers by evaporation under nitrogen gas. The 
remaining compound was re-dissolved in ultra-pure water in a final concentration of 10 mg.mL-1 
and the pH was corrected to 6.5. Then, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC, Fluka, Slovakia) was added under agitation for 30 minutes at room 
temperature. Ethylenediamine (EDA, Sigma, Germany) was included at the same molar ratio and 
reacted for 4 hours. The solution was subsequently dialyzed against ultrapure water in order to 
remove the exceeding EDC (cellulose tubing, benzoylated for separating compounds with a 
molecular weight of ≤1,200, Sigma, Germany). The obtained amine terminated PAMAM 
dendrimers (PAMAM-AT) were mixed with methanol (Sigma, Germany) and methyl methacrylate 
(Fluka, Germany) and kept under agitation in a water bath at 50ºC for 24 hours. After methanol 
removal under nitrogen gas, appropriate volumes of hydrochloric acid (HCl, Panreac, Portugal) 
and trifluoroacetic acid (TFA, Sigma, Germany) were added to the solution. Meanwhile, 1 g of 
CMCht was dissolved in 50 mL of water. The PAMAM methyl esther terminated dendrimers were 
dissolved in a 20/80 water/methanol solution and the CMCht was added and kept under 
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agitation for 72 hours, after which the CMCht/ PAMAM dendrimer nanoparticles with carboxylic-
terminated groups were obtained. 
 
2.1.2. Methylprednisolone incorporation into CMCht/PAMAM dendrimer 
nanoparticles 
 
Methylprednisolone (MP) was incorporated in the nanoparticles by mixing an aqueous solution of 
CMCht/PAMAM dendrimer nanoparticles with an ethanolic methylprednisolone solution with a 
final concentration of 5×10-4 M (w/w) and kept under vigorous agitation. Saturated sodium 
carbonate solution (Na2CO3, Aldrich, Germany) and acetone (Pronalab, Portugal) were then added 
to the mixture. The resulting precipitates were collected by filtration and then dispersed in 
ultrapure water. Extensive dialysis (cellulose tubing, benzoylated for separating compounds with a 
molecular weight of ≤1,200, Sigma, Germany) was performed during 48 hours. Both 
CMCht/PAMAM dendrimer nanoparticles and MP-loaded CMCht/PAMAM dendrimer 
nanoparticles were obtained by freezing the final solution at -80ºC and freeze-drying (Telstar-
Cryodos-80, Spain) the samples for approximately 7 days, until the solvents were completely 
removed. 
 
2.1.3. Fluorescent labelling of MP-loaded CMCht/PAMAM dendrimer nanoparticles  
 
Fluorescein isothiocyanate (FITC, Sigma, Germany) labeled MP-loaded CMCht/PAMAM 
dendrimer nanoparticles conjugates were prepared by covalently bonding the amine group of 
CMCht and the isothiocyanate group from FITC. A 10 mg.mL -1 FITC solution was prepared in 
dimethyl sulfoxide anhydrous (DMSO, Riedel-de Haen, Germany) in the dark. Simultaneously, a 
10 mg.mL-1 MP-loaded CMCht/PAMAM dendrimer nanoparticles solution was set in carbonate-
bicarbonate coupling buffer (pH=9.2). Afterwards, 50 μL of the FITC/DMSO solution were added 
per each mL of the MP-loaded CMCht/PAMAM dendrimer nanoparticles buffered solution, under 
agitation. The resulting solution was kept in the dark at 4ºC for 8 hours. The FITC-labeled MP-
loaded CMCht/PAMAM dendrimer nanoparticles solution was then dialyzed (cellulose tubing, 
benzoylated for separating compounds with a molecular weight of ≤1,200, Sigma, Germany) for 
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48 hours against ultrapure water in order to remove the FITC molecules that did not react. 
Finally, the solution was frozen at -80ºC and subsequently freeze-dried (Telstar-Cryodos-80, 
Spain) until the solvents were completely removed. 
 
2.1.4. CD11b antibody conjugation to CMCht/PAMAM dendrimer nanoparticles 
 
In order to conjugate anti-mouse CD11b antibody (BD Biosciences, USA) to the dendrimer 
nanoparticles a crosslinking reaction was performed.25 A 20 mg.mL-1 solution of nanoparticles in 
PBS was mixed with 1 mg.mL-1 EDC (Fluka, Slovakia) and let react for 30 minutes. The remaining 
solution was dialysed against ultrapure water for 24 hours to remove the excess EDC. Afterwards, 
the pH was corrected to 7.4 and 4 nmol of CD11b antibody were added under agitation. One 
hour after CD11b addition, the solution was frozen at -80ºC and subsequently freeze-dried 
(Telstar-Cryodos-80, Spain). 
 
 
Figure 1. Surface modification of MP-loaded CMCht/PAMAM dendrimer nanoparticles with a fluoresecnt 
probe (FITC) and a targeting ligand (CD11b antibody). 
 
2.2. Characterization of the CD11b antibody conjugated dendrimer nanoparticles 
 
The conjugation effectiveness was analyzed by Fourier transform infrared spectroscopy (FTIR) 
and proton nuclear magnetic resonance (1H NMR). The morphology of the new conjugated 
nanoparticles was assessed by scanning-transmission electron microscopy (S-TEM). To obtain 
the FTIR spectra of the samples, transparent potassium bromide (KBr, Pike Technologies, USA) 
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pellets were prepared containing the samples to be analyzed. The readings were run in an 
infrared spectroscope (IR Prestige-21, Shimadzu, Japan). For the 1H NMR analyses the samples 
were dispersed in deuterium oxide (D20, Aldrich, Germany) at a final concentration of 10 mg.mL-1. 
The one-dimensional 1H spectra were acquired in a Varian Unity Plus spectrometer at 300 MHz 
and 20ºC. The morphology was then verified by S-TEM (Nova™ NanoSEM 50 series, FEI 
Company, The Netherlands). For that purpose, the lyophilized CD11b-antibody conjugated MP-
loaded CMCht/PAMAM dendrimer nanoparticles were dispersed in ultrapure water to a final 
concentration of 1 mg.mL-1, stained with 1% phosphotungstic acid and placed on copper grids for 
further observation.  
 
2.3. In vitro cell culture studies 
 
2.3.1. Isolation and culturing of rat cortical glial cells 
 
Neonatal rat cortices were isolated from P4 Wistar rat pups as previously described.26 Upon 
removal under aseptic conditions, cortices were maintained in Hanks’ balanced salt solution 
(HBSS, Gibco, USA) and mechanically dissected. Afterwards, the cortical fragments were 
incubated in an enzymatic medium of 30 mg.mL-1 DNAse solution (Sigma, Germany) with 0.25% 
trypsin (Sigma, Germany) in Ca2+/Mg2+ free HBSS solution for 30 minutes at 37ºC. The trypsin 
reaction was blocked adding 40% foetal bovine serum (FBS, Gibco, USA) and the resulting tissue 
was centrifuged at 800 rpm for 2 minutes and the cells were then plated out at a density of 
4104 cells.cm-2 on poly-L-lysine (Sigma, USA) coated coverslips. Glial cells primary cultures were 
then maintained at 37ºC in a 5% CO2 atmosphere, in Dulbecco’s modified Eagle medium (DMEM, 
Gibco, USA) supplemented with 10% FBS and 1% antibiotic/antimycotic for 7 days.  
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2.3.2. Purification of rat cortical microglial cells 
 
After the glial cells isolation procedure, these were plated out at a density of 1106 cells.cm-2 in 
polystyrene T75 flasks (Thermo Scientific, USA) previously coated with poly-L-lysine (Sigma, 
USA). The glial primary cultures were maintained at 37ºC in a 5% CO2 atmosphere in Dulbecco’s 
modified Eagle medium (DMEM, Gibco, USA) supplemented with 10% FBS and 1% 
antibiotic/antimycotic for two weeks, with periodical medium renewal. After that, the flasks were 
agitated in an orbital shaker at 240 rpm during 4 hours. Following this, the medium containing 
detached microglia cells was collected and the obtained suspension was centrifuged at 1200 
rpm for 5 minutes. The pellet was re-suspended in DMEM medium (Gibco, USA) supplemented 
with 10% FBS and 1% antibiotic/antimycotic and plated out at a density of 4104 cells.cm-2 on 
coverslips previously coated with poly-L-lysine (Sigma, USA). Microglia cells primary cultures were 
then maintained at 37ºC in a 5% CO2 atmosphere, in DMEM medium (Gibco, USA) supplemented 
with 10% FBS and 1% antibiotic/antimycotic for 4 days for further testing. 
 
2.3.3. In vitro cytotoxicity assays 
 
Unmodified and CD11b antibody-conjugated MP-loaded CMCht/PAMAM dendrimer nanoparticles 
were evaluated regarding its influence in the primary cell cultures’ viability. For that purpose, two 
concentrations of nanoparticles were tested: 200 and 400 µg.mL-1 and the cultures were exposed 
to these conditions for a week. For both glial and microglial cell cultures the cell viability was 
verified after incubation of the cells at 37ºC for 3 hours with (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2(4-sulfophenyl)-2H tetrazolium) (MTS, Promega, USA) in a 5:1 ratio. 
This compound is bioreduced by active dehydrogenase enzymes into a brown formazan product 
that is released to the medium. After the incubation, the optical density of each sample was read 
in a multiplate reader (Tecan Sunrise, Switzerland) at 490 nm. 
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2.3.4. Internalization assessment following immunocytochemistry 
 
After a week, the glial cultures were incubated with 200 g.mL-1 of CD11b antibody-conjugated 
and the unmodified FITC-labeled MP-loaded CMCht/PAMAM dendrimer nanoparticles to assess 
their internalization rates, one week after its addition. After this time period, 
immunocytochemistry was performed. The cells were washed in 0.1 M PBS and fixed in a 4% 
paraformaldehyde solution for 30 minutes. For astrocytes recognition the wells were 
permeabilized with Triton-X-100 (Merck, Germany) 0.3% for 5 minutes, following a new wash in 
PBS 0.1 M. Afterwards, a 10% FCS solution in PBS was added to the cells for 1 hour and a new 
wash with PBS 0.1 M was carried out. The next step consisted on the incubation with the 
corresponding primary antibody diluted in 10% FCS in PBS. The following antibodies were used: 
rabbit anti-rat glial fibrillary protein (GFAP, Dako, Denmark, 1:500) for astrocytes recognition; 
mouse anti-CD11b (BD Biosciences Pharmingen, USA, 1:100) in microglial cells identification; 
and mouse anti-O4 (R&D Systems, 1:50) for oligodendrocytes detection. After 1 hour incubation, 
the cells were washed in 0.5% FCS in PBS (v/v) for further 1 hour incubation with the secondary 
antibodies: Alexa Fluor 594 anti-mouse and Alexa Fluor 568 anti-rabbit (both Molecular Probes, 
USA, 1:2000) were incubated for 1 hour. Negative controls were used performing the same 
treatment but omitting the primary antibody addition. The cells were then stained with 4',6-
diamidine-2-phenyl indole (DAPI, Thermo Scientific, USA, 1:2000), for 5 minutes in the dark. The 
coverslips were finally mounted for posterior observation under an Olympus BX-61 Fluorescence 
Microscope (Olympus, Germany). The FITC-labeled dendrimer nanoparticles internalization levels 
for each cell population were determined according to Equation 1 (n=3, 3 random fields/ 
coverslip): 
 
Equation 1: 100
Tc
Pc
I  
 
I: percentage of internalization; 
Pc: number of positive cells for FITC-labeled dendrimer nanoparticles; 
Tc: number of positive cells for FITC-labeled dendrimer nanoparticles. 
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2.4. Statistical analysis 
 
Statistical evaluation was performed using the one-way analysis of variance test followed by the 
Tukey’s post-test to assess the statistical differences between groups in the viability and 
internalization tests. Statistical significance was defined for p<0.05. 
 
3. Results and discussion 
 
The partial failure in CNS disorders’ pharmacological treatments often resides in the lack of 
targeting of the administered therapeutic molecules.4 Even in conditions where the BBB has been 
compromised and the delivery of compounds is considerably facilitated, as in SCI, efficient drug 
delivery to target cells should be carefully considered. Due to the massive inflammatory episodes 
that follow these injuries, a cell-specific drug delivery could be highly advantageous in the control 
and modulation of these deleterious events.9 For instance, MP clinical administration as an anti-
inflammatory drug aggravates a cascade of side effects that could be minimized in a targeted 
delivery strategy.27 Following previous works by our group focusing on the development of a CNS 
targeted dendrimer-based macromolecular carrier,19-21,23 we aimed at further modifying the 
CMCht/PAMAM dendrimer nanoparticles to achieve a higher functionalization degree.28 For this 
purpose, we tested a new surface modification by conjugating a CD11b antibody to the MP-
loaded CMCht/PAMAM dendrimer nanoparticles. The latter had already shown to be easily 
internalized by astrocytes, oligodendrocytes and microglial cells present in a mixed primary 
culture. All these cell types revealed maximum internalization levels 24 hours after exposure to 
these nanoparticles, being microglial cells the ones with faster uptakes.23 If we intend to target the 
delivery of the drug to microglial cells, for instance, minimum amounts should reach the other 
cell types in order to maximize the desired drug actions while minimizing possible side effects. 
Therefore, it was investigated whether this generalized internalization intake would be affected by 
the presence of CD11b antibody, which is specific for microglial cell recognition.  The CD11b 
antibody was chosen to facilitate the permeation of the nanoparticles through the microglial cells 
membrane by specifically interacting with an integrin chain expressed only in this type of cells. 
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Thus, the nanoparticles could be preferentially targeted to microglial cells, affecting the 
availability for entrance in the other cell types. 
In the present study, it was initially investigated the conjugation of the CD11b antibody to the 
CMCht/PAMAM dendrimer nanoparticles. FTIR spectra of the unmodified and antibody-
conjugated CMCht/PAMAM dendrimer nanoparticles are represented in Figure 2.A. From Figure 
2, it is visible that the antibody-conjugated nanoparticles disclose an altered FTIR spectrum as 
compared to the unmodified nanoparticles. The 520 cm-1 free amino acid peak and the 1120 cm-1 
NH3+ vibration appear after modification of the nanoparticles in the antibody-conjugated 
nanoparticles spectrum. Consequently, the comparative FTIR spectra analysis of the unmodified 
and CD11b conjugated dendrimer nanoparticles seems to suggest that the antibody was, in fact, 
successfully conjugated to the nanoparticles. Also the 1H NMR spectra of CD11b antibody-
conjugated and unmodified CMCht/PAMAM dendrimer nanoparticles (Figure 2.B) revealed new 
proton signals which indicate that the conjugation actually occurred. Some characteristic peaks of 
the CMCht/PAMAM dendrimer nanoparticles are maintained in both spectra, such as the 2.17 
ppm CH2 protons from the PAMAM dendrimer and the 4.07 ppm CH2COO- protons from CMCht.  
 
Figure 2. Characterization of the CD11b-conjugated CMCht/PAMAM dendrimer nanoparticles. A. FTIR 
spectra of unmodified (NP) and CD11b-conjugated (NP CD11b) CMCht/PAMAM dendrimer nanoparticles. 
Appearance of new peaks in the conjugated molecule confirms the effective conjugation of the antibody to 
the dendrimer nanoparticles. B. 1H NMR spectra of unmodified (NP) and CD11b-conjugated (NP CD11b) 
CMCht/PAMAM dendrimer nanoparticles. C. S-TEM micrograph of CD11b-conjugated MP-loaded 
CMCht/PAMAM dendrimer nanoparticles evidencing its spherical morphology. 
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Also new signals were observed at 1.26 ppm and 2.71 ppm which are attributed to new COCH3 
and NCH3 protons from the newly formed bonds. These new signals strongly suggest that the 
conjugation of CD11b antibody to the nanoparticles actually occurred. Additionally, STEM 
analysis (Figure 2.C) also revealed the nanosphere-like morphology of these nanoparticles. 
Regarding the biological assays, both the glial and microglial cell cultures were incubated with 
two different concentrations of the CD11b-conjugated and the unmodified MP-loaded 
CMCht/PAMAM dendrimer nanoparticles. The metabolic activity was then quantified by means of 
performing an MTS assay. In all the tested conditions no negative effect in the normal cell activity 
was observed (Figure 3). Both cell populations reduced detectable amounts of MTS in similar 
ways to those of control cultures, showing normal cell viability and metabolism. Only a significant 
increase in the metabolic activity of glial cells after 200 µg addition of CD11b-conjugated MP-
loaded CMCht/PAMAM dendrimer nanoparticles was observed while not being a drastic 
difference, in relation to the control cells. These data suggest that there is no cytotoxicity derived 
from the exposure of these cells to the multifunctionalized nanoparticles. 
 
 
Figure 3. Metabolic activity measured with MTS assay of glial and microglial cultures after exoposure to 
the unmodified (NPmp-FITC) and CD11b-conjugated (CD11b-NPmp-FITC) CMCht/PAMAM dendrimer 
nanoparticles. Values are shown as mean±SD (n=3), *p<0.05.  
 
The internalization of the nanoparticles by each cell type in the mixed primary culture of glial cells 
was then further investigated. To allow both a qualitative and a quantitative evaluation, cells were 
immunostained for observation and the number of cells containing fluorescently labeled 
internalized nanoparticles was determined. A previous study has shown that microglial cells 
presented maximum MP-loaded CMCht/PAMAM dendrimer nanoparticles internalization levels, 
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with all cells evidencing nanoparticles within its cytoplasmic compartment 24 hours after 
nanoparticles addition.23 Moreover, astrocytes also reached high internalization levels around 90% 
followed by oligodendrocytes, which presented a slightly lower percentage of nanoparticles 
internalizing cells (around 80%). As observed in Figure 4, the CD11b conjugation to the MP-
loaded CMCht/PAMAM dendrimer nanoparticles did not alter the percentage of microglial cells 
internalizing the nanoparticles as compared to cultures exposed to MP-loaded CMCht/PAMAM 
dendrimer nanoparticles. Interestingly, this observation was not verified for the other glial cell 
types cultured in the presence of the multifunctionalized nanoparticles. Regarding astrocytes, a 
drastic and significant decrease in the antibody-conjugated nanoparticles uptake was observed 
(around 50%), as seen in Figure 4. Similar to what it was observed in astrocytes, 
oligodendrocytes also revealed a significant decrease regarding the CD11b-conjugated MP-loaded 
CMCht/PAMAM dendrimer nanoparticles uptake. Again, the number of oligodendrocytes 
internalizing the modified nanoparticles was drastically reduced to 40% when compared to the 
unmodified nanoparticles condition.  
The endocytosis pathway is believed to be the major route for dendrimer nanoparticles 
internalization, 21,29and it was already shown that surface modifications modulate this 
mechanism.30 Our strategy to modify the nanoparticles with an antibody that is efficiently taken 
up by microglial cells via receptor-mediated endocytosis seems to be advantageous in the non-
specific uptake modulation by other cell types, such as astrocytes and oligodendrocytes. The 
yield of nanoparticles internalization by microglial cells did not improve, since maximum 
percentage figures were already being reached. However, the receptor-mediated endocytosis 
facilitation to microglial cells, due to the interaction of CD11b antibody-conjugated nanoparticles, 
indeed contributed to the improvement of their intracellular uptake and conferred a targeted 
profile to the system, drastically reducing the uptake by astrocytes and oligodendrocytes. 
Thus, we demonstrate that the CD11b antibody-conjugated MP-loaded CMCht/PAMAM 
dendrimer nanoparticles can be beneficial when envisioning the development of  targeted 
therapies aimed at applications in CNS disorders, namely by carrying anti-inflammatory drugs 
such as MP to inflammation mediator cells. 
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Figure 4. Nanoparticle cell uptake by primary glial cell cultures. A. The presence of the CD11b antibody 
in the nanoparticles induced a significant decrease in the number of astrocytes and oligodendrocytes 
internalizing nanoparticles 7 days after exposure. (n=3; 5 fields/coverslip; mean±SD). 
 
 
4. Conclusions 
 
Within the present study it was possible to describe for the first time the successful 
functionalization of MP-loaded CMCht/PAMAM dendrimer nanoparticles with a microglia-specific 
antibody, acting as a targeting ligand. The new sphere-like CD11b antibody-conjugated 
nanoparticles revealed no cytotoxicity when added to glial and microglial primary cell cultures. 
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Furthermore, a novel nanoparticle uptake profile by astrocytes and oligodendrocytes was 
achieved with the new modified nanoparticles. These cells significantly reduced the levels of 
CD11b antibody-conjugated nanoparticles internalization, while maintaining maximum uptake by 
microglial cells. Further studies will focus on the potential selective anti-inflammatory action of 
these nanoparticles, namely for spinal cord injury applications. 
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CHAPTER IV 
Electrophysiological quantification of cellular internalization, retention and 
exocytosis of drug-loaded dendrimer nanoparticles in astrocytes 
Abstract  
Engineered dendrimers are emerging as potentially safer and more effective nanocarriers to 
deliver therapeutic molecules to damaged tissues. Understanding the mechanisms involving NP 
interaction with cells and its intracellular dynamics are of the utmost importance for future 
clinical use. In this study, the uptake, retention time and clearance routes of MP-loaded 
CMCht/PAMAM dendrimer NPs in astrocytes were investigated using two methodologies: (i) 
patch-clamp electrophysiology to measure alterations in the membrane capacitance following NP 
exposure; and (ii) confocal imaging, in order to track the NP fate in live astrocytes following 
vesicle staining and incubation with fluorescent NPs. Interestingly, the electrophysiology data 
reveals fluctuations in the frequency of endo- and exocytotic events in astrocytes following NP 
incubation, revealing that NPs induce the formation of both endocytotic and exocytotic vesicles. 
Endocytosis is slightly increased when NPs are in contact with the astrocyte membrane, while 
exocytosis is significantly enhanced following 24 hour incubation. NPs also induce the formation 
of larger endosomes, while in the case of exocytotic vesicles NP exposure induces the formation 
of smaller ones. Concurrently, live confocal imaging confirms that NPs are transported within 
astrocytes via endocytotic and exocytotic vesicles. Macropinocytosis is shown to contribute to the 
NP cell uptake mechanism. Additionally, NPs are retained intracellularly in astrocytes for a week, 
while still being co-localized with exocytotic vesicles. These findings confirm the potential and 
suitability of CMCht/PAMAM dendrimer NPs for neurotherapeutics, particularly as intracellular 
drug delivery systems. Moreover, future studies on nanoparticle-cell interaction and fate may 
benefit from our findings involving the combination of these two techniques. 
This chapter is based on the following publication: 
Susana R. Cerqueira, Helena H. Chowdhury, João F. Mano, Joaquim M. Oliveira, Nuno Sousa, Rui L. Reis, 
Robert Zorec, “Electrophysiological quantification of cellular internalization, retention and exocytosis of 
drug-loaded dendrimer nanoparticles in astrocytes”, submitted. 
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1. Introduction 
Nanoparticle (NP) systems with diverse surface chemistries and tunable biological properties are 
emerging as prominent delivery carriers for biomedical applications.1 Envisioned as key players 
with major roles in improving current means of diagnostics, imaging and therapeutics, NPs are 
being engineered to allow, for instance, passage through different biological barriers and deliver 
low molecular weight molecules to particular tissues, damaged sites or sub-cellular 
compartments, thus maximizing the healing effects while reducing inconvenient side effects.2 
Some of the conditions that would urgently benefit from improved therapeutic moieties are 
related to central nervous system (CNS) degeneration such as Parkinson and Alzheimer’s 
diseases, amyotrophic lateral sclerosis and others, as well as neurotraumatic condition 
management. CNS-related diseases still present serious challenges in diagnostics and treatment 
being most of them therefore still classified as non-curable. Due to its importance in regulating 
the homeostasis of the nervous tissue, astrocytes were pointed out as ideal targets to be 
considered when dealing with therapies for CNS disorders.3 Besides being essential constituents 
of the blood-brain barrier (BBB), astrocytes play important roles in signaling and intercellular 
communication, both in health and disease, and are critical contributors for the support and 
integration of several CNS functions.4-6 In fact, astrocytes significantly outnumber any other cell 
type in the CNS, thus targeting its protection and repair following traumatic or degenerative 
progression is fundamental for any successful therapeutic intervention. 
Dendrimers are a class of polymeric NPs with unique architectures, exhibiting highly branched 
nano-spherical structures that differ from linear classical polymers in its precise and controlled 
synthesis.7,8 These synthetic polymers seem ideal nanocarriers for drugs and other molecules of 
interest owing to its tunable chemistries, drug payload and pharmacokinetics. An additional and 
quite interesting feature of dendrimers is the intrinsic multivalency that enables several types of 
functionalization and surface engineering.9 Nonetheless, despite the immense amount of 
research presently being conducted involving dendrimer synthesis, functionalization and 
biological evaluation, basic knowledge on the interactions of these NPs with the living systems is 
still scarce. There are still few reports focusing this issue, and not many methodologies have 
been proposed to address NP interplay with the cell membrane and its intracellular trafficking.10 It 
is essential that the mechanisms involving dendrimer internalization and cellular dynamics, in 
addition to cytosolic retention and further clearance, are carefully clarified if an effective and safe 
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therapeutic action is desired. It has recently become clear that dendrimer physical and chemical 
properties affect its interaction with cells, particularly the internalization and trafficking 
mechanisms.11-13 Ideally, NPs would have such characteristics to allow straightforward entrance in 
the target cells, and once inside the intracellular milieu its cargo would be released and delivered 
to the sub-compartments where its action is desired.14 Finally, after providing increased 
bioavailability of the therapeutic agent in the site of action the NPs and the cargo would enter the 
exocytotic pathway to be cleared out from the cells, and eventually from the organism when no 
longer needed. 
Conventional methods employed in NP uptake studies involve confocal microscopy observation, 
often coupled with electron microscopy (EM) or flow cytometry (FC).14 Typically, either specific cell 
structures are labeled to visualize co-localization with the NPs or inhibition of the 
endocytosis/exocytosis pathways is performed and its effects investigated. More recently, other 
techniques such as atomic force microscopy (AFM),15 mathematical correlations from confocal 
laser scanning microscopy (CLSM) and high-throughput fluorescence-activated cell sorting 
(FACS)16 were also suggested for more precise quantification of NP uptake and sub-cellular 
localization. Alternative quantitative methods using electrophysiological measurements to assess 
single-cell real-time quantitative evaluation of the NP internalization dynamics, retention and 
exocytosis have not been reported to our knowledge. Complementing high-resolution patch-clamp 
capacitance measurements with live confocal imaging renders the possibility to both quantify the 
frequency of membrane events, monitoring endocytosis and exocytosis in live cells, and to 
visualize co-localization of NPs with endocytotic and exocytotic vesicles. Patch-clamp 
electrophysiology capacitance measurements consist of real-time evaluation of the membrane 
capacitance (Cm) in living cells, a parameter that is linearly related to the membrane area.17,18 It 
allows the precise live quantification of single endocytotic and exocytotic events and calculation of 
a variety of parameters, such as vesicle diameter and fusion pore properties. As for vesicle 
tracking using confocal observation, there is a vast number of fluorescent probes available that 
label specific compartments within the live cell (e.g., early endosomes, late endosomes, 
lysosomes, and others) allowing co-localization studies to be carried out.19 Both pulse-chase or 
cell transfection experiments can be designed and performed for this end.14  
Our group has recently reported on the surface modification of poly(amidoamine) (PAMAM) 
dendrimers with carboxymethylchitosan (CMCht) increasing its overall surface area and 
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conferring improved biocompatibility and solubility to the PAMAM dendrimers.20 It has been 
confirmed the successful incorporation of lipophilic drugs, such as dexamethasone and 
methylprednisolone (MP) that display a sustained release in vitro and proved to exert actions over 
cell functions.20,21 Moreover, we have devised CMCht/PAMAM dendrimer molecules conjugated to 
targeting molecules, conferring altered cell uptake profiles to these dendrimers.22 These NPs are 
thus being proposed to be used in CNS conditions as therapeutic nanocarriers to be transported 
to the damaged nervous cells.23,24 
In the present study, we investigated the interaction of MP-loaded CMCht/PAMAM dendrimer 
NPs with the astrocyte membrane (single-cell) using real-time patch-clamp electrophysiology 
capacitance measurements to quantify with high sensitivity the endocytotic and exocytotic events 
occurring following incubation with NP. Along with the electrophysiological data, the endocytotic 
and exocytotic vesicles were tracked in live astrocytes following fluorescent labeling, under a 
confocal microscope, to assess possible co-localization of the NPs with these structures. To the 
best of our knowledge, it is the first time that such a study is being conducted using these two 
techniques in combination for purposes of investigating NP uptake, intracellular fate and 
interaction in living CNS cells. 
 
 
2. Materials and methods 
 
2.1. CMCht/PAMAM dendrimer nanoparticle synthesis and functionalization 
 
Carboxymethylchitosan/poly(amidoamine) (CMCht/PAMAM) dendrimer NP were produced as 
previously reported.20 In brief, Starburst® PAMAM-carboxylic acid terminated dendrimers 
(PAMAM-CT) (generation 1.5, 20% w/v in methanolic solution) with an ethylenediamine core were 
purchased (Sigma, Germany) and a series of step-by-step reactions were performed. Firstly, the 
PAMAM-CT generation was doubled and a PAMAM-methyl ester terminated dendrimer was 
produced. Subsequently, a condensation reaction between the methyl ester and amine groups of 
PAMAM and CMCht was made. Finally, the non-reacting methyl ester groups were converted into 
carboxylic ones. Methylprednisolone (MP) was incorporated in the CMCht/PAMAM dendrimer NP 
combining a CMCht/PAMAM dendrimer NP aqueous solution with an ethanolic MP solution with 
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a final concentration of 5×10-4 M (w/w), under vigorous agitation. Saturated sodium carbonate 
solution (Na2CO3, Aldrich, Germany) and acetone (Pronalab, Portugal) were added to precipitate 
the mixture. The precipitate was collected by filtration and dispersed in ultrapure water to 
undergo dialysis (cellulose tubing, benzoylated for separating compounds with a molecular weight 
of ≤1,200, Sigma, Germany) for 48 hours. MP-loaded CMCht/PAMAM dendrimer NP were 
obtained by freeze-drying (Telstar-Cryodos-80, Spain). To label the NP, fluorescein isothyocianate 
(FITC, Sigma, Germany) was added and a covalent bonding reaction was carried out between the 
amine group of CMCht and the isothyocianate group from FITC. The obtained molecules were 
freeze-dried (Telstar-Cryodos-80, Spain). 
 
2.2. Primary astrocyte cultures 
 
Primary cultures of cortical astrocytes were prepared from P3 Wistar rat newborns.25 The care for 
experimental animals was in accordance with International Guiding Principles for Biomedical 
Research Involving Animals which was developed by the Council for International Organizations of 
Medical Sciences and Directive on Conditions for issue of License for Animal Experiments for 
Scientific Research Purposes (Official Gazette of the Republic of Slovenia, No. 38/13). Following 
the tissue dissection, the isolated cells were plated out and grown in high glucose Dulbecco's 
modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 2 mM L-
glutamine, 1 mM sodium pyruvate and penicillin/streptomycin. The cultures were kept at 37°C 
and 95% air/ 5% CO2. The astrocytes were then sub-cultured onto 22 mm diameter poly-L-lysine 
coated glass coverslips at low densities. Control cultures were grown in normal astrocyte culture 
medium while stimulated cells were incubated with astrocyte media supplemented with 200 
µg.mL-1 MP-loaded CMCht/PAMAM dendrimer nanoparticles for 6, 12 or 24 hours prior to 
analysis. All reagents were purchased from Sigma-Aldrich, Germany.  
 
2.3. Electrophysiology recordings 
 
For the electrophysiological recordings the coverslips were bathed in extracellular solution (ECS) 
containing: 130 mM NaCl, 5 mM KCl, 1 mM MgCl, 2 mM CaCl2, 10 mM Na-HEPES and 10 mM 
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D-glucose at pH 7.4. The fire-polished 3–5 MΩ glass pipettes were considerably coated with 
Sylgard (Midland, USA). Cell-attached high resolution membrane capacitance measurements 
were performed using two-phase lock-in amplifier (SWAM IIB; Celica, Slovenia) incorporated into 
a patch-clamp amplifier to record the real and imaginary parts of the admittance of equivalent 
electrical circuit.17 In the compensated mode of recording, one of the two outputs of the dual-
phase lock-in amplifier signal is directly proportional to changes in Cm.26 Signals were filtered (10 
Hz, -3 dB, low pass, Bessel 4-pole) and acquired with an analog-to-digital converter (National 
Instruments BNC-2110, National Instruments, USA) using a custom software (Cell, Celica, 
Slovenia). Membrane patches were voltage-clamped at a holding potential of 0 mV, to which a 
sine wave voltage (111.1 mV rms) was applied (800 Hz). Positive steps in Cm were interpreted as 
single exocytotic and negative steps as single endocytotic events. Steps were resolved by 
progressive filtering of records. The amplitude and frequency of steps in Cm were measured. 
Single astrocytes revealing the typical star-like morphology were chosen for the patch-clamp 
analysis. Recordings were made considering three different conditions: (i) control astrocytes 
grown in regular media and recorded in ECS; (ii) astrocytes cultured in regular media and 
recorded with the membrane exposed to a MP-loaded CMCht/PAMAM dendrimer NP solution 
filled pipette, which was designated as acute NP exposure; and (iii) astrocytes incubated with MP-
loaded CMCht/PAMAM dendrimer nanoparticles for 24 hours and analyzed in ECS. Adenosine 
triphosphate (ATP, Sigma, Germany) was added as a batch solution to the ECS to assess its 
effect in the exocytosis frequency. Off-line data analyses were performed using the software 
MATLAB (MathWorks Inc.). Quantification of the frequency and amplitude of events was 
determined from the obtained recordings. 
 
2.4. Vesicle labeling and live confocal imaging of astrocytes 
 
Co-localization studies in live astrocytes were performed in order to identify both the endocytotic 
and exocytotic vesicles involved in the nanoparticle cellular dynamics. For endocytotic vesicle 
labeling, low dense astrocyte cultures were incubated with Alexa Fluor® 546 Dextran (Molecular 
Probes, USA) for 1.5 hours and thoroughly washed in ECS prior to observation. To observe the 
exocytotic vesicles sub-confluent astrocyte cultures were used and transfected with the plasmid 
DNA encoding Neuropeptide Y (NPY) tagged with mCherry fluorescent protein (NPY-mCherry, a 
kind gift from Dr. Ronald W. Holz, University of Michigan, USA). Briefly, the cells were incubated 
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in lipofection media (DMEM, 1 mM sodium piruvate, 2 mM L-glutamine) and mixed with 
transfecting reagent (Fugene, Promega, USA) with 1 µg of plasmid DNA for 15 minutes, at 37ºC. 
After that, culture medium was added and supplemented with 3% UltraSerG serum (Life 
Technologies, USA) and the cells were observed past 24 hours of incubation. 
Live confocal microscopy images were acquired with an inverted microscope (Zeiss LSM META 
510, Germany) equipped with a 63.2× oil-immersion objective. FITC molecules bonded to the 
NPs were excited by the 488-nm line of the argon laser and the emission light was collected 
through the bandpass filter (505–530 nm). Alexa Fluor 546 labeling the vesicles was excited with 
the He/Ne laser (543 nm) and the emission light was filtered with the long-pass filter, with the 
cutoff below 560 nm. To eliminate possible bleed through, the green and red emission 
fluorescence were acquired sequentially. Time series images were recorded in 20 seconds 
intervals during 45 minutes. All the recordings were performed in 300 mOsm ECS. Cells were 
stimulated with 1 mM ATP to assess alterations in exocytosis. 
 
2.5. Data analysis 
 
Electrophysiological analysis was performed in CellAnn software for MatLab (MathWorks, USA). 
Individual steps, both positive and negative, in the imaginary part of the admittance signal (with 
no projections in the direct current trace) were registered and accounted as endocytotic, transient 
or full fusion exocytotic events for the frequency determination. Vesicle diameters were calculated 
using a specific membrane capacitance of 8 fF.µm-2. Values are presented as mean ± SEM, 
unless stated otherwise. Two-way analysis of variance with Bonferroni post-test was used to 
assess statistical significance.  
 
 
3. Results and discussion 
 
The physico-chemical properties of engineered nanomaterials including size, shape, surface 
charge and chemistry have been recognized to robustly modulate its cellular internalization 
efficiency and fate.10 In our lab, MP-loaded CMCht/PAMAM dendrimer NPs have been previously 
characterized displaying negative zeta potential when dispersed in physiological buffer and a 
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globular structure of about 109 nm in hydrodynamic diameter. Despite the lack of information 
regarding the cellular inward and outward mechanisms, the MP-loaded CMCht/PAMAM 
dendrimer NPs were reported to be easily internalized by primary nervous cells in a time-
dependent manner without altering their viability or metabolic activity.27 Additional in vivo assays 
have also confirmed that no morphological alterations in the liver, kidney or lungs of Wistar rats 
following NP intravenous administration were present, confirming their suitability to be used as 
therapeutic nanocarriers.23 Therefore, in order to fully devise these NPs as optimal drug delivery 
systems a comprehensive understanding of the interaction with the target cell membrane, as well 
as its intracellular trafficking has been investigated herein. 
To further elucidate the uptake and clearance mechanisms, two distinct methods in cultured 
astrocytes were used complementarily. Firstly, we used cell-attached patch clamp 
electrophysiology to monitor discrete alterations in the membrane capacitance (Cm) that reflect 
unitary endocytotic and exocytotic events and allow the quantification of the later, as well as 
vesicle diameter and fusion pore opening time.28 Afterwards, confocal imaging of live astrocytes 
following incubation with fluorescently labeled NPs along with vesicle staining enabled to track its 
co-localization, which demonstrates NP vesicle transport. The cell-attached patch-clamp Cm 
measurements are directly correlated to the plasma membrane surface area, which dynamically 
fluctuates due to exocytosis and endocytosis. We questioned whether any differences in the 
frequency of occurring events was present between control astrocytes and NP-stimulated cells, 
both acute or chronically. In the acute NP stimulus, the astrocyte membrane was exposed to the 
NPs in solution inside the patch pipette during the analysis; whereas the chronically stimulated 
cells were incubated previously with the NPs for 24 hours. In both cases a dose of 200 µg.mL -1 
was used taking into account previous studies reporting no cytotoxicity at this concentration.27 A 
total of 62 astrocyte membrane patches were recorded, each of which being analysed for about 
1000 seconds. In all cells, three types of alterations were detected in the Cm: (i) discrete 
irreversible upward steps, representing full fusion exocytotic events; (ii) single irreversible 
downward steps, indicating the occurrence of endocytosis; and (iii) reversible upward steps 
illustrating transient exocytotic events. 17,18,29 These events are schematically represented in Figure 
1. 
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Interestingly, our data revealed slight and similar increases in the frequency of endocytotic 
vesicles (Figure 2A) formed in the astrocyte membrane following NP incubation, both acute or 
chronically, in relation to control cells that had no exposure to NPs (Figure 2B). Although no 
statistical significance was determined between the groups, a slight amplification tendency is 
observed in the frequency of endocytotic events when NPs are present in the media. To our 
knowledge, it is the first time that endocytosis is analyzed following drug-loaded NP stimulation 
using the patch-clamp electrophysiological technique. Herein, it is suggested the use of this 
technique for similar studies, for its high sensitivity and resolution allow a precise quantification 
of the cell secretory activity. Moreover, the amplitude of the detected discrete steps allows the 
calculation of the vesicle diameter, assuming a spherical geometry, which provides singular 
insights on the vesicle properties. The vesicle diameter distribution revealed no significant 
differences between the control conditions (146±6 nm) and the astrocytes that were incubated 
with NPs for 24 hours (138±5 nm) (Figures 2C,E). Both the frequency and diameter figures were 
equivalent in these two situations. As seen in Figure 2D, however, when NPs are in solution 
inside the patch pipette, thus in contact with the astrocyte membrane, there is a small shift in the 
vesicle diameter distribution resulting in the formation of larger endosomes (173±6 nm). This is 
most likely due to the activation of a specific endocytic pathway that is carrying the 109 nm NPs 
inward to the astrocyte cytosol. The typical behavior of macropinocytosis vesicles seems coherent 
Figure 1 – Schematic representation of the membrane capacitance recordings by patch-clamp technique 
in astrocytes. Each of the possible alterations in the membrane is represented, namely: (i) endocytosis, 
with discrete downward steps in the recording; (ii) and exocytosis, with reversible (transient) or irreversible 
(full fusion) upward steps in the membrane capacitance. 
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and attributable to CMCht/PAMAM NP transport, namely due to the determined average vesicle 
size. PAMAM dendrimers have already been accounted to follow multiple endocytotic pathways to 
enter cells,11,14 from receptor-mediated endocytosis (e.g., clathrin-mediated endocytosis) to non-
specific uptake by macropinocytosis, depending on the surface modification and dendrimer 
generation.30 The CMCht-grafted PAMAM dendrimers have been recently denoted to follow an 
endocytotic uptake mechanism, following a blocking study with colchicine, although no more 
detailed investigations were done.20 Inhibition studies like the one before mentioned are often 
used to investigate the specific endocytotic route associated to the NP uptake, however some 
inhibitors have shown not to be that selective, actually affecting more than a single pathway.31 
Therefore, additional studies are crucial for a better understanding of the cell trafficking 
mechanisms.  
 
 
Figure 2 – A. Representative recording of an irreversible downward step in the imaginary admittance trace (Cm) 
proportional to membrane capacitance, and the corresponding real part of the admittance trace (Ra) proportional to 
access conductance, of a cell-attached recording indicative of the formation of an endocytotic vesicle. B. Graphical 
representation of the average frequency of endocytotic events in single astrocytes: (i) cultured in regular media 
(CONTROL); (ii) cultured in regular media but exposed to NP in the patch pipette solution, during the analysis (NP); 
and (iii) following 24 hours of incubation in NP (incubated NP) and analyzed in ECS. Values are presented as mean ± 
SEM. C-E. Endocytotic vesicle diameter distribution, calculated from the vesicle capacitance amplitude and 
assuming spherical morphology and a specific membrane capacitance of 8 fF/µm2.  
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The endocytosis frequency determination from Cm readings does not allow to completely 
distinguish the different internalization routes, however the vesicle diameter determination can 
provide some insights regarding this.32 In addition, a major gain of using this technique is the 
straightforward assessment of vesicle fusion and fission with temporal resolution, measuring 
events in the live membrane in real-time. From the present study, it appears that the interaction 
of NPs present in the vicinity of astrocyte plasma membranes induces, although to a limited 
extent, not only the formation of new endocytotic vesicles but also larger ones (Fig.2D). In view of 
the fact that no morphological alterations were observed in the cultured astrocytes and previous 
studies have demonstrated that the concentration used is not deleterious to primary nervous 
cells,27 these variations have not been associated with any pathological alteration. However, a 
more detailed analysis dissecting all the endocytotic possible mechanisms occurring would better 
confirm this analysis. 
We have hypothesized that a significant part of the NPs enters the astrocytes via 
macropinocytosis, based on the fact that the NPs possess a diameter that seems to be adequate 
to be transported by this type of vesicles. Nevertheless, we do not exclude the simultaneous 
occurrence of receptor-mediated endocytosis, as it is known that NPs interact with proteins 
present in the media and this corona may react with plasma membrane receptors, inducing 
specific endocytotic pathways. Nevertheless, we have focused our interest on the investigation of 
macropinocytosis given its anticipated relevance in the NP transport to the astrocyte cytosol. As a 
result, pulse-chase experiments were conducted adding labeled dextrans exogenously to primary 
astrocyte cultures, for the specific staining of macropinosomes.11 Simultaneously, FITC-labeled 
MP-loaded NPs were incubated to track its intracellular trafficking and distribution. Confocal live 
imaging revealed extensive uptake of the FITC-labeled MP-loaded NPs after 24 hours of 
incubation with privileged perinuclear localization (Figure 3A), comparable to what has been 
previously reported.21 Co-localization of NPs with the dextran-labeled macropinosomes was 
thoroughly observed evidencing directly and for the first time that the NPs are internalized via 
endocytosis, with an important contribution from the macropinocytic pathway. Confocal 
sequential live imaging allowed us to visualize the continuous trafficking of the endosomes in the 
cytoplasm, and more importantly to validate the co-localization findings with these vesicles. FITC-
labeled NPs were observed circulating concurrently with labeled macropinosomes in the 
astrocyte cytosol. Regardless of the NP incubation times (6, 12 or 24 hours) co-localization of 
FITC-labeled NPs and dextran-labeled macropinosomes was always observed and apparently with 
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no significant differences (Figure 3B). Accordingly, similar co-localization coefficients were 
measured along time, implying that this uptake process is relatively fast (43±9% at 6h; 42±11% 
at 12h; and 36±7% at 24h incubation). Additionally in this study, it was noted that the NPs are 
able to be retained intracellularly in astrocytes for 24 hours, when present in the culture media. 
 
 
Figure 3 – A. Confocal micrographs of live astrocytes following Alexa Fluor® 546-dextran labeling 
(macropinosomes, in red) and incubation with FITC-labeled MP-loaded CMCht/PAMAM dendrimer NPs (in 
green). Co-localizations can be seen in yellow. The corresponding transmission light microscopy images 
are shown. Three different times of NP incubation were investigated: 6, 12 and 24 hours. Scale bars 
represent 20 µm. B. Relative co-localization of NPs with the dextran labeled macropinosomes (in %), 
relative to above threshold NP fluorescence in the cell, at different incubation period of cells with NPs. 
Threshold was 20 %. Error bars denote SEM; numbers in the columns indicate number of cells tested. 
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Notwithstanding, it was noted that the co-localization coefficients between NPs and endocytotic 
vesicles were slightly superior following shorter incubation times, rather than longer exposure to 
the NP, as 24h. We speculate that this is most likely due to a saturation effect and an endocytotic 
recycling regulatory mechanism. The initial input in the NP uptake is indeed the most relevant if 
we consider its therapeutic application; and we are showing that NPs are able to be rapidly 
transported to and retained inside astrocytes. Once in the cytosol, the NPs are expected to be 
retained long enough to allow the drug release, either by passive drug diffusion or as a result of 
NP degradation. Either way, after the therapeutic drug is released from the dendrimers, the NPs 
should be cleared out from the astrocytes. 
Astrocytes, as other eukaryotic cells, contain secretory vesicles that exhibit a variety of diameters 
and serve for luminal cargo release, as well as membrane-associated receptors and 
transporters.33 Comparing to neurons, exocytosis is much slower in astrocytes but it appears that, 
as in neurons, two types of exocytosis can occur (as shown in Figure 1): (i) full fusion, if the 
vesicle fuses in the cell membrane becoming part of the membrane; and (ii) transient, if the 
vesicle remains associated with the membrane, transiently opening the fusion pore and 
eventually returning to the cytosol.33 Not many studies have focused on exocytosis of NPs 
regardless of its relevance, which eventually dictates the NP intracellular retention times and a 
potential chronic toxicity if NPs are not excreted from the cells. These two parameters are critical 
when considering therapeutic applications for NPs.34-37 Ideally, after the NP desired action is 
accomplished intracellularly, extensive exocytosis of the latter should follow leaving the cells 
repaired and intact. To gain further insights into the clearance process of the MP-loaded 
CMCht/PAMAM dendrimer NPs, the frequency of formation of secretory vesicles was monitored 
once more by means of patch-clamp electrophysiology (Figure 4A), together with live confocal 
observation. In order to visualize the exocytotic vesicles and possible co-localization with NPs, 
transfection of astrocytes with mCherry-neuropeptide Y (NPY) was performed. NPY is a 
neurotransmiter that is broadly exocytosed by astrocytes, thus commonly serving as a marker for 
exocytosis.38 The electrophysiological quantification of the exocytotic events occurring in the cell 
membranes revealed remarkable differences amongst the conditions tested (Figure 4B). 
Surprisingly, both the acute and chronic exposure to the NPs suggest an up-regulation of 
exocytosis in astrocytes, albeit at clearly different extents. 
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The total frequency of exocytotic events in astrocytes in the immediate NP contact (0.05±0.01 
events/s) was above the basal levels (0.030±0.005 events/s); however, despite an almost 2-fold 
increase in the frequency, no statistical significance was detected (Figure 4B). Considering that a 
noticeably similar tendency was observed in the endocytosis rates in the acute NP exposure, we 
might infer that these two figures are related assuming, as suggested in the literature, that both 
endocytosis and exocytosis are occurring simultaneously and in a dynamic fashion as a result of 
NP interaction.36 More importantly, a significant statistical difference was verified following a 
longer incubation time of 24 hours (0.11±0.02 events/s) revealing an unquestionable increase in 
the exocytosis frequency in astrocytes. To the best of our knowledge, it is the first time that such 
Figure 4 – A. Representative recording of an irreversible upward step in the imaginary admittance 
trace (Cm) and the corresponding real part of the admittance trace (Ra), indicative of the formation of 
an exocytotic vesicle. Arrow indicates a calibration pulse. B. Graphical representation of the average 
frequency of total exocytotic events in single astrocytes: (i) cultured in regular media (CONTROL); (ii) 
cultured in regular media and exposed to NP in the patch pipette solution during the recording (NP); 
and (iii) following 24 hours of incubation in MP-loaded CMCht/PAMAM dendrimer NP (incubated NP). 
Values are presented as mean ± SEM. * p<0.05 C-E. Endocytotic vesicle diameter distribution, 
calculated from the vesicle capacitance amplitude and assuming spherical morphology and a specific 
membrane capacitance of 8 fF/ µm2.  
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an increase in exocytosis is reported from electrophysiological quantification of the secretory 
vesicle frequency after incubation of NPs in live astrocytes. The herein reported data reveals that 
following 24 hours of incubation with MP-loaded CMCht/PAMAM dendrimer NPs a drastic ≈4-fold 
increase in the frequency of exocytosis is detected in the astrocyte membrane patches (Figure 
4B). Some authors suggest the occurrence of a recycling process of the membrane when in 
interaction with particulate systems, with the formation of exocytotic vesicles in response to the 
endocytosis of NPs.39 Nonetheless, the frequencies of exocytosis we have measured are 
significantly superior to the endocytosis rates seen after chronic NP stimulation. However, if we 
take into account the vesicle diameter distributions (Figure 4C-E) it is evident that the exocytotic 
vesicles are significantly smaller in size than the endosomes, with an average diameter of 77±6 
nm in basal conditions. Moreover, there is an additional shift in the exocytotic vesicle size 
distribution following NP acute or chronic exposure that indicates the formation of smaller 
vesicles, averaging 69±7 nm for acute NP exposure and 60±3 nm after prolonged 24 hour 
incubation. This might suggest that some NPs are being cleared out already with some extent of 
degradation. 
A regulated balance between the endocytosis and exocytosis events occurring in the cells is of 
extreme importance, otherwise there would be a significant change in the membrane area and 
consequently in the cell volume that could be disturbing for the homeostasis and normal cell 
functioning. As corroborated by others, when macropinocytosis occurs there is a momentary 
increase in the cellular fluid uptake,40 result of liquid and solutes engulfing from the extracellular 
media. Following this process, up-regulation of exocytosis may occur as a compensatory 
mechanism. Besides, since exocytosis is slower in astrocytes, its fluctuations in frequency are 
most likely to be noticed later, as it was observed after 24 hours of exposure to the NPs. We 
further confirmed that the NPs were indeed being exocytosed 24 hours after incubation, 
identifying co-localization spots of FITC-labeled NPs with the NPY-mCherry labeled exosomes, 
under a confocal microscope. Unlike endocytosis, the number of co-localized NPs with exocytotic 
vesicles found in astrocytes, visibly increased with time (Figure 5) corroborating the obtained 
electrophysiological data. Lower incubation times (6 hours) revealed the lowest percentage of co-
localization (14±4%), while the higher incubation times (12 and 24 hours) uncovered significantly 
higher degrees of co-localization (38±10% and 40±6%, respectively). Thus, our findings indicate 
the direct dependence of this process with the time of exposure to NPs. For the first time, we are 
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confirming that the MP-loaded CMCht/PAMAM dendrimer NPs are cleared out from astrocytes 
via exocytosis, by two complimentary techniques that show compliant results.  
 
 
 
Figure 5 – A. Confocal micrographs of live astrocytes following mCherry-NPY transfection (exocytotic 
vesicles, in red) and incubation with FITC-labeled MP-loaded CMCht/PAMAM dendrimer NP (in green). Co-
localizations can be seen in yellow. The corresponding transmission microscopy images are shown. Three 
different periods of NP incubation were investigated: 6, 12 and 24 hours. Scale bars represent 20 µm. B. 
Relative co-localization of NPs with the NPY exocytotic vesicle marker (in %), relative to above threshold NP 
fluorescence in the cell at different incubation period of cells with NPs. Threshold was 20 %. Bars denote 
SEM, asterisks indicate statistically significant differences between groups (* p<0.05), numbers in the 
columns indicate the number of cells tested. 
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The detailed investigation of the exocytotic mechanism occurrence after NP internalization in 
astrocytes was also considered (Figure 6A), as well as the influence of ATP as an exocytotic 
stimulant (Figure 6B). Intracellular ATP has been described as one of the energy sources for the 
formation of exocytotic vesicles inducing this process, and also functioning as an astrocytic 
transmitter.33 We studied whether the astrocytes still respond as expected after ATP stimulation 
when NPs are also present. The patch-clamp Cm readings after addition of physiological solution 
of ATP (1 mM) to control astrocytes have revealed induced levels of exocytosis, as anticipated 
(Figure 6B). The same trend occurred after acute exposure to NPs, indicating that the NP 
interaction with the plasma membrane does not affect the response to this exocytosis stimulant.  
 
 
 
Figure 6 – A. Representative recording of reversible upward steps in the imaginary admittance trace 
(Im) and the corresponding real part of the admittance trace (Re), indicative of the formation of a 
transient type exocytotic vesicle. Arrow indicates a calibration pulse. B. Graphical representation of 
the average frequency of total exocytotic events in single astrocytes with stimulation of ATP when: (i) 
cultured in regular media (CONTROL); (ii) cultured in regular media and exposed to NP in the patch 
pipette solution during the recording (NP); and (iii) following 24 hours of incubation in MP-loaded 
CMCht/PAMAM dendrimer NP (incubated NP). C-D. Frequency (C) and percentage (D) of exocytosis 
type occurrence (transient or full fusion) in the above mentioned conditions; in the presence or 
absence of ATP stimulation. SEM are shown;* p<0.05; **<0.01. 
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Interestingly, the presence of both NPs and ATP inside astrocytes has a signifficant effect in 
exocytosis frequency. Conversely, ATP addition had no effect on the frequency of exocytosis when 
cells were incubated previously with NPs for 24 hours. In this case, it is believed that the 
exocytosis process was in a saturation level already and consequently there was no further 
possible boost in the frequency of exocytosis, even after stimulation with ATP. 
To further dissect the exocytosis mechanisms occurring in astrocytes following NP interaction, we 
discerned between the two mechanisms of exocytosis (transient and full fusion) to investigate if 
the NPs were causing any alterations in its usual profile. As seen in Figures 6C and 6D, our 
findings reveal a prevalence of transient exocytosis events in all the conditions, with no alterations 
in the exocytotic subtype profile, even in the presence of NPs. Figure 6C indicates that the 
addition of ATP to the control astrocytes induced an approximate 2-fold increase in the frequency 
of transient events with only a modest decrease in the number of full fusion events. The same 
happened with the addition of NPs, suggesting once more that the presence of NPs stimulates 
exocytosis, in this case, in a similar proportion as the stimulant ATP. Equivalent frequency 
response was observed either in the presence of NPs or ATP, denoting that both ATP and NPs 
have similar exocytotic stimulant effects in astrocytes, particularly inducing transient event 
occurrence. When acute stimulation is provided to astrocytes, with ATP and NPs added 
simultaneously, the most significant boost in exocytosis frequency is observed. Nevertheless, no 
changes in the exocytotic subtype profile are detected (Figure 6D), with an approximately 90:10 
ratio of transient:full fusion events taking place, and similar to the other conditions tested. The 
maintenance of the exocytotic subtype profile, with the same response after ATP or NP 
stimulation, might be an indicator that the interaction of NPs with astrocytes is not being 
deleterious or disturbing to the typical clearance mechanisms. Despite notorious frequency level 
variations, the ratio between the two exocytotic profiles is maintained.  
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Figure 7 - NP co-localization with astrocyte vesicles (endocytotic and exocytotic) prior and after 
stimulation with 1 mM ATP. Co-localization coefficient of NPs in % with: macropinosomes labeled with 
Alexa Fluor® 546 dextrans (left); and mCherry-NPY labeled vesicles (right). Non-stimulated conditions 
(black columns) and 1 mM ATP astrocyte stimulation (gray columns) are represented. Error bars indicate 
SEM; numbers within columns indicate the number of analyzed cells. (* P< 0.05) 
 
Finally, in an additional long-term study the astrocyte cultures were maintained for a week after 
an initial 24 hour exposure to the NPs. The media was replaced every day during a week to 
certify that no NPs were being exogenously added to the cells, besides the initial input, and all 
NPs present in the culture media were removed. Afterwards, both the endocytotic and exocytotic 
vesicles were labeled and the cells observed. As seen in Figure 8A, results demonstrate that 
FITC-labeled NPs were still present abundantly in the confluent astrocyte cultures with high 
retention rates in the cytosol. Nonetheless, very modest co-localization with endosomes was 
visualized and quantified (15±2%), which was significantly lower than after 24h of incubation 
(36±7%). On the other hand, co-localization of NPs with exocytotic vesicles was slightly increased 
one week after incubation (52±5% vs. 40±6%) and extensive co-localization spots were still 
observed. This is a strong indication that the NPs are still being cleared out of the astrocytes one 
week after internalization and with no NP renewal for a week, demonstrating a continuous 
clearance NP process. In addition, it was also confirmed that endocytosis is highly reduced under 
these circumstances, since no NPs are exogenously being added to the cells. The MP-loaded 
CMCht/PAMAM dendrimer nanoparticles seem to enter the astrocyte typical trafficking pathways, 
both endocytotic and exocytotic. More importantly, they are continuously cleared out from the 
cells even one week after the exposure. 
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Figure 8 – A. Confocal micrographs of live astrocytes following mCherry-NPY transfection (above, 
exocytotic vesicles in red) or Alexa Fluor® 546 dextrans incubation (below, macropinosomes in red).  
FITC-labeled MP-loaded CMCht/PAMAM dendrimer NP (in green) were incubated for 24 hours and 
then removed from the media, with daily media change for one week. Co-localizations can be seen in 
yellow. Scale bars represent 20 µm. B. Co-localization coefficient of NP with membrane vesicles in % 
with the Alexa Fluor® 546 dextrans labeled macropinosomes and with the mCherry-NPY labeled 
vesicles immediately after 24h cell incubation with NP (black columns) and one week after (gray 
columns). Error bars indicate SEM, numbers in columns indicate numer of cells analyzed, asterisks 
denote statistically significant difference (* P< 0.05). 
 123  
 
4. Conclusions 
 
CMCht/PAMAM dendrimer NP have been showing many attractive features that renders them as 
great candidate nanocarriers to be used in biomedical applications, namely in CNS disorders.  
Despite biocompatibility and in vivo beneficial therapeutic effects have already been reported, the 
mechanisms underlying the interaction of the NPs with cells still remain unaddressed up to now. 
In this study, we thoroughly investigated the interaction of MP-loaded CMCht/PAMAM dendrimer 
NPs with astrocytes envisioning a potential targeted delivery to these cells following trauma or 
disease. The combination of the quantitative data obtained from patch-clamp electrophysiology 
readings and the live cell confocal imaging revealed to be appropriate to study endocytotic and 
exocytotic events, and have provided valuable and reliable information of the NP interaction and 
fate in astrocytes. It was noticed that endocytosis is slightly increased in the presence of the NPs, 
with a tendency to induce the formation of considerably larger vesicles. Confocal imaging 
confirmed the importance of macropinocytosis in the endocytotic uptake of the NPs and the time 
dependence of this uptake process. Exocytosis, on the other hand, is significantly increased 
following incubation with NPs suggesting that they are cleared out from astrocytes inside 
secretory vesicles. The reduction of the exocytotic vesicle diameter suggests that some 
degradation might have already occurred during the NPs intracellular trafficking. Live imaging of 
the astrocytes confirmed the presence of the NPs inside exocytotic vesicles, namely one week 
after incubation showing that this is a continuous and dynamic NP clearance process. There is 
an indication that NPs stimulate exocytosis, as ATP for instance, having similar effects on the 
exocytotic mechanism subtype profile, and reducing considerably the occurrence of full fusion 
events. The NPs were still found inside astrocytes one week after incubation, with more 
exocytotic transport occurring, while endocytosis was drastically decreased. The recycling of NPs, 
herein reported for the first time to occur via endocytosis and exocytosis, is relevant information 
providing new insights on the interaction of these NPs with nervous cells. No deleterious effects 
were detected during NP trafficking, confirming the suitability of these intracellular nanocarriers. 
Additionally, it is expected that the scientific community appreciates the potential relevance of 
patch-clamp measurements for studies involving nanomaterials and cell membrane interaction 
studies, given its high resolution and sensitivity. 
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CHAPTER V 
Dendrimer nanoparticle diffusion in the rat brain parenchyma following 
intracisternal administration 
 
 
Abstract 
Drug delivery to the central nervous system (CNS) still is a challenge in biomedical research, with 
new exciting nanocarrier solutions arising from the nanotechnology field. Nonetheless, the real 
therapeutic applicability of nanoparticle (NP) systems can only be fairly predicted after its 
distribution properties in contact with live cells and biological tissues/organs are investigated. In 
this study, it was investigated the ability of fluorescein-labeled methylprednisolone (MP)–loaded 
CMCht/PAMAM dendrimer NPs to diffuse in the brain parenchyma following intracisternal 
administration in healthy rats. Confocal imaging revealed that the NPs were able to penetrate the 
nervous tissue, reaching areas such as the hippocampus, cerebellum and inner pre-frontal cortex 
parenchyma. The fluorescent NPs were detected intracellularly 72 hours post-administration. No 
morphological discrepancies were observed in astrocytes, suggesting no deleterious effects after 
administration of the NPs. The expression levels of glucocorticoid receptors (GR) in the brain 
following NP injection were also investigated. A decreased protein level of the GR following NP 
administration was detected, indicating that MP is being released from the NPs and acting 
intracellularly. Moreover, it was observed that NPs can be retained in the brain tissue while being 
able of delivering drugs, such as the corticosteroid MP. These findings provide new compelling 
arguments for the use of CMCht/PAMAM dendrimer nanoparticles as drug delivery nanocarriers 
for CNS. 
 
This chapter is based on the following publication: 
Susana R. Cerqueira, Fernanda Marques, Joaquim M. Oliveira, João F. Mano, Nuno Sousa, Rui 
L. Reis, “Dendrimer nanoparticle diffusion in the rat brain parenchyma following intracisternal 
administration”, submitted. 
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1. Introduction: 
 
In a progressively aging population it is expected that the incidence of neurodegenerative 
diseases will soon increase significantly.1 The gradual loss of function and structure of neurons 
can be highly debilitating, leading to chronic disabilities that include failure to control movements, 
organ malfunctions as well as severe cognitive and emotional impairments. For these conditions, 
as for neurotraumatic episodes as well, there is no successful therapeutic intervention yet. 
Currently, clinicians still face a number of limitations and obstacles to treat central nervous 
system (CNS) disease, namely the inability of therapeutic drugs to cross the blood-brain barrier 
(BBB) and consistently target the affected tissue.2 Since classical drugs are failing to succeed, 
also due to short half lives and unwanted side effects, alternative and more sophisticated vehicles 
are being developed and studied to reach the target sites and treat these disabilities in a more 
effective manner.3 Nanotechnology, as the scientific field originating and engineering materials 
with dimensions from few to about 100 nanometers, is promising unique advances in biomedical 
applications, namely in neuroscience. These new nanomaterials can bring enhanced properties 
for use as drug carriers in regenerative strategies, namely: (i) increasing the drug bioavailability, 
with extended circulation times; (ii) the possibility to overcome the blood-CNS barriers; and (iii) 
the possibility to be functionalized, adding targeting, imaging or therapeutical features to the 
nanoparticle systems; while making use of traditional routes of administration. There is an 
immense set of nanoparticles recently proposed for use as nanocarriers for therapeutic 
applications, from classical linear polymers to novel spherical molecules. Dendrimers are 
particularly interesting monodisperse synthetic molecules with spherical morphology and highly 
ramified branches that resemble a tree.4 They can be surface functionalized and its size 
thoroughly controlled, influencing its drug payload and targeting features.5 Being the most 
investigated dendrimer molecules, poly(amido)amine (PAMAM) molecules have been recently 
suggested for use in central nervous system applications, mostly for malignant glioma therapies.6 
Functionalization of PAMAM dendrimers with targeting agents to allow transport across the BBB, 
such as transferrin, resulted in efficient distribution of the dendrimers in the brain tissue.7 
Furthermore, boronated-PAMAM dendrimers are also being explored for neuron boron capture 
therapies and already showed improved efficacy in rat glioma models.8 
Recently, a new functionalization on PAMAM dendrimer nanoparticles was reported by grafting 
the dendrimer core with carboxymethylchitosan (CMCht), which led to an improvement in the 
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drug loading capacity and biocompatibility of the molecule.9 The developed CMCht/PAMAM 
dendrimer NPs were suggested to be used as intracellular drug delivery vehicles, namely in CNS 
applications.10 Moreover, these nanocarrier systems have already shown to be internalized by 
primary neuron and glial cell cultures without interfering with their viability and metabolic 
activity.11 In another study, the corticosteroid methylprednisolone (MP) was shown to be able to 
be efficiently incorporated into the NPs.12 These promising features led us to investigate further 
the NP distribution in the nervous tissue, namely in the brain, in order to have a preliminary 
insight on its dispersion properties and assess the potential applications in vivo. In a recent 
report, intravenous injections of fluorescently-labeled CMCht/PAMAM dendrimer NPs revealed 
their presence in peripheral organs and in the choroid plexus, while not intracellularly in the brain 
parenchyma.13 This study has revealed that CMCht/PAMAM dendrimer NPs are not yet capable 
of crossing neither the BBB nor the blood-cerebrospinal fluid (CSF) barrier, located at the choroid 
plexus level, without further functionalization. Nonetheless, several direct administration 
techniques, such as intraparenchymal, intraventricular or subarachnoid injections have been 
used to target molecules directly in the nervous tissue and assess its ability to diffuse within it.14 
Injections in the cisterna magna, particularly, are considered substantially less invasive than 
intraventricular or intraparenchymal, and might subsequently be regarded for prospective clinical 
use.15 
In the present study, it is aimed to assess the distribution of MP-loaded CMCht/PAMAM 
dendrimer NPs in the nervous tissue, and further investigate the MP intracellular release and 
action. The administration of fluorescently labeled NPs was performed directly into the CSF in the 
cisterna magna of Wistar rats in a simple and rapid procedure, as illustrated in Figure 1. 
Confocal imaging of relevant cerebral areas such as the hippocampus (HPC), pre-frontal cortex 
(PFC) and cerebellum (CB) was performed 72 hours post-injection to study the NP accumulation 
and distribution. Additionally, the intracellular action of the released MP, glucocorticoid receptor 
(GR) protein levels were analyzed in HPC, PFC and CB lysates using western blot analysis. Thus, 
it was both qualitative and quantitatively investigated the NP location in the brain following 
dispersion in the CSF, therefore adding new and valuable features for future studies and 
application in CNS conditions. 
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2. Materials and methods: 
 
2.1. CMCht/PAMAM dendrimer nanoparticle synthesis and functionalization 
 
Carboxymethylchitosan/poly(amidoamine) (CMCht/PAMAM) dendrimer NPs were produced as 
previously described.9 Briefly, Starburst® PAMAM-carboxylic acid terminated dendrimers 
(PAMAM-CT) (generation 1.5, 20% w/v in methanolic solution) with an ethylenediamine core were 
purchased (Sigma, USA) and the following reactions were carried out: (i) increase in the PAMAM-
CT generation; (ii) production of a PAMAM-methyl esther terminated dendrimer; (iii) condensation 
between the methyl esther and amine groups of PAMAM and CMCht; and (iv) conversion of the 
non-reacting methyl esther groups into carboxylic ones. MP was incorporated mixing an aqueous 
solution of CMCht/PAMAM dendrimer NP with an ethanolic MP solution with a final concentration 
of 5×10-4 M (w/w) and kept under vigorous agitation. Saturated sodium carbonate solution 
(Na2CO3, Sigma) and acetone (Pronalab, Portugal) were then added to the mixture. The 
precipitates were collected by filtration and dispersed in ultrapure water to undergo dialysis 
(cellulose tubing, benzoylated for separating compounds with a molecular weight of ≤1,200, 
Sigma) for 48 hours. MP-loaded CMCht/PAMAM dendrimer NP were obtained by freeze-drying 
the solution (Telstar-Cryodos-80, Spain) during 1 week. Additionally, fluorescein isothyocianate 
(FITC, Sigma) labeled MP-loaded CMCht/PAMAM dendrimer NPs were prepared by covalently 
bonding the amine group of CMCht and the isothyocianate group from FITC. 
 
2.2. Intracisternal nanoparticle administration 
 
All experiments were carried out using male 10-week old Wistar rats (n=10) (Charles River, 
Spain). Animal handling and experiments were conducted in accordance with the Portuguese 
national authority for animal experimentation, Direção Geral de Veterinária (ID:DGV9457). 
Animals were kept in accordance with the guidelines for the care and handling of laboratory 
animals in the Directive 2010/63/EU of the European Parliament and Council. Animals were 
maintained for 12 hours in light/dark cycles at 22.5°C and 55% humidity, and fed with regular 
rodent’s chow and tap water ad libitum.16 The animals were anesthetized before surgery by 
intraperitoneal injection of 150 mg.Kg-1 ketamine hydrochloride and 0.3 mg.Kg-1 medetomidine. 
Then, the animals were placed in a stereotaxic frame with the head curved 45° downwards and 
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the dorsal base of the skull was shaved and soaked with ethanol and chlorohexidin. An occipito-
cerebral midline incision was made and the muscles retracted until the meninges were visible. A 
small amount of CSF was withdrawn from the cistern magna and afterwards 15 µL of solution 
were injected with a Hamilton syringe (Hamilton, Switzerland). The animals were divided into two 
groups: (i) in the first, the animals received 0.9% saline injection; (ii) in the other, 5 mg.mL -1 FITC-
labeled MP-loaded CMCht/PAMAM dendrimer NP. Following surgery, rats received analgesic 
(Butorphanol tartrate, 1 mg.mL-1, Fort Dodge, Spain) and antibiotic (Enrofloxacine, 1 mg.mL-1, 
Bayer, Germany) and were kept for 72 hours. After that, the animals were sacrificed and the 
brains were collected, freeze-sectioned and stained with rabbit GFAP antibody (Dako, Denmark, 
1:500) and the secondary antibody Alexa Fluor 568 anti-rabbit (Molecular Probes, USA, 1:1000). 
The specimens were then observed under a confocal microscope (FV1000; Olympus, Germany). 
 
 
Figure 1 – Schematic representation of the intracisternal injection of fluorescent-labeled 
methylprednisolone-loaded CMCht/PAMAM dendrimer nanoparticles in healthy Wistar rats. 
 
 
2.3. Western blot analysis 
 
Proteins were extracted from the CB, HPC and PFC and homogenized in RIPA buffer (NaCl 0.1 
M; tris(hydroxymethyl)aminomethane (Tris) pH 8.0, 0.01 M; EDTA pH 8.0, 0.001 M and 
complete protease inhibitor cocktail; Roche, Switzerland). Afterwards, sonication for 30 seconds 
in Laemmli buffer (SDS 4%, Tris pH 8, 0.12 M, glycerol 20% and dithiothreitol 0.2 M) was 
performed. Proteins were then quantified using the Bio-Rad protein assay (Bio-Rad, Hercules, 
USA). Samples were separated by SDS-PAGE (50 μg/lane) and then transferred into a 
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nitrocellulose membrane. Membranes were then stained with Ponceau S (Sigma) to confirm 
transfer efficiency; blocked with 5% skim milk in PBS and probed with anti-glucocorticoid receptor 
(GR) antibody (M-20) (Santa Cruz Biotechnology, USA, dilution 1:1000) at 4°C overnight. 
Membranes were washed and incubated with goat anti-rabbit IgG-HRP (Santa Cruz 
Biotechnology) and diluted to 1:10000. The blot was developed using the SuperSignal West Pico 
Chemiluminescent Substrate (PIERCE, USA) and exposed to X-ray film. Finally, the membranes 
were stripped with 2% SDS and 100 mM β-mercaptoetanol solution, warmed to 50°C for 30 
minutes, thoroughly washed, blocked, re-blotted with mouse anti-alpha-tubulin (Santa 
Cruz Biotechnology) and diluted to 1:5000 to normalize for protein load. 
 
2.4. Statistical analysis 
 
Statistical evaluation was performed using the two-way analysis of variance test followed by 
Bonferroni post-test to assess the statistical differences between groups regarding the protein 
expression quantification. Statistical significance was defined for p<0.05. 
 
 
3. Results and discussion: 
 
NP transport from the systemic circulation across the healthy CNS barriers is often restricted by 
the BBB and blood-CSF barriers, therefore limiting the current knowledge concerning their 
diffusion, retention and distribution in the nervous tissue.17 Yet, in order to understand NP fate 
following in vivo administration and predict its therapeutic applicability these two parameters 
must necessarily be considered. In the present study, FITC-labeled MP-loaded CMCht/PAMAM 
dendrimer NPs were injected into the cisterna magna of healthy adult rats and its distribution in 
the nervous tissue was analyzed. Intracisternal administration is a straightforward method of 
accessing the CSF, merely requiring a small incision in the back of the neck of the animal, and 
after the visualization of the dura mater an injection can be easily performed. It can then be 
regarded as a less invasive technique than intraparenchymal injections, for instance, and as well 
suited for molecule diffusion studies in the CNS. Due to the growing interest in nanoparticle use 
as DDS, in vivo studies assessing the interaction of nanocarriers with living tissues is becoming 
essential in order to realize its potential clinical use.  
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Herein, FITC-labeled MP-loaded CMCht/PAMAM dendrimer NPs were administered 
intracisternally and tracked using confocal microscopy. Observation of the cryo-sectioned brain 
slices 72 hours following NPs injection, revealed a broad distribution of clear green fluorescent 
signals confirming intracellular localization of the NPs and consequently successful NP diffusion 
from the CSF to the brain tissue. Moreover, high magnification images (Figure 2) revealed 
preferential perinuclear localization inside astrocytes, that is comparable to previously reported in 
vitro observations.12 Also, FITC-labeleb MP-loaded CMCht/PAMAM dendrimer NPs were also 
identified in other locations rather than in astrocytes, although in the present study those cells 
have not been identified. It is known, however, that other glial cells, such as microglia and 
oligodendrocytes do internalize these NPs as well, as shown in vitro.12 
 
Figure 2 – High magnification confocal micrograph of the FITC-labeled NPs (in green) located 
intracellularly in astrocytes (arrow) and non-identified cell types (star), in rat hippocampus. DAPI (blue) 
designates cell nuclei and GFAP (red) identifies astrocytes. Scale bar corresponds to 20 µm. 
 
 
The analysis of selected brain sections allowed the detection of internalized NPs not only in 
cortical areas of the PFC that are in close contact with the CSF but also, and more abundantly, in 
its inner parenchyma 72 hours post-injection (Figure 3). Control animals were injected with saline 
solution and did not display any green fluorescence, either in cortical or parenchyma PFC regions 
(Figures 3a,c). This observation confirms that the green fluorescent spots when detected are in 
fact due to the presence of FITC-labeled MP-loaded CMCht/PAMAM labeled NPs in the tissue 
(Figures 3b,d). Closer observation of the PFC tissue certifies a preferential inner distribution of 
the NPs 72 hours after injection, whereas the cortical areas reveal significantly less green 
fluorescent spots. This data indicates that following injection, the NPs followed a transport route 
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across the more superficial layers of the nervous tissue, allowing them to move to more internal 
levels. Following dispersion into the CSF of healthy animals, molecules are expected to exit this 
space through the CSF flow tracts to the blood stream.18 The entry of substances into the brain 
parenchyma is typically mediated by a slow process which is diffusion. Only when molecules 
escape binding to efflux transporters and metabolism, they are able to be effectively diffused and 
retained in the brain parenchyma. The results herein presented indicated that diffusion of MP-
loaded CMCht/PAMAM dendrimer nanoparticles effectively occurs and is fast enough to allow its 
retention in different layers of the brain 72 hours post-injection in the CSF. Under the tested 
conditions the NPs were able to traverse from the pial surface to the inner medullar areas, being 
preferentially retained in the latter. In pre-frontal cortex (PFC) preparations, only a reduced 
number of NP was found close to the pial membrane while the majority of the uptake was visible 
in deeper parenchymal areas (Figure 3e). This indicates that the NPs introduced in the CSF 
entered the cortical layers of the PFC and diffused crosswise, being most abundantly retained in 
the inner layers. Astrocyte labeling of the PFC sections showed no significant morphological or 
GFAP expression alterations between saline (control) and NP injected animals, suggesting that no 
astrogliosis is being induced by the presence of NPs (Figure 3a-d). Astrocytes are known to play a 
vital role in continuously monitoring the neuronal environment, and when an insult is detected 
these cells become reactive and initiate a protective mechanism designated astrogliosis.19 During 
this process astrocytes become hypertrophic and are morphologically distinct from resting 
astrocytes. The presence of FITC-labeled MP-loaded CMCht/PAMAM NPs does not seem to 
induce astrocyte activation, even when NPs are internalized by astrocytes. These findings validate 
the therapeutic potential of CMCht/PAMAM dendrimer nanoparticles as carriers for astrocyte 
intracellular targeted delivery, which were recognized as important therapeutic targets in 
neuroinflammation and neurodegeneration.20 Moreover, the fact that MP is an anti-inflammatory 
drug being transported inside the nanocarriers adds significance to astrocyte targeting, since this 
drug inhibits astrocyte activation and proliferation during inflammatory processes. 
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In terms of brain biodistribution, the NPs were also thoroughly found in other areas such as the 
choroid plexus, the lateral ventriculus and the HPC (Figure 4). Co-staining of GFAP and nuclear 
 
Figure 3 – Confocal microscope photographs of rat brain frozen sections stained for astrocytes (GFAP, 
in red) and nuclei (DAPI, in blue) following intracisternal injection. a,c) Controls with saline injection, no 
green fluorescence is observed. b,d) Following FITC-labeled MP-loaded nanoparticles injection, green 
fluorescence is observed both in the cortical and inner regions of the pre-frontal cortex parenchyma. e) 
Overview of a PFC brain slice following BP injection. Scale bar corresponds to 50 µm. 
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labeling indicated once more that the NP green fluorescence was located intracellularly in 
astrocytes but also in other cell types that were not yet identified and will be further investigated 
in future studies. From Figure 4, it is evident that the layers in contact with the CSF tend to 
possess significantly a decreased NP-related fluorescence (green color), suggesting an effective 
NP trafficking along the depth of the brain parenchyma. 
 
 
Abundant NP retention was observed in the choroid plexus (Figure 4c,d). It is unclear however, 
whether the movement of the NPs from the CSF to the choroid plexus was through the epithelial 
layer or the blood flow. In this case, probable re-circulation of NPs through CSF and the blood 
flow could allow entry in the choroid plexus, since the capillaries within the choroid plexus are 
Figure 4 – Confocal microscope photographs of frozen sections from rat brain stained for astrocytes 
(GFAP, in red) and nuclei (DAPI, in blue) following NP intracisternal injection. Green fluorescence 
emitted by the FITC-labeled MP-loaded NP was found in: a) pre-frontal cortex; b) hippocampus; c) lateral 
ventricles (in the CSF side); and d) choroid plexus. Scale bars represent 50 µm. 
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fenestrated and not with the tight junctions that endothelial cells typically present in the CNS. The 
present study has demonstrated the ability of MP-loaded CMCht/PAMAM dendrimer NPs not only 
to diffuse but also be intracellularly retained in distinct areas of the brain. 
CMCht/PAMAM dendrimer NPs were already shown to be easily internalized in vitro in primary 
neurons and glia whilst not affecting their normal metabolism.11-12 Additionally, the present study 
revealed that if injected in the CSF there are no apparent morphological and structural 
differences in the nervous tissue, namely in astrocytes that are involved in the response to 
environment alterations. 
It was recently shown by Albertazzi et al. that the surface properties of PAMAM dendrimers affect 
its diffusion in the brain following intraparenchymal and subarachnoid injection, therefore slight 
alterations in the dendrimer composition may dramatically change its uptake and distribution in 
the CNS.21 Herein, our findings have demonstrated that the grafting of G3 PAMAM dendrimers 
with CMCht and subsequent MP incorporation do not hamper its ability to diffuse within the 
several layers of nervous tissue and to be internalized by astrocytes and other CNS cells.  
Next, and in order to have a deeper insight on the MP release from the NP and intracellular 
action while retained in the brain tissue, protein expression of the GR was investigated. Two types 
of GR can be found in the rat brain: (i) the high-affinity mineralocorticoid receptor (MR) that is 
most densely present in the HC; and (ii) the ubiquitously distributed GR.22 When glucocorticoids 
are exogenously administered in rats there is a typical down-regulation effect in the GR 
expression, with some regional and affinity differences.23 These in vivo changes in GR expression 
in the rat brain were shown to be effectively quantified by western blot, without the need for prior 
adrenalectomy of the animals.23-24 Figure 5 shows that the intracisternal administration of MP 
resulted in a down-regulation of the expression of the GR both in the HPC and the PFC, in relation 
to control animals injected with saline solution. Both in HP and PFC lysates an almost 2-fold 
significant decrease was noted in the presence of MP-loaded NPs. No alteration was observed in 
the CB however, which is explained by the fact that the density of GR in this particular area is 
lower than in the HP and PFC, thus resulting in an overall diminished protein expression (Figure 
5B). Notably, the administration of FITC-labeled MP-loaded CMCht/PAMAM dendrimer NPs 
reached similar protein expression levels as the drug when administered alone, with statistically 
significant differences to the controls. As MP alone, NP administration induces significant GR 
expression down-regulation in the HPC and the PFC, though not as drastically as the 
administration of the corticosteroid solution. The analysis of the GR expression results thus 
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indicated that MP is indeed being released from the NPs and acting intracellularly via activation 
of its cytosolic GR, as predicted, and resulting in altered protein expression profiles. 
The fact that MP-loaded CMCht/PAMAM dendrimer NPs show a broad distribution in the cerebral 
tissue along with a convenient intracellular retention, with no apparent astrogliosis, associated to 
the MP release and intracellular action renders this NP system attractive features with exciting 
prospects to be considered for therapeutic applications, namely as drug delivery systems in CNS 
disorders. 
 
 
 
 
 
Figure 5 – Western-blot analysis of lysates (hippocampus – HPC; pre-frontal cortex – PFC; and 
cerebellum – CB) following intracisternal injection of saline (SAL), methylprednisolone solution (MP) or 
methylprednisolone-loaded CMCht/PAMAM dendrimer nanoparticles (NP). Bars show the quantification of 
the expression level of the 95 kDa glucocorticoid receptor (GR) compared with the expression of 55 kDa α-
tubulin. Data expressed as mean ± SEM. *p<0.05; **p<0.01; ***p<0.005. 
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4. Conclusions: 
 
This study demonstrated that MP-loaded CMCht/PAMAM dendrimer NPs broadly diffuse in the 
healthy rat brain following administration in the CSF. Our findings showed that the NPs are 
retained intracellularly in the choroid plexus, lateral ventricles, PFC and HPC, 72 hours post-
administration. Moreover, histological observation of the brain tissue showed no morphological 
differences between control and NP injected animals suggesting no deleterious effects. 
Additionally, altered expression of GR receptors in PFC and HPC were detected following NP 
administration pointing to an intracellular drug release and action. These observations can open 
up new and exciting possibilities for the use of these NP as intracellular drug delivery carriers for 
the nervous system. 
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CHAPTER VI 
Microglia response and in vivo therapeutic potential of methylprednisolone-
loaded dendrimer nanoparticles in spinal cord injury 
 
Abstract  
The control and manipulation of cells that trigger secondary mechanisms following spinal cord 
injury (SCI) is one of the first opportunities to minimize its highly detrimental outcomes. Herein, 
we investigate the ability of surface engineered carboxymethylchitosan/polyamidoamine 
(CMCht/PAMAM) dendrimer nanoparticles to intracellularly deliver methylprednisolone (MP) to 
glial cells, allowing a controlled and sustained release of this corticosteroid in the injury site. The 
negatively-charged MP-loaded CMCht/PAMAM dendrimer nanoparticles comprising sizes of 109 
nm enable a MP sustained release, which was detected for a period of 14 days by HPLC. In vitro 
studies in glial primary cultures show that incubation with 200 μg.mL-1 nanoparticles do not affect 
the cells’ viability or proliferation, while allowing the entire population to internalize the 
nanoparticles. At higher concentrations microglial cells’ viability was proved to be affected in 
response to the MP amounts released.  Following lateral hemisection lesions in rats, we observed 
the nanoparticles uptake by the spinal tissue 3 hours upon administration. Moreover, significant 
differences in the locomotor output between the controls and the MP-loaded nanoparticles 
treated animals one month after the lesion were observed. Therefore, the MP-loaded 
CMCht/PAMAM dendrimer nanoparticles may prove to be useful in the reduction of the 
secondary injury following SCI. 
 
This chapter is based on the following publication: 
Susana R. Cerqueira, Joaquim M. Oliveira, Nuno A. Silva, Hugo Leite-Almeida, Silvina M, Samy, 
Armando Almeida, João F. Mano, Nuno Sousa, António J. Salgado, Rui L. Reis, “Microglia 
response and in vivo therapeutic potential of methylprednisolone loaded dendrimer nanoparticles 
in spinal cord injury”, Small, 9(5) 738-749, 2013. 
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1. Introduction 
 
Trauma to the central nervous system (CNS) is still a major cause of disability worldwide. In the 
US alone 10,000 new spinal cord injury (SCI) cases are reported every year, bearing tremendous 
costs along with greater expenses of human suffering.1 Given the complexity of the triggered 
events following SCI and the still poor understanding of the mechanisms underlying it, so far 
there are no fully restorative therapies for this condition.2 As a consequence of the injury severe 
impairments can occur and loss of function, particularly associated to the motor and sensory 
levels, commonly lead to tetraplegia or paraplegia.3 Therefore, the harsh economical and physical 
burdens of SCI emphasize the need to develop new therapeutic approaches aimed at improving 
these patients’ quality of life. 
The devastating consequences following SCI are the outcome of a two-step process that initiates 
with a mechanical insult to the spinal cord. The primary injury results in immediate cell death 
and vascular leakage, as well as disruption of ascending and descending pathways.4a These 
events lead to a subsequent cascade of secondary mechanisms that widen the magnitude of the 
initial lesion.4 A complex response follows, extending from massive neuroinflammation reactions 
to the formation of a glial scar that inhibits axonal regeneration. The secondary phase is also 
characterized by the occurrence of different phenomena,5 such as: (i) excitotoxic biochemical 
events, e.g., formation of free radicals and nitric oxide, glutamate and protease release; (ii) 
cellular responses, such as invasion by immune cells, neuronal and glial cell death and 
demyelination; and (iii) vascular changes, involving edema, ischemia and hypoxia. The extension 
of this secondary injury has significant implications in the lesion volume itself, as well as in the 
tissue potential for functional recovery. Therefore, one of the first opportunities to intervene after 
a SCI in an effort to minimize its detrimental outcomes is precisely the control of the negative 
impact of the secondary injury. 
To the present, high dose methylprednisolone (MP) administration is still the only recommended 
neuroprotective route to prevent further secondary injury damage, which has been already tested 
in multicenter clinical trials.6 MP is a synthetic corticosteroid with anti-inflammatory and 
antioxidant actions that when administered in a high dose systemic injection during the first 
hours post-injury has shown to reduce neurological deficits after SCI.7 Although not completely 
unveiled yet, MP action mechanisms involve the modulation of inflammation at the injury site. 
This is achieved by astrocyte reactivity inhibition, down-regulation of inflammatory cytokine 
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production by microglia and also by an antagonistic effect on lipid peroxidation.8 In addition to 
being a potent anti-inflammatory drug, recent studies suggest that methylprednisolone promotes 
its neuroprotective effects also via a selective anti-apoptotic mechanism on oligodendrocytes, 
which are essentially implicated in white matter injuries such as SCI.9 Nevertheless, the 
necessary systemic high dose injections of MP also seriously aggravate adverse side effects such 
as wound infections, pneumonia and acute corticosteroid myopathy.10 These undesired effects 
critically limit the drug’s neuroprotective potential often inducing only modest overall 
improvements in the neurological functions.11 As a result, its clinical use remains quite 
controversial. 
A directed and sustained delivery of MP by means of using a controlled drug delivery system, as 
a nanoparticle-based system, could be extremely advantageous in these situations. With such a 
strategy the drug’s action could be maximized in the affected nervous cells, enhancing its 
efficiency as an anti-inflammatory and neuroprotective agent, while eliminating its systemic 
negative side effects. The use of different nanoparticle formulations [e.g., cerium oxide,12 
monomethoxy PEG–poly(D,L-lactic acid),13 PEG-silica,14 poly(lactic-co-glycolic acid)15] has been 
recently investigated for SCI treatment. These nanoparticles were proposed to act in SCI 
neuroprotection either by sealing the damaged axonal membranes,13,14 by an intrinsic antioxidant 
mechanism12 and also as a MP drug delivery system15 revealing some promising and satisfactory 
results. Within the present study we are proposing the use of a recently described dendrimer-
based intracellular drug delivery system to act in the control of the secondary injury damage.16 
For SCI applications, this  nanoparticle system will be loaded with MP and intracellularly delivered 
to glial cells, particularly microglia, which are in part responsible for the secondary events after 
SCI. From the vast range of nanocarriers, dendrimers are nature-inspired highly ramified and 
spherical synthetic nanoparticles that not only present precise and controlled architectures, but 
also possess tunable molecular weights and superior drug loading capacities.17 Also, they have 
the potential to be further engineered to achieve higher functionalization degrees, such as 
targeting and imaging properties.18 The water-soluble dendrimer nanoparticles developed by our 
group consist of a highly branched nanospherical poly(amidoamine) (PAMAM) dendrimeric core 
grafted with carboxymethylchitosan (CMCht), a natural biocompatible polymer.16 This engineered 
macromolecular carrier has already shown to efficiently transport biological agents intracellularly 
to rat bone marrow stromal cells via the endocytic pathway.16,19 Moreover, they were shown to be 
easily internalized by neurons and glial cells, while not evidencing any cytotoxicity, both in vitro 
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and in vivo.20 Thus, in the present study we aim to produce MP-loaded CMCht/PAMAM dendrimer 
nanoparticles that have the potential to modulate the inflammatory reaction after CNS traumatic 
injury, namely by attenuating the microglial cell response. The corticosteroid is effectively 
incorporated in the nanoparticles and these are easily internalized by glial cells. We demonstrate 
that these nanoparticles are able to intracellularly release MP having an impact on microglial cell 
viability. Also, when administered locally following lateral hemisection lesions to the spinal cord of 
Wistar rats the MP-loaded nanoparticles significantly improved the locomotor outcome of the 
treated animals. These initial results lead us to consider this system as a potential promising 
therapy for SCI. 
 
2. Materials and methods 
 
2.1. CMCht/PAMAM dendrimer nanoparticle synthesis 
 
Carboxymethylchitosan/ poly(amidoamine) (CMCht/PAMAM) dendrimer nanoparticles were 
produced in a stepwise manner, as previously described by Oliveira et al.16 Starburst® PAMAM-
carboxylic acid terminated dendrimers (PAMAM-CT) (generation 1.5, 20% w/v in methanolic 
solution) with an ethylenediamine core were purchased (Sigma, Germany) and the following 
reactions were carried out: (i) an increase in the PAMAM-CT generation; (ii) the production of a 
PAMAM-methyl esther terminated dendrimer; (iii) a condensation reaction between the methyl 
esther and amine groups of PAMAM and CMCht; and finally (iv) the conversion of the non-
reacting methyl esther groups into carboxylic ones in the CMCht/PAMAM dendrimer 
nanoparticles. Afterwards, MP was incorporated in these molecules (Figure 2c) mixing an 
aqueous solution of CMCht/PAMAM dendrimer nanoparticles with an ethanolic MP solution with 
a final concentration of 5×10-4 M (w/w) and kept under vigorous agitation. Saturated sodium 
carbonate solution (Na2CO3, Aldrich, Germany) and acetone (Pronalab, Portugal) were then added 
to the mixture. The resulting precipitates were collected by filtration and then dispersed in 
ultrapure water. Extensive dialysis (cellulose tubing, benzoylated for separating compounds with a 
molecular weight of ≤1,200, Sigma, Germany) was performed during 48 hours. Both 
CMCht/PAMAM dendrimer nanoparticles and MP-loaded CMCht/PAMAM dendrimer 
nanoparticles were obtained by freeze-drying (Telstar-Cryodos-80, Spain) for approximately one 
week, until the solvents were completely removed. Additionally, fluorescein isothyocianate (FITC, 
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Sigma, Germany) labeled MP-loaded CMCht/PAMAM dendrimer nanoparticles were prepared by 
covalently bonding the amine group of CMCht and the isothyocianate group from FITC.16 
 
2.2. Nanoparticle characterization 
 
Both the zeta potential and diameter of the CMCht/PAMAM dendrimer nanoparticles and the MP-
loaded CMCht/PAMAM dendrimer nanoparticles were determined in a particle size analyzer 
(Zetasizer Nano ZS, Malvern, UK). At first, 1×10-3 mg.mL-1 solutions of each sample were 
prepared in ultrapure water for determination of the nanoparticles diameter. Each sample was 
filtered and placed in polystyrene cuvettes (Malvern, UK) to be analysed. For the zeta potential 
determinations, samples were prepared in three different buffer solutions: (i) citrate buffer (pH 
5.0); (ii) phosphate buffer saline (PBS, pH 7.4); and (iii) sodium carbonate buffer (NaOH, pH 
10.0). Each sample was filtered and slowly loaded to folded capillary cells for the zeta potential 
measurements. The efficiency of the MP incorporation into the CMCht/PAMAM dendrimer 
nanoparticles was assessed by Fourier transformed infrared (FTIR) spectrometry. To obtain the 
FTIR spectra of the samples, transparent potassium bromide (KBr, Pike Technologies, USA) 
pellets were prepared, containing the samples and after that, the analyses were run in an infra-
red spectroscope (IR Prestige-21, Shimadzu, Japan). Also 1H NMR spectroscopy was performed 
to assess the effectiveness of the FITC conjugation. For that purpose the samples were dispersed 
in deuterium oxide (D20, Aldrich, Germany) at a final concentration of 10 mg.mL -1. The one-
dimensional 1H spectra were acquired in a Varian Unity Plus spectrometer at 300 MHz and 20ºC.  
 
2.3. In vitro methylprednisolone release studies 
 
The amount of MP released from the CMCht/PAMAM dendrimer nanoparticles was quantified 
using the high performance liquid cromatography equipment (HPLC, Knauer Smartline, 
Germany) with an UV detector set at 250 nm. The mobile phase was composed of acetonitrile: 
ammonium phosphate buffer (0.1 M, pH 4.6) (50:50, v/v) at a flow rate of 1 mL.min-1. Two 
distinct solutions were prepared: (i) 1 mg.mL-1 MP-loaded CMCht/PAMAM dendrimer 
nanoparticles in PBS solution (pH 7.4); and (ii) 1 mg.mL -1 MP-loaded CMCht/PAMAM dendrimer 
nanoparticles in citrate buffer solution (pH 5.0). These two solutions were prepared both in the 
absence and presence of 15% fetal bovine serum (FBS, Gibco, USA). Also 0.01% sodium azide 
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(Merck, Germany) was added to each solution. The in vitro release profiles were determined at 
37ºC and 60 rpm for times ranging from 1 hour up to 14 days. At each time point, samples were 
collected for analysis and the same volume replaced with the respective buffer solution. After 
collection at each time-point and preceding the analysis, the samples were centrifuged at 2000 
rpm for 10 minutes and integrated in a solution of sample:acetonitrile:phosphate buffer 
(50:25:25, v/v) for further detection through a C18 analytical column (Atlantis T3, Waters, USA). 
The MP retention time was approximately 3 minutes. A calibration curve was previously acquired 
by diluting a MP stock solution to the final concentrations of 0.5, 2.5, 10, 25 and 100 µg.mL -1 
standards and the results were expressed as an average ± standard deviation, n=3. 
 
2.4. Isolation and culturing of rat cortical glial and microglial cells 
 
Neonatal rat cortices were isolated from P4 Wistar rat pups as previously described elsewhere.34 
Glial cells primary cultures were maintained at 37ºC in a 5% CO2 atmosphere, in Dulbecco’s 
modified Eagle medium (DMEM, Gibco, USA) supplemented with 10% FCS and 1% 
antibiotic/antimycotic (Sigma, USA) for a week for further testing. Microglia cultures were 
obtained from these mixed glial cell cultures. For microglia isolation, glial cells were plated out at 
a density of 1×106 cells.cm-2 in polystyrene T75 flasks (Thermo Scientific, USA) previously coated 
with poly-L-lysine (Sigma, USA). The glial primary cultures were maintained in the same above 
referred conditions, with periodical media renewal. After two weeks of culturing, the cell flasks 
were agitated in an orbital shaker at 240 rpm during 4 hours. Following this, the medium 
containing detached microglia cells was collected and centrifuged at 1200 rpm for 5 minutes. 
The pellet was re-suspended and plated out at a density of 4×104 cells.cm-2 on coverslips 
previously coated with poly-L-lysine (Sigma, USA). Microglia cells primary cultures were then 
maintained at 37ºC in a 5% CO2 atmosphere, in DMEM medium (Gibco, USA) supplemented with 
10% FBS (Gibco, USA) and 1% antibiotic/antimycotic (Sigma, USA) for 3 days for further testing. 
 
2.5. In vitro cytotoxicity and proliferation assays 
 
The viability and proliferation of the glial cells were tested and compared: (i) after a single 
addition of 200 µg of MP-loaded CMCht/PAMAM dendrimer nanoparticles to the wells in the first 
day of the experiment; or (ii) with periodical addition of 200 µg of MP-loaded CMCht/PAMAM 
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dendrimer nanoparticles, every 48 hours during a week. In both cases, the cell viability was 
verified after incubation of the cells at 37ºC for 3 hours with (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2(4-sulfophenyl)-2H tetrazolium) (MTS, Promega, USA) in a 5:1 ratio. 
After the incubation, the optical density of each sample was read in a multiplate reader (Tecan 
Sunrise, Switzerland) at 490 nm. Also high dosages of CMCht/PAMAM and MP-loaded 
CMCht/PAMAM dendrimer nanoparticles were evaluated regarding in microglia cultures viability: 
1000 and 1500 µg, as well as the corresponding MP amount released from the MP-loaded 
CMCht/PAMAM dendrimer nanoparticles (1.5 and 2.25 mg). The cell proliferation was 
ascertained in glial cell cultures using the 5-bromo-2’-deoxyuridine assay (BrdU, Roche, USA), 
which quantifies the BrdU incorporation during DNA synthesis in replicating cells. BrdU was 
added to the glial cell cultures for 24 hours and after that the medium was removed. The cells’ 
DNA was denatured with FixDenat (Roche, USA), after which the anti-BrdU peroxidase antibody 
(Roche, USA) was added. The immune complexes were detected by the quantification of the 
substrate reaction product, measuring the optical density at 405 nm (reference filter set at 655 
nm) in a multiplate reader (BioRad, USA). 
 
2.6. Internalization study – immunocytochemistry 
 
The glial cultures were incubated with 200 µg of FITC-labeled MP-loaded CMCht/PAMAM 
dendrimer nanoparticles for periods of 1, 3, 12, 18 and 24 hours (n=3/ time point). Subsequent 
to each incubation time, the cells were washed in 0.1 M PBS and fixed in a 4% paraformaldehyde 
solution for 30 minutes.20a The following primary antibodies were used: rabbit GFAP antibody 
(Dako, Denmark, 1:500, v/v) for astrocyte recognition; mouse CD11b antibody (BD Biosciences 
Pharmingen, USA, 1:100, v/v) was used in microglial cell identification; and mouse O4 antibody 
(R&D Systems, 1:50, v/v) for oligodendrocyte detection. Then, cells were incubated with the 
secondary antibodies: Alexa Fluor 594 anti-mouse and Alexa Fluor 568 anti-rabbit (both 
Molecular Probes, USA, 1:2000 in 10% FCS in PBS, v/v). Nuclei were stained with 4',6-
diamidine-2-phenyl indole (DAPI, Thermo Scientific, USA, 1:2000, v/v). The FITC-labeled MP-
loaded CMCht/PAMAM dendrimer nanoparticles internalization levels for each cell population 
were determined according to Equation (1) (n=3, 3 random fields/coverslip): 
 
Equation (1):  100
Tc
Pc
I  
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I: percentage of internalization; 
Pc: number of positive cells for FITC-labeled MP-loaded CMCht/PAMAM dendrimer nanoparticles; 
Tc: total number of each cell type. 
 
Microglial cells in microglial cultures were also immunostained following a similar procedure to 
the described for glial cells. Mouse CD11b antibody (BD Biosciences Pharmingen, USA, 1:100, 
v/v) was incubated for an hour, followed by secondary antibody AlexaFluor 594 anti-mouse 
(Molecular Probes, USA, 1:2000 in 10% FCS in PBS, v/v) incubation. Nuclei were then stained 
with DAPI (Thermo Scientific, USA, 1:2000, v/v). 
 
2.7. Hemisection SCI 
 
8 weeks old male Wistar rats (n=15) from Charles River were housed in light and temperature 
controlled rooms and all the procedures involving the animals were in accordance with the 
Animal Care Guidelines.35 Before the surgery, the animals were anesthetized by intraperitoneal 
injection of 150 mg.Kg-1 ketamine hydrochloride and 0.3 mg.Kg-1 medetomidine. The surgical 
area was shaved and soaked with ethanol and chlorohexidin. A laminectomy at T8-T9 level was 
performed to expose the spinal cord. After that, a unilateral defect was made on the cord by 
removing approximately 2 mm of the tissue. Immediately after the lesion, 5 µL of either: (i) saline 
(control group); (ii) CMCht/PAMAM dendrimer nanoparticles (NP group); (iii) MP-loaded 
CMCht/PAMAM dendrimer nanoparticles (NPmp group); and (iv) methylprednisolone, were 
injected circa 1 mm rostral and 1 mm caudal to the lesion. Both the methylprednisolone and the 
nanoparticles were prepared in 5 mg. mL-1 solutions. To stabilize the vertebral column in the 
lesion area, a semi tubular starch/poly-caprolactone (SPCL) scaffold was implanted in alignment 
with the vertebrae in all the animals.36 The muscles and skin were sutured and disinfection was 
carried out with chlorohexidin. Following surgery rats were kept under heat lamps and received 
vitamins (Duphalyte, Farmoquil, Portugal), analgesic (Butorphanol tartrate, 1mg.mL-1, Fort 
Dodge, Spain) and antibiotic (Enrofloxacine, 1mg.mL-1, Bayer, Germany). Throughout the 
experimental period, animals were examined for symptoms of illness or potential reaction to the 
treatment. Animals were maintained for 4 weeks however an extra NP group (n=3) was sacrificed 
three hours after the lesion to assess the presence of the fluorescently labeled MP-loaded 
CMCht/PAMAM dendrimer nanoparticles in the tissue after the injection in the cord. The spinal 
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cords were collected, freeze-sectioned and stained with rabbit GFAP antibody (Dako, Denmark) 
and the secondary antibody Alexa Fluor 568 anti-rabbit (Molecular Probes, USA). 
 
2.8. BBB locomotor assessment 
 
Rats were allowed to move freely in the open-field arena and scored during a 4 min period for 
their ability to use their hindlimbs by two independent blinded observers. Joint movements, paw 
placement, weight support, and fore/hindlimb coordination were judged according to the 21-
point BBB locomotion scale. A BBB score of 0 indicates no hindlimb movement. A BBB score of 
1 through 8 indicates joint movement, but no weight support. A BBB score of 9 through 20 
indicates an ability to support weight and use the limb for locomotion but with some degree of 
abnormality. A BBB score of 21 corresponds to the locomotion of a normal rat. Scores obtained 
by 2 independent observers were averaged for the left hindlimb. 
 
2.9. Statistical analysis 
 
Statistical evaluation was performed using the one-way analysis of variance test followed by the 
Tukey´s post-test to assess the statistical differences between groups in the viability and 
proliferation assays. For the BBB scores, significant differences between the groups were 
determined using two-way ANOVA repeated measures followed by the Bonferroni´s post-test. 
Statistical significance was defined for p<0.05. 
 
3. Results and Discussion 
 
3.1. Characterization of the MP-loaded nanoparticles 
 
The use of nano-sized carriers for the local delivery of therapeutic agents is an exciting and 
promising approach in CNS traumatic conditions, for which there are no therapeutic solutions 
yet. MP is the corticosteroid clinically administered in SCI cases but it presents low efficacy and 
occasionally devastating undesired side effects in patients. In an attempt to overcome these 
major impediments for the success of pharmacological therapies in SCI, we herein propose a 
nanoparticle-based system that incorporates MP to be intracellularly delivered to glial cells. The 
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design of such nano-vehicles for drug release purposes in vivo, demands assessing first of all its 
physicochemical properties and biological performance in vitro. 
Following MP loading into the CMCht/PAMAM dendrimer nanoparticles we evaluated its new 
features, such as: size, zeta potential, morphology and drug loading efficiency. Figures 1a,b refer 
to the electron micrographs of the MP-loaded CMCht/PAMAM dendrimer nanoparticles, when 
freeze-dried or dispersed in solution. It is possible to discern its spherical morphology when 
dispersed in solution and an elongated nature after the solvents evaporation.  
 
 
Figure 1. Electron micrographs of MP-loaded CMCht/PAMAM dendrimer nanoparticles. a) SEM image of 
the elongated freeze-dried MP-loaded CMCht/PAMAM dendrimer nanoparticles. b) S-TEM image of the 
spherical MP-loaded CMCht/PAMAM dendrimer nanoparticles dispersed in water. Scale bars represent 
500 nm. Distributions of the diameter and zeta potential determined by DLS analysis are shown (n=6; 
mean ± SD). 
 
Moreover, the average diameter determined by STEM observation was 125 ± 30 nm, which is in 
accordance with the Zetasizer determinations. The latter indicated that MP-loaded 
CMCht/PAMAM dendrimer nanoparticles dispersed in ultrapure water comprise average sizes of 
109 nm, while the non-loaded samples disclose average sizes of 85 nm. Thus, the incorporation 
of MP into the CMCht/PAMAM dendrimer nanoparticles resulted in an average diameter increase 
of around 28%. Also, some aggregates were detected with average diameters of 334 nm and 
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2088 nm due to the interaction of the PAMAM amine groups with the CMCht carboxyl groups 
that favors electrostatic interactions. Since these results were obtained in water dispersion, we 
expect that this aggregation decreases in culture media and biological fluids dispersion due to the 
presence of proteins that dynamically interact with the nanoparticle corona, decreasing its 
reactivity.21 Additionally, the zeta potential determination of these nanoparticles indicated that this 
parameter is strongly affected by pH, being that at physiological pH both CMCht/PAMAM 
dendrimer nanoparticles and MP-loaded CMCht/PAMAM dendrimer nanoparticles have stable 
negative net charges of -14.7 mV and -26.4 mV, respectively. The MP incorporation renders an 
increased stability to the CMCht/PAMAM dendrimer nanoparticles due to the new charge balance 
after the corticosteroid loading. As previously reported, CMCht possesses protonated amino 
groups in acidic conditions and negative carboxylic ions at physiological pH.16 This fact is reflected 
in the nanoparticles’ positive net charge measured at pH 5.0, while both at physiological pH and 
at pH 10.0 it remains negative. The effective MP incorporation into the nanoparticles was 
confirmed by the comparative analysis of the characteristic absorption band spectra in the 
infrared (IR) region of CMCht/PAMAM and MP-loaded CMCht/PAMAM dendrimer nanoparticles, 
as well as MP. From the IR spectra shown in Figure 2a it is possible to observe that MP-loaded 
CMCht/PAMAM dendrimer nanoparticles disclose an altered IR spectrum in relation to the 
CMCht/PAMAM dendrimer nanoparticles spectrum due to the MP characteristic peaks’ 
appearance. Therefore, it was possible to detect characteristic absorption bands referable to both 
CMCht/PAMAM dendrimer nanoparticles, such as the 3580 cm-1 free OH group and the 2887 
cm-1 CH stretching vibration associated bands, and MP by the 3420 cm -1 associated OH group 
and 2922 cm-1 CH2 asymmetric stretching band. This result indicates the successful incorporation 
of the corticosteroid in the nanoparticle system. 
Additionally, and in order to track the internalization of MP-loaded CMCht/PAMAM dendrimer 
nanoparticles in vitro, a green fluorescent probe (FITC) was conjugated to the nanocarriers. To 
investigate the effectiveness of the conjugation, 1H NMR analysis of MP-loaded CMCht/PAMAM 
dendrimer nanoparticles and the FITC-labeled MP-loaded CMCht/PAMAM dendrimer 
nanoparticles was performed. From Figure 2b, it is possible to observe that the FITC-labeled MP-
loaded CMCht/PAMAM dendrimer nanoparticles spectrum has new proton signals located at 
6.68 ppm that are attributed to the aromatic ring of the FITC molecule. Therefore, the formation 
of this new signal is evident and strongly suggests that the conjugation of FITC actually occurred, 
by the formation of a new thiourea bond between the amine groups of CMCht/PAMAM and the 
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isothyocianate group of FITC. There were no other significant changes in the spectral profile of 
MP-loaded CMCht/PAMAM dendrimer nanoparticles. 
 
 
Figure 2. a) FTIR spectra of CMCht/PAMAM dendrimer nanoparticles (NP), methylprednisolone (MP) 
and MP-loaded CMCht/PAMAM dendrimer nanoparticles (MP-NP) evidencing the successful incorporation 
of MP in the nanoparticles. (*) 3580 cm-1 corresponds to OH group free, (#) 3420 cm-1 is attributed to 
OH group associated, (•) 2922 cm-1 corresponds to CH2 asymmetric stretching band, (#) 2887 cm-1 is 
attributed to CH stretching symmetric band, and (+) 1655-1630 cm-1 corresponds to amide I. b) 1H 
NMR spectra of MP-loaded CMCht/PAMAM dendrimer nanoparticles (MP-NP) and FITC-labeled MP-loaded 
CMCht/PAMAM dendrimer nanoparticles (MP-NP-FITC) demonstrating the successful conjugation of the 
fluorescent molecule. c) Schematic representation of the methylprednisolone loading into the 
CMCht/PAMAM dendrimer nanoparticles and the fluorescent labeling of these molecules. 
 
 
The release of MP from the MP-loaded CMCht/PAMAM dendrimer nanoparticles was investigated 
after incubating the nanoparticles at 37ºC under agitation. Two different buffer solutions were 
used at pH 5.0 and 7.4, each of which simulating the endocytic and cytoplasmic compartments 
which are acidic and physiological, respectively. On the other hand, the effect of proteins was 
also considered by adding 15% FBS to each solution in order to evaluate the contribution of these 
proteins in the MP release. At pre-determined times, samples from each condition were 
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collected, centrifuged and the supernatant analyzed by high performance liquid chromatography 
(HPLC). In all the four solutions tested the corticosteroid was released in a sustained manner, as 
displayed in Figure 3a. Moreover, the MP release followed a biphasic pattern characterized by an 
initial burst release in the first 24 hours followed by a slower sustained release phase that was 
observed during 14 days. In addition, the detected amount of MP as a free drug was shown to be 
affected both by the pH and the presence of serum in the buffer solution. In PBS buffer (pH 7.4) 
about 100 µg of the drug were released during the first 24 hours. In the presence of FBS there is 
a slight increase (125 µg), although not statistically significant. A slower sustained release is then 
observed in the following 6 days in a similar way both in the absence or presence of serum 
proteins. However, at day 14 in the presence of FBS a statistically significant higher MP quantity 
was detected. This data suggests that the presence of serum proteins can contribute to the 
release of higher amounts of drug from the nanoparticles. This is most likely related with possible 
nanoparticle degradation along time, the prevention of aggregation via protein adsorption to the 
nanoparticles corona or even due to the protein-drug interactions that facilitate the drug’s 
release.16,22a Comparatively, the MP release rate from the nanoparticles was significantly inferior 
when dispersed in citrate buffer (pH 5.0) being only 30 µg of the corticosteroid released in the 
initial burst phase. As already reported, the relatively hydrophobic core of the PAMAM dendrimer 
molecules and the stronger interactions of drug molecules with the more protonated dendrimer 
tertiary amine groups at pH 5.0 can result in a minor release of the incorporated drug due to 
these stronger interactions.23 Likewise, these protonated tertiary amines may produce more 
tightened intramolecular branched structures, restricting the MP release.24 Nanoparticle 
aggregation is also more likely to occur under these circumstances, owing to the charge 
instability and it can prevent and diminish the MP release from the drug delivery system.16 
Interestingly, this acidic pH effect is completely eliminated in the presence of serum proteins with 
a significant and drastic increase in the MP release. Once again the interaction of the 
nanoparticles with proteins, namely by protein adsorption to its surface, was shown to affect the 
dendrimers’ conformation and consequently its behaviour and responses.22 The pH conformation 
alteration of the nanoparticles and protein interaction events can be used as a possible trigger for 
encapsulation and release of guest molecules given its effects in these nanoparticles behaviour. 
The different conformations that PAMAM dendrimers present according to the pH and 
independently of the molecule size were recently described.24 Indeed, these pH-induced 
conformational changes occur revealing a “dense core” conformation of the dendrimer at high 
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pH while at low pH it emerges as a “dense shell” molecule, occurring an intermediate 
conformation when the pH remains neutral. Particularly in MP-loaded CMCht/PAMAM dendrimer 
nanoparticles, both the pH variation and the protein interaction affect the nanoparticles’ 
conformation and consequently its drug release, being the higher amounts of MP detected in 
acidic pH in conjunction with serum proteins. This can possibly be translated in a triggering event 
being initiated inside the endocytic compartment during the nanoparticles internalization by cells. 
Therefore, this dendrimer nanoparticles system may display an inherent pH-responsive triggering 
mechanism for the drug release. However, one thing that will be investigated in the future is the 
extent of endosomal and lysosomal accumulation, since long exposure to highly acidic 
environments and hydrolytic enzymes can eventually become harmful to the drug, altering and 
degrading it.25 
 
Figure 3. a) Methylprednisolone release from CMCht/PAMAM dendrimer nanoparticles, determined by 
HPLC. MP was detected for the period ranging from 1 hour up to 14 days. Solutions of 1 mg.ml-1 were 
prepared in PBS buffer solution (pH 7.4) or citrate buffer solution (pH 5.0), in the presence or absence of 
15% FBS (n=3; mean ± s.d.). b) Percentage of cell viability and proliferation of cortical glial cell cultures 
after MP-loaded CMCht/PAMAM dendrimer nanoparticles’ addition, using the MTS and BrdU assays, 
respectively. Single addition of 200 µg.ml-1 MP-loaded nanoparticles (single) and periodical addition every 
48 hours (periodical) were performed (n=6, mean ± SD; * p<0.05, ** p<0.01) 
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3.2. Internalization of MP-loaded CMCht/PAMAM nanoparticles by glial cells 
 
As initially stated, the MP-loaded CMCht/PAMAM dendrimer nanoparticles are proposed to be 
used in the modulation of inflammatory events lead by glial cells, acting as a MP release system 
and therefore protecting the nervous tissue from further damage. Glial cells play an important 
role in the secondary events that follow CNS traumatic injury, namely by the inflammatory actions 
of astrocytes and microglia. Previous studies have already demonstrated that void 
CMCht/PAMAM dendrimer nanoparticles are efficiently internalized by glial cells and neurons, 
while not affecting these cells’ viability.17,20a To further investigate the influence of the MP-loaded 
nanoparticles in the metabolic activity of glial cells, primary cultures were exposed to 200 μg.mL-1 
MP-loaded CMCht/PAMAM dendrimer nanoparticles for 7 days: (i) after one single addition on 
day 1; and (ii) following periodical additions every 48 hours. As evidenced in Figure 3b, MP-
loaded CMCht/PAMAM dendrimer nanoparticles do not negatively affect the cells’ viability, for a 
period of 7 days. In both cases large amounts of a brown formazan product were formed during 
the MTS viability assay indicating normal cell metabolic activity. Additionally, the observed 
increase in metabolic activity after the nanoparticles addition, namely in the single addition group 
when compared to the control group, can be interpreted as the result of an activation of 
microglial cells that leads to a subsequent metabolic activity increase. In line with these results, 
we are able to report that the MP-loaded CMCht/PAMAM dendrimer nanoparticles are not 
cytotoxic over primary cultures of glial cells in the concentration range tested. Then, in order to 
explore the effect of the nanoparticles on proliferation, cells were subjected to the same exact 
before mentioned conditions. After nanoparticles incubation, bromodeoxyuridine (BrdU) was 
added and maintained in the last 24 hours of culturing. This nucleoside is incorporated during 
DNA synthesis and can be quantified providing a direct indication of cell proliferation. Our results 
revealed similar proliferation rates in the nanoparticles addition groups and in the control group 
not exposed to the nanoparticles. However, a statistically significant decrease in proliferation after 
a single addition of nanoparticles was observed. Nevertheless, this was not confirmed following 
periodical additions of the same MP-loaded CMCht/PAMAM dendrimer nanoparticles. Since an 
increase in the metabolic activity also occurred after a single nanoparticles addition, this can 
indicate that in this situation the cells are more committed to metabolic processes than in its 
proliferation. Yet, the MP-loaded CMCht/PAMAM dendrimer nanoparticles do not significantly 
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interfere in the regular glial cells’ proliferation and metabolic activity at a concentration of 200 
µg.mL-1. 
After this initial screening of the nanoparticles possible cytotoxic effects and interference in the 
cell proliferation, we decided to evaluate the dynamics of the nanoparticles uptake by each glial 
cell type. The cells were cultured with the FITC-labeled MP-loaded CMCht/PAMAM dendrimer 
nanoparticles and their uptake was assessed both by fluorescence and confocal microscopy 
observation following immunocytochemistry. Each cell type in the glial mixed population was 
stained with the appropriate primary antibody: GFAP for astrocytes; O4 for oligodendrocytes; and 
CD11b for microglia. The number of cells for each subpopulation internalizing green FITC-labeled 
MP-loaded CMCht/PAMAM dendrimer nanoparticles were counted at different time-points for a 
maximum of 24 hours. All cell types revealed to be amenable to the nanoparticle internalization 
having all reached the maximum internalization during this time period. Moreover, as seen in 
Figure 4b the accumulation of the nanoparticles inside the cells did not affect the normal 
morphology of the astrocytes and oligodendrocytes, whereas in microglia an increase in volume 
and in cytoplasmic extensions was evident. The microglia subpopulation of cells also internalized 
the nanoparticles at a higher rate due to its well-known phagocytic nature.26 Approximately 50% of 
the observed microglial cells accumulated FITC-labeled MP-loaded CMCht/PAMAM dendrimer 
nanoparticles in its intracellular compartment after 1 hour of culturing. The entire subpopulation 
of microglial cells had internalized nanoparticles 12 hours after its addition and these levels were 
maintained at 24 hours. On the other hand, oligodendrocytes showed a linear growing 
internalization rate along time, starting with about 20% of oligodendrocytes internalizing FITC-
labeled MP-loaded CMCht/PAMAM dendrimer nanoparticles one hour after its addition and 
reaching 85% of nanoparticles internalization at 24 hours. Still, astrocytes take longer to 
recognize the nanoparticles and initiate the internalization process. This is showed by the fact 
that they evidenced lower percentage rates of nanoparticle-bearing cells both at one and three 
hours after incubation with figures around 15% (Figure 4a). However, 12 hours after FITC-labeled 
MP-loaded CMCht/PAMAM dendrimer nanoparticles exposure a 50% increase in nanoparticle 
internalizing cells was observed. Eventually, more than 90% internalization by astrocytes was 
achieved 24 hours after nanoparticles addition, as in the other cell types. The lower astrocytic 
nanoparticle internalization rates can be related to the low cell division rates and also lower 
endocytic activity in comparison to the other glial cell types.27 In previous works, PAMAM 
dendrimer nanoparticles were pointed to be mainly internalized by the endocytic pathway and 
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possessing an inherent buffering capacity provided by its amine groups that allows endosomal 
escape.25,28 CMCht/PAMAM dendrimer nanoparticles were already proved to be mainly 
internalized by the endocytosis.16 The observable regular distribution of the MP-loaded 
nanoparticles over the cells’ cytoplasm suggests that they already escaped the endosomal route 
of internalization being widespread in the cytoplasm. Despite some particular variations in the 
initial time-points it was clear that 24 hours after incubation with the nanoparticles all glial cells 
were internalizing the nanoparticles present in the media. 
 
 
 
Figure 4. a) Percentage uptake rates of FITC-labeled MP-loaded CMCht/PAMAM dendrimer 
nanoparticles in each glial cell type (n=3; mean ± s.d.). b) Representative immunocytochemistry images 
of astrocytes, microglia and oligodendrocytes, after 1 week of culturing before (control) and after the 
nanoparticles addition (FITC-labeled MP-NP). Images obtained by fluorescence and confocal microscopy 
observation. c) Astrocytes and microglia confocal z-stack images demonstrating that intracellular 
localization of the accumulated nanoparticles. 
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3.3. Impact of the MP released from CMCht/PAMAM nanoparticles on microglial cell 
cultures 
 
Following this, we strived to obtain a first in vitro insight of a possible therapeutic action of this 
new system. We decided to study the MP effects in the viability and metabolic activity of the 
microglia after being released into the cytoplasm from the MP-loaded CMCht/PAMAM dendrimer 
nanoparticles. To observe such an effect, we tested higher dosages of MP-loaded CMCht/PAMAM 
dendrimer nanoparticles in glial and microglial cultures knowing from previous works that MP can 
exert drastic effects in these populations above certain doses, namely affecting astrocytic and 
microglial viability.8c,29 Subsequent to a range concentration test of different dosages of MP-loaded 
nanoparticles in glial cells (supplementary information), we decided to proceed with experiments 
considering MP-loaded CMCht/PAMAM dendrimer nanoparticles concentrations above 1000 
μg.mL-1. Above this concentration the cultures started to display variations in the viability assay 
results that were performed. To investigate the cause of this alteration we also treated the 
cultures with void CMCht/PAMAM nanoparticles, in order to see if the effect was due to the 
released corticosteroid action or the nanoparticles formulation itself. Additionally, we added a MP 
concentration similar to the one being released by the MP-loaded CMCht/PAMAM dendrimer 
nanoparticles estimating from the previously obtained MP release profile (supplementary 
information). Figure 5a reveals that in mixed glial cultures the addition of CMCht/PAMAM 
dendrimer nanoparticles to the culture medium had no effect in the cells’ metabolic activity in the 
two high dosages tested. However, a significant decrease after MP and MP-loaded 
CMCht/PAMAM dendrimer nanoparticles exposure was observed. In view of the fact that a 
significant decrease on cell viability in relation to the control group occurred after MP and MP-
loaded CMCht/PAMAM dendrimer nanoparticles addition, we can assume that MP is the main 
factor responsible for affecting the glial cells’ viability. However, these glial cultures are mixed 
cultures and it is known that MP has differential effects in the different subpopulations of nervous 
cells.8c,9b,29 As a result, the overall variations detected in the glial cells response are, in fact, a 
balance of the possible different responses of each cell type. It has been pointed out in the 
literature that the more drastic effects of MP in viability occur in microglial cells, via an apoptotic 
induction mechanism.29 For that reason, the exact same previously referred conditions were 
evaluated in pure microglial cells’ cultures. The addition of CMCht/PAMAM dendrimer 
nanoparticles both at 1000 μg.mL-1 and 1500 μg.mL-1 to microglia induced an augment in the 
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cells’ metabolic activity rates. This increase is probably related to the activation of these 
phagocytic cells which in response to the presence of the nanoparticles change from a resting 
state to an activated state, becoming metabolically more active.26b,30 On the contrary, addition of 
MP to microglia significantly affected its viability. In this case, a 30% decrease was verified in the 
higher concentration. 
 
 
Figure 5. a) Percentage cell viability of glial and microglial cultures after 1000 and 1500 µg addition of 
CMCht/PAMAM (NP) and MP-loaded CMCht/PAMAM (MP-NP) dendrimer nanoparticles, and the 
corresponding acute MP addition (MP) (n=3, mean ± SD; * p<0.05, ** p<0.01, *** p<0.001). b-d) 
Representative immunocytochemistry images of microglia after exposure to 1500 µg addition of NP (b), 
MP (c) and MP-NP (d) are shown. It is evident the negative effect of MP acute addition to microglial 
population (MP), which is attenuated by the sustained release from the nanoparticle system (MP-NP). 
Images were obtained by fluorescence microscopy. Scale bars represent 100 nm. 
 
 
The MP-loaded CMCht/PAMAM dendrimer nanoparticles addition also induced differences in 
microglia metabolic activity when at 1500 μg.mL-1, having this a significant 20% reduction effect. 
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However, the MP released from the 1000 μg.mL-1 addition of MP-loaded CMCht/PAMAM 
dendrimer nanoparticles is not sufficient to induce significant alterations in the viability of 
microglial cells. This seems to be evidence that the MP effects are distinct according to the drug 
formulation itself, whether via an acute or prolonged delivery when released from the 
nanoparticles. We also proved that the MP-loaded CMCht/PAMAM dendrimer nanoparticles 
negative effect in microglial cells viability is due to the toxic action of the MP released from the 
nanoparticles. The control CMCht/PAMAM dendrimer nanoparticles did not induce any noxious 
effects in microglia indicating that the nanoparticles per se have no influence in these alterations. 
These findings were further confirmed by observation of the cultures after immunostaining the 
microglia. It is evident in Figure 5b-d that in the higher dosage both the MP solution and the MP-
loaded CMCht/PAMAM dendrimer nanoparticles induce observable differences in the microglial 
cells’ cultures. The MP acute addition not only significantly reduced the number of cells in culture 
but also caused visible morphological changes in microglia, decreasing its volume and inducing a 
more rounded morphology (Figure 5c). On the other hand, the MP-loaded CMCht/PAMAM 
dendrimer nanoparticles appears to preferentially affect the microglial cells in its density, clearly 
reducing the cell number while not apparently affecting its morphological state. 
 
3.4. In vivo evaluation of the therapeutic potential of MP-loaded CMCht/PAMAM dendrimer 
nanoparticles  
 
In order to have a preliminary insight of the therapeutic potential of these MP-loaded 
nanoparticles in vivo we tested its local administration in a rat model of lateral hemisection. The 
dorsal left side of the rats’ spinal cords was surgically removed around T8-9 vertebrae, while the 
right side remained intact. This partial spinal cord laceration disconnects the ascending and 
descending axonal tracts at the left thoracic spinal cord level impairing the animals’ locomotion. 
In this study, these functional deficits and its potential recovery were the main parameters to be 
analyzed in a first assessment of our therapeutic intervention. The Basso, Beattie and Bresnahan 
open-field locomotor rating scale was chosen to assess both the degree of functional deficits 
upon the injury and the extent of recovery, once it can be correlated with the amount of spared 
white matter.31 
Initially, using confocal microscope imaging we were able to detect the presence of green FITC-
labeled nanoparticles around the lesioned tissue site 3 hours upon local injection (Figure 6a). The 
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assessment of the efficacy of the lesion was demonstrated in the obtained BBB scoring of the 
rats one week after the lesion. In all groups, the animals scored below 5 revealing only modest 
movement of the joints with no stepping or plantar placement in the injured paw. These scores 
are indicative of the severity of the induced thoracic unilateral lesion that accurately distressed 
the axonal traits, namely the corticospinal tract and consequently affecting the animals’ 
locomotion. During the subsequent three weeks only slight improvements but not significant 
differences were observed in the locomotor performance of the control group, as well as the NP 
and MP injected animals (Figure 6b). However, we registered a statistically significant 
improvement in the functional outcome of the rats receiving the MP-loaded CMCht/PAMAM 
dendrimer nanoparticles, standing out from all the other groups (Figure 6b). The MP-loaded 
nanoparticles injected animals achieved an average score of 9 revealing extensive movement of 
the three hindlimb joints as well as plantar placement of the left foot with weight support in 
stance. This score is significantly different from all the other animal groups, indicating that the 
animals that received the therapeutic intervention are less impaired and more prone to recovery 
4 weeks after the lesion. This restoration of function after hemisection injuries was pointed out to 
be achieved by two possible mechanisms: via regeneration of severed axons or by the formation 
of alternative pathways.32 The axon re-growth can be enhanced in a suitable environment in the 
presence of growth factors and absence of inhibitory molecules, such as the ones derived from 
the inflammatory response. Our findings reveal no apparent spontaneous recovery in our control 
animals 4 weeks after injury. Interestingly, it seems that the MP-loaded nanoparticles create a 
more suitable environment in the lesioned area that allows visible improvements in the overall 
functional outcome of the affected paws. The mechanisms underlying this are most likely due to 
the action of the MP being released in a sustained manner from the nanoparticles, modulating 
the inflammation following the injury, namely by affecting the microglial population density, as we 
have shown in vitro. The microglial activity modulation in conjunction with astrocyte activation 
inhibition,8c also contributes to the suppression  of  inhibitory molecules formation during the 
inflammatory response and, not only decreases cell death after injury but also allows the axon re-
growth process.32 It was already shown by several authors that although necessary, if one 
minimizes the inflammation mediators’ action around the lesion site the tissue degeneration can 
be prevented and the functional outcomes can improve.33 
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Figure 6. a) Internalized nanoparticles in the lesioned spinal tissue 3 hours after the lesion (blue – 
nuclei; green – MP-loaded NPs; red - astrocytes). b) BBB scoring of the hemisected animals from 7 to 28 
days post-surgery. Rats injected with MP-loaded nanoparticles were significantly different from the other 
groups (mean BBB scores ± s.d., *p<0.05, **p<0.01). c) Schematic representation of the local injections 
performed after the hemisection. 
 
 
Within the present study, we demonstrated the feasibility and applicability of the developed 
dendrimer nanoparticles for drug delivery in central nervous system therapies, particularly in the 
control of the secondary injury events that follow neurotraumatic conditions such as SCI. These 
MP-loaded nanoparticles exhibit interesting and promising potential in applications involving the 
modulation of inflammation upon spinal injuries and future studies aiming at the comprehension 
of the specific mechanisms occurring in this therapeutic intervention are of the utmost 
importance. 
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4. Conclusions 
 
In this study we report a new approach to modulate inflammation after neurotrauma, using MP-
loaded CMCht/PAMAM dendrimer nanoparticles. It was demonstrated the effective loading of MP 
into the nanoparticles and a sustained release of this drug during 14 days. Our studies further 
indicate that the MP-loaded nanoparticles possess a sphere-like shape and an average diameter 
range of 109 ± 46 nm with negative zeta potential. These nanoparticles are easily internalized by 
astrocytes, oligodendrocytes and microglia. The nanoparticles were found to be non-cytotoxic and 
they do not interfere with the cells’ morphology or proliferation when added at concentration of 
200 µg.mL-1. The intracellular internalization of high concentrations of MP-loaded CMCht/PAMAM 
dendrimer nanoparticles modulates the metabolic activity of microglia cells, by the action of MP. 
In an in vivo study the MP-loaded nanoparticles proved to be effective in improving the functional 
outcome of partially hemisected rats, after administration and internalization in the spinal tissue. 
We foresee that these nanoparticles can still undergo additional surface modifications in order to 
render them a cell targeted profile. Therefore, these nanoparticles may provide a new opportunity 
for the treatment and modulation of secondary events following SCI, limiting the damage extent 
and providing neuroprotection to the lesioned tissue. 
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CHAPTER VII 
Biocompatibility and functionality studies of MP-loaded CMCht/PAMAM 
dendrimer nanoparticles in Schwann cell cultures 
 
Abstract 
Schwann cells have been investigated for SCI transplantation, since they have been shown to 
promote axonal regeneration and myelination following injury. Combination of Schwann cell 
transplantation and the systemic administration of the corticosteroid methylprednisolone (MP) 
has been also reported to improve repair and function in SCI animal models. However, there is a 
lot of controversy surrounding MP administration in human patients, since high dosage systemic 
administration is required, thus severely affecting other peripheral organs and causing undesired 
side effects. One way of circumventing this issue is to use adequate drug delivery systems that 
can act specifically and more effectively in the target tissue. In the present study, it is aimed to 
investigate the interaction of MP-loaded nanoparticles with Schwann cells, namely assessing the 
uptake profile and possible interference in its myelination ability. Incubation of MP-loaded 
nanoparticles in Schwann cell cultures have revealed straightforward internalization in a time 
dependent profile, reaching maximum internalization levels 24 hours post-incubation. 
Additionally, the presence of nanoparticles has not significantly affected co-cultures of Schwann 
cells with dorsal root ganglia neurons, particularly the axon myelination function of Schwann 
cells. Extensive myelination was observed following nanoparticle incubation, with no significant 
differences to the controls. The conjugation of Schwann cell transplantation and MP-loaded 
nanoparticle administration may therefore be reasonable in the development effective therapeutic 
strategies for SCI repair. 
 
 
This chapter is based on the following publication: 
Susana R. Cerqueira, Yee-Shuan Lee, Yelena Pressman, Joaquim M. Oliveira, João F. Mano, 
Nuno Sousa, Rui L. Reis, Mary B. Bunge “Biocompatibility and functionality studies of MP-loaded 
CMCht/PAMAM dendrimer nanoparticles with Schwann cell cultures”, submitted. 
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1. Introduction: 
Spinal cord injury (SCI) frequently follows a mechanical trauma that damages the spinal tissue. It 
has severe consequences associated with it, which dramatically affect the victims quality of life.1 
Following this primary insult where massive cell death and vascular leakage occur, a chain of 
biochemical and cellular secondary reactions is initiated broadening the lesion impact and 
altering the environment surrounding the injury.2 In brief, the secondary injury is dominated by 
excitotoxicity, hemorrhage and edema, infarction, reactive oxygen species (ROS) production, lipid 
peroxidation, axonal disruption and degeneration, and further cell necrosis and apoptosis, 
particularly in neurons and oligodendrocytes.3,4 The post-lesion environment thus becomes 
extremely inhibitory for axonal growth and reconnection. In a chronic phase, regeneration 
becomes even more difficult to manage due to the formation of a glial scar.5 Consequently, 
patients suffering from severe SCI commonly develop several motor, respiratory and cardiac 
dysfunctions, among others.6 Therefore, therapeutic options that can modulate the post-lesion 
environment and create more permissive conditions for repair to occur are urgently needed.  
The clinically recommended, and still very controversial, pharmacological agent to treat SCI is the 
corticosteroid methylprednisolone (MP).7 MP is a potent anti-inflammatory and antioxidant drug 
that has been shown to improve motor and sensory functioning, following high dosage systemic 
administration to SCI patients.8 Although the range of MP action mechanisms is not yet 
completely understood, it is known to involve astrocyte and microglia proliferation inhibition, as 
well as anti-apoptotic oligodendrocyte protection.9,10 However, simultaneous occurrence of severe 
wound infections, gastric bleeding, sepsis, pneumonia, pulmonary embolism and even death 
have also been described following high dosage systemic MP administration, questioning the 
safety and effectiveness of this option.11  
Tissue engineering as an interdisciplinary field that aims at restoring, maintaining or improving 
tissue function merging the knowledge of different scientific fields, is bringing new hopes for more 
effective neural regeneration strategies.12 It suggests the use of cell transplantation, biomolecular 
therapies and/or biomaterial-based advanced strategies in order to provide more suitable 
conditions for regeneration to occur.13 Several cell types are currently under investigation for SCI 
repair, amongst them autologous Schwann cell (SC) transplantation is believed to be one of the 
more promising approaches.14 SCs are the myelinating cells of the peripheral nervous system and 
they have been shown not only to myelinate central axons after transplantation into SCI animal 
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models, but also to provide a more permissive substrate environment for axon regeneration.15 
These cells have proved to enhance the invasion of host SCs into the lesioned area, which 
favorably contributes to regeneration.16 SC transplantation combined with MP administration has 
also demonstrated improved axonal regeneration following SCI in rat models.17 In this study, it is 
proposed the use of an innovative drug delivery system for MP administration, allowing a local 
and sustained release and eliminating the severe side effects of systemic high dose 
administration, in conjunction with SC culturing. Biocompatibility assays involving biomaterials 
and Schwann cells have mostly been assessed for guidance conduits for SC aligned growth, 
either using nanofibers18 or polymer macrostructures.19 To our knowledge, there have been no 
reports on drug delivery nanocarriers compatibility with SCs. 
From the variety of recently developed nanoparticles (NPs), dendrimers possess extraordinary 
features that make them ideal vehicles for the controlled and sustained delivery of drugs.20 
Dendrimers possess a spherical highly branched structure that can entrap molecules, and from 
which emanate external surface groups that can be further functionalized.21 Poly(amidoamine) 
(PAMAM) dendrimers, the most extensively used for biomedical applications, have been recently 
surface grafted to carboxymethylchitosan (CMCht), in order to enhance biocompatibility and drug 
payload capabilities.22 MP has also been successfully incorporated in the surface engineered 
CMCht/PAMAM dendrimers, demonstrating a sustained and controlled release in vitro.23 The 
interaction of MP-loaded CMCht/PAMAM dendrimer NPs with primary cultures of SC, as well as 
co-cultures of SC with dorsal root ganglia neurons (DRGN) was investigated in the present report. 
Following NP exposure to pure SC cultures, fluorescence microscopy studies were conducted to 
assess the NP uptake profile and possible morphological/spatial distribution discrepancies. 
Transmission electron microscopy analysis was performed to investigate the cell ultrastructure 
after MP-loaded CMCht/PAMAM dendrimer nanoparticles uptake. Finally, co-cultures of SC and 
DRG were also exposed to NPs and the myelination ability of SC quantified, following 
immunocytochemistry and Sudan black staining.  
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2. Materials and methods 
 
2.1. Nanoparticle synthesis 
 
Carboxymethylchitosan/polyamidoamine (CMCht/PAMAM) dendrimer nanoparticles were 
produced as previously reported by Oliveira et al. 22 Generation 1.5 Starburst® PAMAM-carboxylic 
acid terminated dendrimer solution (PAMAM-CT) in 20% methanol (w/v) were purchased from 
Sigma (Germany). The following reactions were carried out: (i) increase in the PAMAM-CT 
generation; (ii) production of a PAMAM-methyl esther terminated dendrimer; (iii) condensation 
reaction between the methyl esther and amine groups of PAMAM and CMCht; and (iv) conversion 
of the non-reacting methyl esther groups into carboxylic ones in the CMCht/PAMAM dendrimer 
nanoparticles. Initially, the methanol was removed from the PAMAM-CT dendrimers by 
evaporation under nitrogen gas. The remaining compound was re-dissolved in ultra-pure water in 
a final concentration of 10 mg.mL-1 and the pH was corrected to 6.5. Then, 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC, Fluka, Slovakia) was added under 
agitation for 30 minutes at room temperature. Ethylenediamine (EDA, Sigma, Germany) was 
added at the same molar ratio of EDC, and the solution let to react for 4 hours under vigorous 
agitation. The solution was subsequently dialyzed against ultrapure water in order to remove the 
exceeding EDC (cellulose tubing, benzoylated for separating compounds with a molecular weight 
of ≤1,200, Sigma, Germany). The obtained amine terminated PAMAM dendrimers (PAMAM-AT) 
were mixed with methanol (Sigma, Germany) and methyl methacrylate (Fluka, Germany), and 
kept under agitation in a water bath at 50ºC for further 24 hours. After methanol removal under 
nitrogen gas, appropriate volumes of hydrochloric acid (HCl, Panreac, Portugal) and 
trifluoroacetic acid (TFA, Sigma, Germany) were added to the solution. Meanwhile, 1 g of CMCht 
was dissolved in 50 mL of water. The PAMAM methyl esther terminated dendrimers were 
dissolved in a 20/80 water/methanol solution and the CMCht was added and kept under 
agitation for 72 hours, after which the CMCht/ PAMAM dendrimer nanoparticles with carboxylic-
terminated groups were obtained. 
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2.2. Methylprednisolone incorporation into the CMCht/PAMAM dendrimer 
nanoparticles 
 
Methylprednisolone (MP, Sigma, Germany) was incorporated in the nanoparticles by mixing an 
aqueous solution of CMCht/PAMAM dendrimer nanoparticles with an ethanolic solution 
containing methylprednisolone in a final concentration of 5×10-4 M (w/w). Saturated sodium 
carbonate solution (Na2CO3, Aldrich, Germany) and acetone (Pronalab, Portugal) were then added 
to the mixture and kept under vigorous agitation. The resulting precipitates were collected by 
filtration and then dispersed in ultrapure water. Extensive dialysis (cellulose tubing, benzoylated 
for separating compounds with a molecular weight of ≤1,200, Sigma, Germany) was performed 
during 48 hours. Both CMCht/PAMAM dendrimer nanoparticles and MP-loaded CMCht/PAMAM 
dendrimer nanoparticles were obtained by freezing the final solution at -80ºC and freeze-drying 
(Telstar-Cryodos-80, Spain) the samples for approximately 7 days, until the solvents were 
completely removed. 
 
2.3. Fluorescent labeling of MP-loaded CMCht/PAMAM dendrimer nanoparticles  
 
Fluorescein isothiocyanate (FITC) labeled MP-loaded CMCht/PAMAM dendrimer nanoparticles 
conjugates were prepared by covalently bonding the amine group of CMCht and the 
isothiocyanate group from FITC. A 10 mg.mL-1 FITC (Sigma, Germany) solution was prepared in 
dimethyl sulfoxide anhydrous (DMSO, Riedel-de Haen, Germany) in the dark. Simultaneously, a 
10 mg.mL-1 MP-loaded CMCht/PAMAM dendrimer nanoparticles solution was set in carbonate-
bicarbonate coupling buffer (pH 9.2). Afterwards, 50 µL of the FITC/DMSO solution were added 
per each mL of the MP-loaded CMCht/PAMAM dendrimer nanoparticles buffered solution, under 
agitation. The resulting solution was kept in the dark at 4ºC for 8 hours. The FITC-labeled MP-
loaded CMCht/PAMAM dendrimer nanoparticle solution was then dialyzed (cellulose tubing, 
benzoylated for separating compounds with a molecular weight of ≤1,200, Sigma, Germany) for 
48 hours against ultrapure water in order to remove the FITC molecules that did not react. 
Finally, the solution was frozen at -80ºC and subsequently freeze-dried (Telstar-Cryodos-80, 
Spain) until the solvents were completely removed. 
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2.4. Schwann cell cultures 
 
SCs were obtained from adult male Fischer rats and isolated from the sciatic nerves as previously 
reported.24 In brief, the sciatic nerves from five rats were cut into small 1–2 mm pieces and 
placed into 35 mm uncoated tissue culture dishes. Every week nerve segments were re-plated, 
until after 3 weeks in culture (the nerve segments were now essentially depleted from fibroblasts) 
SCs were enzymatically  and mechanically dissociated before transferring to new dishes for SC 
expansion in the presence of mitogens (20 µg/mL bovine pituitary extract and 2 µM forskolin). 
SC purity was between 95 and 98%. 
 
2.5. Dorsal root ganglia cultures 
 
DRGs were dissected from embryonic P15 Sprague-Dawley rats and incubated in trypsin 
(Worthington Biochemical Corporation, USA). The tissue was centrifuged and the pellet was re-
suspended in serum-containing medium. Following mechanical dissection, the pellet was re-
suspended in NLA medium (neurobasal medium and B27 (Invitrogen, USA)) supplemented with 
nerve growth factor (NGF, Invitrogen, USA). One drop of DRG cell suspension in NLA medium 
was plated in the center of collagen-coated dishes. Approximately 5,000–7,000 neurons were 
plated per culture. After the cells attached to the collagen, the cultures were flooded and treated 
with NLA medium containing fluorodeoxyuridine (FUDR, Sigma, Germany) on days 2 to 4, 6 to 8, 
and 10 to 12, to exclude the non-neuronal cells (fibroblasts, SCs, and phagocytes). After the anti-
mitotic treatment, the resulting DRGN cultures were maintained on NLA medium for at least 1 
week to ensure that no residual FUDR remained when SCs were added. 
 
2.6. Immunocytochemistry 
 
Cultures were stained with antibodies against S100, neurofilament (NF) and myelin basic protein 
(MBP) to identify SCs, neurons and myelin, respectively. Cultures to be stained for S100 were 
rinsed with L-15 before fixing in 4% PFA in 0.1 M PBS for 10 min at room temperature. The cells 
were permeabilized with 4% PFA and 0.2% Triton X-100 for 10 minutes. The rabbit S100 
polyclonal primary antibody (Dako, USA, 1:400) was incubated for one hour at room 
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temperature. After incubation, the cultures were rinsed three times with 0.1 M PBS containing 
10% serum. The secondary antibody, goat anti-rabbit AlexaFluor 594 (Invitrogen, USA, 1:500) 
was applied for 30 minutes. Cultures were rinsed three times in 0.1 M PBS containing 10% 
serum. Cultures to be stained for MBP or NF were fixed in 4% PFA in 0.1 M PBS at room 
temperature. The cultures were permeabilized for 15 min with 4% PFA containing 0.2% Triton X-
100 in 0.1 M PBS at room temperature. The cultures were then treated with ice-cold 50% 
acetone for 2 minutes, ice-cold 100% acetone for 2 minutes, and 50% acetone for 2 minutes. 
Cultures were then rinsed twice with 0.1 M PBS for 5 minutes each and incubated with mouse 
monoclonal anti-MBP (SMI 94, Sternberger Monoclonals, Inc., USA, 1:1000) or mouse 
monoclonal anti-neurofilament (SMI 31, Sternberger Monoclonals, Inc., USA, 1:1000). After 
washing in PBS, secondary antibody goat anti-mouse Alexa Fluor 594 or 488 (Invitrogen, USA, 
1:500) was added for 30 minutes. Coverslips were then mounted in Citifluor containing Hoechst 
33342 (Pierce, USA).  
 
2.7. Myelination in SC/DRGN co-cultures 
 
For myelination experiments, co-cultures were prepared by adding 50,000 SCs to purified DRGN 
cultures. The DRGN co-culture media was replaced every other day with NLA medium for 2 
weeks. For inducing myelination, the co-culture media was replaced by medium containing 
ascorbic acid (NLA medium + ascorbic acid). All cultures were then maintained for an additional 
2 weeks, with regular media renewal every 2–3 days. The total period of co-culturing was 4 
weeks. Myelination was observed as expected in SC/DRGN cultures before the end of the co-
culturing period.  
 
2.8. Sudan black staining 
 
Co-cultures of DRGN/SCs were fixed for 15 minutes in 4% PFA, rinsed in PBS, and further fixed 
in 0.1% OsO4 for 1 hour. The cultures were then rinsed washed in PBS followed by dehydration 
in 25, 50, and 70% ethanol, each for 5 minutes. The 0.5% Sudan black in 70% ethanol solution 
was applied for 1 hour. The cultures were rehydrated in ethanol (70%, 1 minute; 50%, 5 minutes; 
25%, 5 minutes) and then rinsed in PBS and mounted. Myelinated axons were counted using a 
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square grid eyepiece during three scans across the coverslip. The number of Sudan black-stained 
myelin sheaths crossing the scan line was counted. 
 
2.9. Transmission electron microscopy 
 
The cultures were maintained in 2% phosphate buffered glutaraldehyde with 100 mM sucrose 
overnight at 4°C. Afterwards they were placed in 2% buffered OsO4 for 1 hour at room 
temperature. Cultures were further processed for EMbed plastic (Electron Microscopy Sciences, 
Fort Washington, USA) embedding. Areas were chosen for semi-thin sectioning; the 1 µm 
sections were stained with toluidine blue/methylene blue/sodium borate. Thin sections, stained 
with uranyl acetate and lead citrate, were examined in a Philips CM-10 electron microscope (FEI 
Company, USA). Sections were cut perpendicular to the plane of the coverslip. 
 
2.10. Statistical analysis 
 
Statistical analysis was done to compare the myelin quantification using one-way ANOVA followed 
by the Bonferroni post-test between groups to assess statistical differences. Statistical 
significance was defined for p<0.05. 
 
3. Results and discussion 
 
The emergence of new nanotools for regenerative medicine can have tremendous future impact 
in the design of new enhanced reparative strategies, namely for complex pathologies such as 
neurological diseases. In particular, SCI treatments can benefit from more effective drug delivery 
systems (DDS), with prolonged and sustained profiles as the ones provided by recently developed 
nanocarriers. Moreover, combination of biomaterial-based DDS with cell transplantation can 
provide better means to reach the proper environment for successful SCI repair and 
regeneration. More effective delivery of therapeutic agents, such as MP, that modulate the 
inflammatory/inhibitory lesion site, associated with SC transplantation strategies intended at 
replacing the cell population and supporting axonal regeneration may prove to be valuable 
therapeutic approaches. In fact, it is now widely accepted that such combinatorial strategies will 
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more likely overcome the complexity of SCI pathology, dealing simultaneously with several of the 
events that make the environment so harsh for regeneration. 
In the present study, it was investigated the in vitro interaction of MP-loaded CMCht/PAMAM 
dendrimer NPs with Schwann cells foreseeing a combined tissue engineering strategy for nerve 
regeneration. In order to do so, the effect of the MP-loaded CMCht/PAMAM dendrimer NPs in the 
SC myelinating capacity was evaluated, as well as the spatio-temporal uptake profile. Primary rat 
SC cultures were exposed to 200 µg.mL-1 FITC-labeled MP-loaded CMCht/PAMAM dendrimer NPs 
to assess intracellular distribution and quantify NP cell uptake at different culturing times. During 
the incubation periods, proliferation and density of SC cultures was followed, and no observable 
differences to control SCs grown in regular media were detected. These NPs have been 
previously tested in primary glial cultures with no reported differences in metabolic activity or 
proliferation rates of the NP incubated cells, thus no cytotoxicity was expected to occur in primary 
SCs as well.23 Figure 1 shows the fluorescence microscopy images of the temporal NP uptake 
profile in pure SC cultures. Assessment of NP intracellular distribution following 
immunocytochemistry and fluorescence microscopy observation pointed out, similarly to what it 
has been previously observed for glial cultures, to a preferential intracellular localization in the 
perinuclear region. This was verified for all the different incubation periods tested, for a maximum 
of 24 hours. Figure 1 also indicates that the internalization of FITC-labeled MP-loaded 
CMCht/PAMAM dendrimer NPs by SCs is a time-dependent process that reaches a saturation 
point 24 hours following incubation, denoting that at this time point each SC in culture has 
internalized NPs. The levels of internalization are maintained for at least 7 days of culturing 
showing that the NPs can be intracellularly retained in SCs, which can be advantageous for drug 
delivery therapeutic purposes. In fact, SCs have the additional possibility to act also as NP 
carriers in a combined transplantation strategy due to the dynamic cellular NP transport, namely 
through transcytosis or exocytosis.25 Moreover, all the cultures exposed to NPs have revealed the 
typical SC bipolar morphology and longitudinal orientation, with parallel arrangement, indicating 
that NP do not disturb the SC typical distribution in the culture dish.24 Observation of the obtained 
SC cultures indicated high levels of purity, with no fibroblast contamination and successful 
expansion and extension of SC processes, as the obtained fluorescence images confirm. 
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Figure 1 – Primary Schwann cell cultures incubated with MP-loaded FITC-labeled CMCht/PAMAM 
dendrimer nanoparticles. Nuclei are stained with Hoescht (blue), and SC with GFAP (red). Nanoparticles 
are visible in green. 
 
 
Additionally, at each time-point cells were fixed and the number of SCs displaying fluorescent-NP 
uptake was quantified. Figure 2 shows the graphical representation of the quantification of NP 
uptake in SC cell cultures, confirming its time dependence. The rate of NP uptake has shown to 
be relatively slow with modest internalization rates during the first 6 hours of incubation with NPs 
reaching around 30% culture uptake after this time period. The dynamics seems to follow a linear 
progression trend reaching the maximum internalization figures 24 hours following NP incubation 
with practically all SCs presenting internalized NPs. This internalization profile corroborates the 
previously reported observations for the uptake of astrocytes and oligodendrocytes in glial 
primary cultures that display a very similar trend.23 Since SCs are the myelinating glial cells from 
the peripheral nervous system, a similar response from the CNS glia is expectable after NP 
uptake, particularly oligodendrocytes. The mechanism leading to MP-loaded CMCht/PAMAM 
dendrimer internalization in astrocytes has been recently confirmed to be associated with 
endocytotic mechanisms. Considering the observed NP uptake profile similarities for these two 
cell types – SCs and astrocytes - it is likely that SCs also display the same intracellular transport 
mechanisms, however additional studies are needed to confirm that hypothesis. NP binding and 
interaction with the cell membrane have been shown to be highly dependent not only on the NP 
characteristics (e.g., size, shape, and charge), but also on the target cell type.26 In the present 
study, it was unveiled the MP-loaded CMCht/PAMAM dendrimer NPs particular uptake profile by 
SCs. 
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Figure 2 – Percentage uptake rates of FITC-labeled MP-loaded CMCht/PAMAM dendrimer NPs in rat 
primary Schwann cells (n=3; mean ± SD). 
 
In this investigation, co-cultures of SCs and DRG neurons have also been established by means 
of plating the previously obtained SCs onto established DRGN cultures. As seen in Figure 3, that 
shows the fluorescence images of the co-cultures, the SCs were successfully plated onto DRG 
neurons and promptly aligned along the axon, even in the presence of MP-loaded 
CMCht/PAMAM dendrimer NPs. A particular feature of SCs is precisely the affinity relation for 
axons, typically associating with the neurites and extending its processes to migrate along the 
neurites, when co-cultured with DRGN. This was thoroughly observed in the SC/DRGN co-
cultures, as it is shown in Figure 3. Functionally in vitro SCs are capable of forming a myelin 
sheath around cultured axons, mimicking the in vivo SC function. Thus, these SC/DRGN co-
cultures are commonly used for investigation of the myelination mechanism, as well as testing of 
new strategies in nerve regeneration.27,28 Herein, it was investigated if MP-loaded CMCht/PAMAM 
NPs do affect SC myelination capacity on DRGN neurites. In the presence of FITC-labeled MP-
loaded NPs, SCs normally lined up along the neurites extending their processes along the axons 
signaling the initiation of the myelination process. No differences in the co-cultures, with or 
without NP incubation, were observable regarding this. 
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Figure 3 – A. Co-cultures of Schwann cells and dorsal root ganglia neurons, labeled with S100 (red). B. 
Detail of a labeled DRGN axon (labeled with NF) and the lined up Schwann cells with internalized FITC-
labeled MP-loaded CMCht/PAMAM dendrimer nanoparticles (green spots). Scale bars correspond to 50 
µm. 
 
Additionally, the co-cultures of SC and DRGN axons were observed under a TEM microscope 
(Figure 4), in order to investigate if ultrastructural differences in the cells were observable after 
NP exposure. Cross-sections of the cultures allowed the visualization of SCs attached to the 
collagen matrix, and in close proximity with the DRGN axons that abundantly surrounded the SC 
cell body (Figure 4A). The same distribution and cell proximity was observed in the presence of 
NPs (Figure 4B). Initiation of the axon typical encirclement process by a SC is also suggested by 
the observation of evaginations of the SC membrane around the DRGN axons (arrows in Figure 
4). No apparent morphological differences between the cells in the two different conditions were 
detected, indicating that NPs are not exerting any deleterious effects in the co-cultures. 
Additionally, the 109 nm diameter NPs were not distinguishable, even at higher magnification 
images, from the spherical vesicles and organelles. In future studies, conjugation to a contrast 
agent (such as phosphotugstic acid) will be done, since it was noticed that this is required for NP 
discrimination and identification via electron microscopy methodologies. 
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Figure 4 – Electron micrographs of cross-sections of co-cultures of Schwann cells and dorsal root 
ganglia neurons (non-myelinating conditions), in control (A) and NP exposure (B) conditions. Initiation of 
DRGN axon by a SC is visible (arrow). Scale bars correspond to 1 µm. 
 
More importantly, SC functionality was assessed by means of adding myelination media to the 
co-cultures.29 In order to visualize the formed myelin two different treatments were performed: 
Sudan black staining and anti-myelin-basic protein (MBP) immunolabeling. Figure 5 shows the 
microscopy images after SC/DRGN cultures were subjected to Sudan black staining, and the 
myelin identification is visible. Myelin was abundantly formed and positively stained in both 
conditions, i.e., in regular myelination media with and without NP previous exposure. Sudan 
black staining reveals thickened phase-dark segments that appear along the neurites and 
correspond to myelin formation (Figure 5A). From both micrographs (control and NP stimulated), 
along the myelinated axons it is possible to discern the SC bodies enwrapping the neurites and 
extending the processes beside them. Once again, it can be observed that SCs displayed the 
typical behavior when in contact with neurons following MP-loaded CMCht/PAMAM dendrimer NP 
incubation. Moreover, the myelinated axon quantification has showed no statistical differences 
between the two culturing conditions, with very similar average figures (Figure 5B). From TEM 
analysis and Sudan black staining data, both visual observation and myelinated axon 
quantification, it was confirmed that neither the SC contact with DRGN or myelin production were 
affected by the presence of NPs in culture. 
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Figure 5 – A. Bright field micrographs, after Sudan black staining for myelin visualization. Co-cultures of 
Schwann cells and dorsal root ganglia neurons cultured in myelinating media, in control conditions (CTRL) 
and following MP-loaded CMCht/PAMAM dendrimer NP incubation (NPmp). Scale bars represent 50 µm. 
B. Graphical representation of the myelinated axon quantification in control conditions (CTRL) and 
following MP-loaded CMCht/PAMAM dendrimer NP incubation (NPmp).  
 
To validate the previous findings, immunostaining for MBP, a myelin specific marker, has also 
been performed. Figure 6 shows the fluorescence microscopy images of the co-cultures of SC 
and DRGN following myelin (anti-MBP antibody) and SC (anti-S100 antibody) labeling. This 
experiment has revealed that extensive myelination has occurred in the absence and presence of 
NPs, thus confirming that SCs are functionally active in the presence of MP-loaded 
CMCht/PAMAM dendrimer NPs. These results also confirm the presence of the FITC-labeled MP-
loaded dendrimer NPs in the co-culture, as it can be seen from the green spots appearing inside 
the cells. Moreover, in both conditions SCs visibly proliferated in the DRGN culture, and closely 
aligned along the axons while forming myelin sheaths. Therefore, it was once more demonstrated 
that despite the presence of NPs and the extended period in culture that myelination studies 
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require, the interaction of NPs with SCs do not affect myelin sheath production, which is these 
cells foremost function and essential in nerve regeneration. 
 
 
Figure 6 – Fluorescence microscopy images of Schwann cells and dorsal root ganglia neurons following 
myelination induction, in control conditions (CTRL) and following FITC-labeled MP-loaded CMCht/PAMAM 
dendrimer NP incubation (NPmpFITC). Immunolabeling was performed with S100 for SC identification 
(green) and MBP for myelin (red). A detailed image is presenting showing myelinated axons (in red) and 
the dispersion of NPs in the culture (green spots). Scale bars correspond to 50 µm. 
 
 
The present study corroborates that combined therapies with the investigated MP nanocarrier 
and SC transplantation are encouraging and may be an applicable strategy for SCI management 
after pre-clinical and subsequent clinical validation. The conjunction of an appropriate sustained 
and specific delivery of MP - that will modulate inflammation while reducing oligodendrocyte 
death10 - with SC transplantation - which supports nerve growth and provides neurotrophic factors 
- seems an attractive and potentially successful strategy for SCI repair. Potentiating beneficial 
actions while reducing undesired side effects will hopefully maximize tissue healing in a safer and 
more effective approach. 
 
 
4. Conclusions 
 
In the present work, MP-loaded CMCht/PAMAM dendrimer NPs and SC interactions were 
investigated. SCs were able to easily internalize MP-loaded NPs in a time dependent manner. 
Results have also shown that NPs do not affect the typical SC morphology or spatial arrangement 
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in culture. Moreover, when in contact with DRGN, the NP-incubated SCs profusely encircle and 
myelinate the axons, confirming that the cells function in not altered by the presence of the NPs. 
This study confirm the suitability of combining the two proposed tissue engineering strategies 
envisioning the development of more effective SCI therapies. In a near future, in vivo testing of 
this approach should be conducted in lesion models. 
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Chapter VIII 
 
General Conclusions and Final Remarks 
 
Tissue engineering as the field that brings together physics, materials science, biology, chemistry 
and medicine is promising the development of enhanced strategies to restore, maintain and 
improve tissue function. One of the major challenges in regenerative medicine nowadays is 
central nervous system (CNS) repair, due to the complexity of the nervous tissue as well as the 
cascade of reactions that follow injury and disease. However, the body of knowledge regarding 
neurodegeneration following neurotrauma has considerably evolved in the last decades, 
unraveling new therapeutic targets and providing a more complete understanding of the 
spatiotemporal post-injury processes. Based on tissue engineering concepts and approaches a 
novel strategy to protect the spinal cord following injury, while providing an appropriate 
environment for regeneration has been proposed in this work. In order to overcome the current 
constraints on drug delivery to CNS, particularly following spinal cord injury (SCI), it has been 
proposed the use of a drug delivery system that can act intracellularly on glial cells. Glial cells, 
particularly astrocytes and microglia, are some of the main responsible cells for the deleterious 
and inhibitory reactions that follow SCI and obstruct nerve regeneration. A concerted strategy that 
tackles specific modulation of these cells could improve the lesion environment and provide the 
means for regeneration to occur. 
The main aim of this thesis was to design and explore the potential of a dendrimer-based 
multifunctional nanocarrier in SCI protection and repair. Drug delivery targeting neuroprotection 
during secondary injury reactions is the main point of action for the developed nanoparticle 
system, since this is the first opportunity to act on the lesion site in an attempt to prevent further 
damage. Thus, the therapeutic potential of MP-loaded CMCht/PAMAM dendrimer nanoparticles 
as intracellular drug delivery systems has been assessed both in vitro and in relevant animal 
models. MP has shown to promote functional recovery following SCI, but it presents serious 
adverse side effects in patients. In order to overcome this problem, MP was incorporated in a 
nanoparticle-based DDS to intracellularly deliver the corticosteroid to glial cells. The main 
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objective of this approach is the maximization of neuroprotection and repair, while at the same 
time minimizing peripheral damage. 
In the work herein described, the CMCht/PAMAM dendrimer nanoparticles were initially multi-
functionalized: (i) with a targeting ligand, to evaluate desired targeting features; (ii) loading MP 
and evaluating the profile release of the drug; and (iii) binding a fluorescent probe to allow 
intracellular tracking of the nanoparticles. 
In Chapter III the conjugation and characterization of CD11b antibody functionalized 
nanoparticles was performed. For the first time CMCht/PAMAM dendrimers were successfully 
linked to a cell-targeting agent, in this case specifically recognizing microglia cell membrane 
receptors. The addition of CD11b antibody was confirmed by spectroscopic techniques, and 
revealed to be biocompatible in primary glial cell cultures. Significant differences in the NP 
uptake profile were found after CD11b antibody conjugation. Preferential internalization in 
microglial cells was observed, with visible reduction of the NP internalization in astrocytes and 
oligodendrocytes. It was thus provided an initial proof-of-concept for the targeted drug delivery 
using this nanoparticle system, reporting for the first time altered uptake of the multifunctional 
CMCht/PAMAM dendrimer nanoparticles. In the case of MP delivery for SCI application this can 
be of utmost relevance, since this corticosteroid has already shown to have the ability to 
modulate astrocyte and microglia inflammatory actions. 
Next, in Chapter IV the analysis of the interaction of MP-loaded CMCht/PAMAM dendrimer 
nanoparticles with the astrocyte cell membrane, in order to investigate endocytic and exocytotic 
transport, has been performed. Patch-clamp electrophysiology has demonstrated to be a relevant 
technique to take into consideration for similar studies, providing reliable quantitative temporal 
information on the formation and fusion of vesicles in the cell membrane following NP incubation. 
From the obtained data, it was observed that incubation with MP-loaded CMCht/PAMAM 
dendrimer nanoparticles contribute to the stimulation of exocytotic vesicle formation, indicating 
that after its intracellular action the nanoparticles are extensively cleared out from the target cells. 
This fact decreases the possibility of eventual long-term nanoparticle toxicity, which brings 
additional advantages for the therapeutic use of this nanoparticle system. Live astrocyte confocal 
imaging confirmed that the NPs are indeed transported in exocytotic vesicles, being the first time 
that it has been directly reported. Investigation of the intracellular NP trafficking mechanisms 
provides essential information in understanding how these nanocarriers interact with biological 
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systems, and may open up new possibilities for therapeutic actions in SCI repair. It has been 
proposed an innovative combination of a reliable quantitative technique (patch-clamp 
electrophysiology) and a visual qualitative methodology (live confocal imaging) to thoroughly 
investigate uptake and NP clearance. It is expected that more studies using these techniques and 
profoundly investigating nanoparticle intracellular trafficking will be performed in the future. 
From these in vitro results, a CNS biodistribution study was conducted in healthy rats to predict 
where the NPs tend to accumulate when dispersed in the cerebrospinal fluid (CSF), in direct 
contact with the CNS, overcoming the BBB. In chapter V, we demonstrate that the MP-loaded 
CMCht/PAMAM dendrimer nanoparticles broadly diffuse in the brain parenchyma and are 
intracellularly retained 72 hours post-CSF injection. Moreover, protein expression analysis has 
revealed up-regulation of the glucocorticoid receptor confirming MP intracellular release and 
action through the expected GR activation pathway. No visible morphological alterations were 
detected in the brain tissue. The obtained data have confirmed the functionality of MP-loaded 
CMCht/PAMAM dendrimer nanoparticles as efficient nanocarriers that not only transport MP 
intracellularly but also preserved its integrity thus allowing intracellular action. Its broad diffusion 
in the brain brings the possibility of additional therapeutic applications, namely in brain 
neurodegenerative disorders and traumatic brain injury or stroke. 
An in vivo proof-of-concept in an animal model of SCI was then performed following an initial 
physicochemical evaluation of the MP-loaded CMCht/PAMAM dendrimer nanoparticles, as 
described in Chapter VI. MP-loaded nanoparticles proved to be stable in physiological conditions. 
Furthermore, a prolonged and sustained release of MP was measured during 14 days using 
chromatographic analysis. Internalization in primary glia was confirmed, and successful 
modulation of microglia proliferation was possible testing higher dosages of the MP-loaded 
CMCht/PAMAM dendrimer nanoparticles added to pure primary cultures. Finally, MP-loaded 
nanoparticles were locally administered following spinal thoracic hemisection and significant 
locomotor improvements were detected in the treated animals. The MP-loaded nanoparticles 
have induced faster and more prominent hind-limb motor recovery, confirming the benefits of 
delivering MP in a local sustained manner, via a nanoparticle drug delivery system such as the 
one proposed herein. 
Based on these encouraging results, Chapter VII addresses a preliminary assessment of the 
potential therapeutic combination of MP-loaded CMCht/PAMAM dendrimer nanoparticle 
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administration and Schwann cell transplantation. It is proposed the simultaneous use of these 
two strategies aiming at: (i) modulating the secondary injury inflammatory reactions; and (ii) 
providing the trophic needs and support that Schwann cells have shown to supply, for 
regeneration to occur. MP-loaded CMCht/PAMAM dendrimer nanoparticles do not alter Schwann 
cell morphology or typical arrangement when cultured. Moreover, nanoparticle internalization 
profile has resembled the previously described glia uptake profile. Myelination studies in co-
cultures of Schwann cells and dorsal root ganglia neurons exposed to MP-loaded CMCht/PAMAM 
dendrimer nanoparticles have revealed extensive myelination was, with no differences to the 
control conditions. The combination of these two strategies may prove to be useful in more 
effective treatments for SCI.  
As final remarks, the work performed and described in this thesis presents an innovative tissue 
engineering-based strategy for SCI neuroprotection suggesting that a sustained local MP delivery 
via specifically designed nanocarriers can bring tremendous advantages in SCI repair and tissue 
regeneration. It is expected that more studies following the herein proposed strategy will follow, to 
confirm the suitability of nanotechnology-based strategies in drug delivery to the injured spinal 
cord. Moreover, an original combination of methodologies to investigate NP intracellular 
trafficking has been presented that may impact the field prompting its use in the scientific 
community in order to obtain more robust data on this matter. Finally, therapeutic assessment of 
this system in more relevant injury models, such as rodent contusion models and primate pre-
clinical testing, should be performed next to validate the herein obtained results. Moreover, nerve 
regeneration and reconnection should be further investigated in the previously referred models as 
well as motor recovery and sensory testing, to fully evaluate the recovery following SCI. Finally, 
the investigation of the proposed combination of nanoparticle administration and Schwann cell 
transplantation could bring new benefits in SCI therapies and should also be more thoroughly 
addressed.  
 
 
 
